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Summary 
The development of radiation therapy treatment planning has always 
relied strongly on the available imaging technologies. Anatomical 
imaging techniques like computed tomography (CT) can visualize spatial 
changes in physical properties within patients. Additionally, tumor 
biology plays an important role in the diagnosis, treatment decision-
making and the assessment of therapeutic response. Recent advances in 
biological imaging techniques, mainly based on positron emission 
tomography (PET), offer the opportunity to further individualize 
radiotherapy. 
Highly structured dose distributions can be delivered using intensity- 
modulated radiation therapy (IMRT). IMRT can thus reduce toxicity by 
allowing a selective reduction of the dose to organs at risk, or allow dose 
escalation with the aim to improve local control. In current clinical 
practice, IMRT optimization is based on the assumption of a uniform 
biology distribution within each target volume and aims at achieving 
geometrically conformal dose distributions. By using the spatially 
heterogeneous biology distribution provided by one or several biological 
imaging modalities to guide the IMRT dose prescription, biologically 
conformal radiation therapy (BCRT) can be delivered.  
In this thesis, BCRT is implemented into the IMRT treatment planning 
process at Ghent University Hospital by developing a biology-based 
segmentation tool and extending the objective function. A bound-
constrained linear relationship between the image signal and the desired 
radiation dose is put forward. Additional tools are developed to assess 
the obtained biological conformity of the final treatment plan. 
The feasibility of [18F]fluoro-deoxy-glucose (FDG)-PET guided BCRT for 
head and neck cancer is demonstrated in a planning study. It is shown 
that BCRT does not compromise the planning constraints for the organs 
at risk. The obtained biological conformity is the best for the lowest level 
of dose escalation. Compared to uniform dose escalation within a 
contoured FDG-PET lesion, improved target dose coverage is achieved 
using BCRT. 
 x
Monte Carlo (MC) can be used to calculate radiation therapy dose 
distributions with great accuracy. The use of MC is especially 
advantageous in case of small, irregular treatment fields delivering dose 
to regions of great tissue inhomogeneity, for example in IMRT treatment 
of head and neck or lung tumors. In this thesis, the added value of MC 
compared to pencil beam and convolution/superposition algorithms is 
demonstrated for IMRT lung cancer patients.  
Monte Carlo Dose Engine (MCDE) was developed at Ghent University as 
a highly accurate MC dose engine for IMRT patient dose calculations. In 
this thesis, the conversion of CT numbers into material composition data 
for MC dose calculations is studied in detail. Stoichiometric CT scanner 
calibration and the creation of dosimetrically equivalent tissue subsets 
result in a 14 bin CT conversion scheme. MCDE is further improved by 
the introduction of uncertainty-based stopping criteria, enabling accurate 
clinical treatment plan evaluation in the shortest possible time. Finally, 
the feasibility of integrating MCDE into the IMRT optimization process at 
Ghent University Hospital is demonstrated for an ethmoid sinus cancer 
patient case. 
Optimal use of the new tools for incorporating biological imaging 
information into the treatment planning process will require an improved 
understanding of the radiobiology of tumors. Patients may benefit from 
the improvements in dose calculation accuracy using full MC. While 
faster but less accurate MC dose engines are currently being implemented 
into commercial treatment planning systems, highly accurate dose 
engines like MCDE remain indispensable benchmarking tools. 
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Samenvatting 
Ontwikkelingen in de radiotherapieplanning hangen doorgaans sterk af 
van de beschikbare beeldvormingstechnieken. Anatomische 
beeldvorming, bijvoorbeeld computertomografie (CT), laat toe om 
ruimtelijke verschillen in fysische kenmerken binnen een patiënt in beeld 
te brengen. Daarnaast spelen de biologische eigenschappen van een 
tumor een belangrijke rol bij de diagnose, de keuze van de therapie en de 
beoordeling van het effect van de therapie. Recente ontwikkelingen op 
het vlak van biologische beeldvorming, voornamelijk gebaseerd op 
positronemissietomografie (PET), maken radiotherapie op maat van de 
individuele patiënt verder mogelijk. 
Met intensiteitsgemoduleerde radiotherapie (IMRT) kunnen sterk 
gestructureerde dosisdistributies toegediend worden. IMRT kan hierdoor 
de dosis in de kritische organen verminderen en zo de toxiciteit verlagen, 
of de lokale controle verhogen door dosisescalatie mogelijk te maken. De 
optimalisatie van IMRT in de huidige klinische praktijk gaat uit van een 
homogene verdeling van de biologische eigenschappen binnen elk 
doelvolume, met een geometrisch conforme dosisdistributie als doel. 
Door het dosisvoorschrift te baseren op de met biologische beeldvorming 
verkregen heterogene verdeling van de biologische eigenschappen, kan 
biologisch conforme radiotherapie (BCRT) toegediend worden. 
In deze thesis wordt BCRT geïmplementeerd in het IMRT 
planningsproces van het UZ Gent. Hiervoor wordt een biologisch 
gestuurde segmentatiemethode ontwikkeld en wordt de objectieve 
functie uitgebreid. Tussen de biologische beeldintensiteit en de 
voorgeschreven dosis wordt een begrensd lineair verband vooropgesteld. 
Er worden ook methodes ontworpen om de resulterende biologische 
conformiteit te beoordelen. 
De haalbaarheid van [18F]fluoro-deoxy-glucose (FDG)-PET-gestuurde 
BCRT voor hoofd- en halskanker wordt bewezen in een planningsstudie. 
Er wordt aangetoond dat BCRT de planningsbeperkingen voor de 
kritische organen niet in gevaar brengt. De beste biologische conformiteit 
wordt bereikt voor het laagste dosisescalatieniveau. In vergelijking met 
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uniforme dosisescalatie binnen een afgelijnde FDG-PET lesie wordt het 
doelvolume beter gedekt door BCRT. 
Met behulp van Monte Carlo (MC) kunnen radiotherapeutische 
dosisverdelingen zeer nauwkeurig berekend worden. MC biedt 
voornamelijk voordelen bij de bestraling van gebieden met sterke 
weefselinhomogeniteiten met kleine, grillige bestralingsvelden, 
bijvoorbeeld bij de IMRT-behandeling van hoofd- en halstumoren of 
longtumoren. In deze thesis wordt de toegevoegde waarde van MC ten 
opzichte van potloodbundel- en convolutie/superpositie-algoritmes 
aangetoond bij de IMRT-behandeling van longkankerpatiënten. 
Aan de Universiteit Gent werd Monte Carlo Dose Engine (MCDE) 
ontwikkeld, een uiterst nauwkeurig MC dosisberekeningsprogramma 
voor de berekening van de patiëntdosis bij IMRT-behandelingen. In deze 
thesis wordt de omzetting van CT nummers in materiaalgegevens voor 
MC dosisberekeningen in detail bestudeerd. Zo leiden een 
stoichiometrische calibratie van de CT scanner en het invoeren van 
dosimetrisch gelijkwaardige weefselgroepen tot een CT conversieschema 
met 14 groepen. MCDE wordt verder verbeterd door het invoeren van 
onzekerheidsgestuurde stopvoorwaarden, die een zo snel mogelijke, 
nauwkeurige beoordeling van klinische behandelingsplannen toelaten. 
Tenslotte wordt de mogelijkheid om MCDE te integreren in het IMRT-
optimalisatieproces van het UZ Gent aangetoond voor een paranasale 
sinustumor. 
Het optimaliseren van de nieuwe methodes die ontwikkeld werden om 
biologische beeldvorming in het planningsproces te integreren, vereist 
een beter inzicht in de radiobiologische eigenschappen van tumoren. 
Patiënten kunnen gebaat zijn bij een meer nauwkeurige dosisberekening 
met MC. Terwijl snellere maar minder nauwkeurige MC 
dosisberekeningsprogramma’s commercieel beschikbaar worden, blijven 
uiterst nauwkeurige programma’s zoals MCDE onmisbaar als maatstaf. 
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Résumé 
Le développement de la planification de la radiothérapie dépends 
fortement des techniques d’imagerie médicale disponibles. L’imagerie 
médicale anatomique, par example la tomodensitométrie (TDM), permet 
de visualiser les changements spatiaux des charactéristiques physiques à 
l’intérieur du corps. Par contre, les caractéristiques biologiques de la 
tumeur influencent le diagnostic, le choix du traitement et la réponse à la 
thérapie. Les développements récents dans le domaine de l’imagerie 
médicale biologique, principalement fondés sur la tomographie par 
émission de positons (TEP), facilitent la radiothérapie à la mesure de 
chaque patient. 
Des distributions de dose fortement structurées peuvent être administrées 
avec une radiothérapie conforme avec modulation d’intensité (IMRT). Par 
conséquent, l’IMRT peut diminuer la dose administrée aux organes à 
risque et ainsi réduire la toxicité, et augmenter le contrôle local en 
permettant une escalade de dose. Dans la pratique clinique actuelle, 
l’optimisation de l’IMRT suppose que les caractéristiques biologiques 
sont distribuées uniformément dans les volumes tumoraux, et 
l’optimisation cherche à atteindre une distribution de dose qui est 
géométriquement conforme. En basant la prescription de dose sur la 
distribution hétérogène des caractéristiques biologiques obtenue au 
moyen de l’imagerie médicale biologique, une radiothérapie conforme 
selon la biologie (BCRT) peut être administrée. 
Dans cette thèse de doctorat, la BCRT est implémentée dans le processus 
de planning IMRT de l’Hôpital Universitaire de Gand. A cet effet, une 
méthode de segmentation biologique est développée et la fonction 
objective est étendue. Une relation linéaire délimitée est postulée entre le 
signal d’image et la dose prescrite. De plus, des méthodes pour évaluer la 
conformité biologique résultante sont développées. 
La faisabilité de la BCRT dirigée par [18F]fluoro-deoxy-glucose (FDG)-PET 
est démontrée pour des tumeurs de la tête et du cou au moyen d’une 
étude de planning. Il est prouvé que la BCRT ne menace pas les 
restrictions de planning établies pour les organes à risque. La meilleure 
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conformité biologique est atteinte pour l’escalade de dose la plus basse. 
Comparé à une escalade de dose uniforme dans une lésion FDG-PET 
cernée, la BCRT couvre mieux le volume tumoral. 
A l’aide de Monte Carlo (MC), les distributions de dose administrée par la 
radiothérapie peuvent être calculées d’une manière très précise. MC a un 
avantage principalement en cas d’irradiation de régions qui contiennent 
de grandes hétérogénéités de tissus, avec des champs d’irradiation petits 
et capricieux, par exemple pour le traitement IMRT de tumeurs de la tête 
et du cou ou de tumeurs pulmonaires. Dans cette thèse de doctorat, la 
valeur ajoutée de MC comparé aux algorithmes faisceau-crayon ou 
convolution/superposition est démontrée pour le traitement IMRT de 
tumeurs pulmonaires. 
Monte Carlo Dose Engine (MCDE), un programme de calcul de dose avec 
MC, a été développée à l’Université de Gand pour calculer les 
distributions de dose d’une manière extrêmement précise chez les 
patients recevant de l’IMRT. Dans cette thèse de doctorat, la conversion 
de valeurs TDM en charactéristiques matérielles pour des calculs de dose 
avec MC est étudiée en détail. Une calibration stoechiométrique du TDM 
et l’introduction de groupes de tissus équivalents selon la dosimétrie 
mènent à un schéma de conversion CT avec 14 groupes. MCDE est 
amélioré davantage par l’introduction de conditions d’arrêt dirigées par 
des incertitudes de dose, qui permettent l’appréciation rapide et précise 
d’un plan de radiothérapie. Finalement, la possibilité d’implémenter 
MCDE dans le processus d’optimisation IMRT de l’Hôpital Universitaire 
de Gand est démontrée pour une tumeur des fosses paranasales. 
L’optimisation des méthodes développées pour introduire l’imagerie 
médicale biologique dans le processus de planification demande une 
compréhension améliorée des caractéristiques radiobiologiques des 
tumeurs. Les patients peuvent bénéficier d’un calcul de dose plus précis 
avec MC. Tandis que des programmes plus rapides (mais moins précis) 
de calcul de dose avec MC sont introduits commercialement, des 
programmes très précis comme MCDE restent indispensable en tant que 
résultat de référence. 
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Chapter  1  
Introduction 
1.1 Radiation therapy 
Radiation therapy (RT) is the medical use of ionizing radiation as part of 
cancer treatment to control malignant cells. Radiation in high doses kills 
cells or keeps them from growing and dividing. Because cancer cells grow 
and divide more rapidly than most of the surrounding normal cells, RT 
can successfully treat many kinds of cancer. Normal cells are also affected 
by radiation but, unlike cancer cells, most of them recover from the effects 
of radiation. The goal of RT is to kill the cancer cells while minimizing 
normal tissue complications. To keep the risk of normal tissue 
complications at an acceptable level, the total radiation dose is limited 
and the treatment is spread out over time. Additionally, as much normal 
tissue as possible is shielded while the radiation is aimed at the site of the 
cancer. 
RT can be delivered externally or internally, depending on the location of 
the radiation source (outside or inside the body). This thesis is devoted to 
external photon beam RT, in which specialized equipment is used to 
produce high energy X-rays. The linear accelerator (linac) is the most 
common type of treatment machine. Primary electrons are accelerated 
within the wave guide of the linac up to energies of 4-25 MeV, after which 
they are forced to hit a metal target composed of material with a high 
atomic number and produce bremsstrahlung photons. A variety of filters 
and collimating devices is used to shape the final photon beam. Figure 1.1 
shows the Elekta SLiplus linear accelerator installed at Ghent University 
Hospital (GUH). 
Biologically conformal RT and Monte Carlo dose calculations in the clinic 
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Figure 1.1: The Elekta Sliplus linear accelerator at Ghent University Hospital. 
Since the discovery of X-rays by Röntgen in 1896, RT has developed from 
an experimental application of X-rays to a highly sophisticated treatment 
of cancer [1]. Cross-fertilization of multiple disciplines proves to be 
essential as experts from many fields – mainly clinicians, physicists,  
engineers and biologists – have contributed to these advances. RT has 
particularly been revolutionized by linac and computer technology, 
through improvements in imaging, treatment planning and delivery.  
Radiological imaging has become a cornerstone for diagnosis, staging, 
treatment planning and delivery, and follow-up evaluation of modern RT 
[2]. The ideal imaging technique is non-invasive, repeatable, safe and has 
a sensitivity (ability to detect disease) and specificity (ability to predict the 
absence of disease) of 100% [3]. 
1.2 Anatomical imaging 
Anatomical imaging techniques provide regional spatial information. 
Tumors are distinguished from normal tissues based on morphological 
characteristics, density, size, vascularity, and fat and water content. With 
the introduction of computed tomography (CT) in the early 1970s [4] and 
magnetic resonance imaging (MRI) in the late 1970s [5], cross-sectional 
imaging of tumors became a reality. This strongly improved the accuracy 
and resolution of tumor imaging compared to plain radiography [3]. 
Chapter 1: Introduction 
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1.2.1 CT 
The first CT scanner was built by Godfrey Hounsfield and his colleagues 
in 1972. In 1979, Hounsfield shared a Nobel Prize with Allan Cormack for 
their scientific contributions to the development of CT technology. X-rays 
transmitted transversely through the patient by an X-ray tube are 
detected by an array of detectors on the opposite side of the tube that 
rotates around the patient. The detected projection images are 
reconstructed into digital data and then converted to grayscale levels for 
display. The produced image depends (amongst others) on the physical 
characteristics of the imaged tissue, such as its density and atomic 
number. Although CT is particularly good at depicting bone detail, soft 
tissue contrast is suboptimal, and intravenously administered contrast 
agents are frequently required to enhance its tissue-discriminating ability. 
In general, CT has a very good spatial and temporal resolution [6]. 
1.2.2 MRI 
In MRI, hydrogen nuclei are polarized by a magnetic field and excited 
from ground states to higher energy states by varying radiofrequency 
pulses. When these nuclei return to their ground energy state, they emit 
radiofrequency waves that are detected by sensitive wire coils. 
Differences in the time it takes for the nuclei to return to this ground state, 
called T1 (spin-lattice) and T2 (spin-spin) relaxation times, are the source 
of the distinctions between benign and malignant tissues [3]. Specialized 
pulse sequences and magnetic field gradients are used to label the signal 
as a function of space and, after appropriate post-processing, provide an 
anatomic image of the changes in proton density and relaxation 
properties. T1-weighted images are used in particular for showing 
anatomical detail and can be enhanced with gadolinium. T2-weighted 
images mainly depict the water content and are better at showing 
pathological conditions. Typically, tumors appear darker than 
surrounding normal tissue on T1-weighted images and bright white on 
T2-weighted images. Like CT, the spatial resolution of MRI is excellent, 
although geometric distortions may arise due to differences in 
susceptibility for the magnetic field, for example around metal implants. 
Such 3D deformations may hamper the accurate localisation of 
anatomical abnormalities. The temporal resolution of MRI is worse 
compared to CT and both the sensitivity and specificity of MRI in terms 
of tumoral properties are suboptimal [7]. 
Biologically conformal RT and Monte Carlo dose calculations in the clinic 
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1.3 Intensity-modulated radiation therapy 
The development of highly accurate anatomical imaging techniques like 
CT and MRI has enabled the detection of complex target geometries, for 
instance head and neck tumors wrapped around the spinal cord or 
prostate tumors surrounding the rectum [8]. This has undoubtedly 
strengthened the call for advanced treatment techniques like intensity-
modulated radiation therapy (IMRT). In 1982, Brahme et al. demonstrated 
the potential of intensity-modulated beams to create homogeneous 
concave dose distributions [9]. Their paper is generally considered to be 
the cornerstone IMRT paper. 
The basic idea of IMRT is to modulate the fluence [10] of the incoming 
beams of radiation and to use the additional degrees of freedom 
(compared to conventional beams of uniform intensity) to achieve a better 
target dose conformity and/or better sparing of critical structures [11]. 
The trade-off between tumor control and normal tissue side-effects is 
characteristic of IMRT dose prescription and treatment planning [12]. 
IMRT could never become a clinical reality without inverse treatment 
planning [13]. In inverse planning, computer algorithms are used to 
calculate the beam intensity profiles that will approximate the desired 
dose distribution as closely as possible within the physical and technical 
limitations of the treatment machine. The inverse problem of IMRT was 
first formulated as an optimization problem by Webb [14]. 
 
Figure 1.2. Elekta MLC, consisting of 40 leaf pairs, used to create an irregular field shape. 
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A variety of IMRT delivery techniques exists, including tomotherapy [15] 
and multi-leaf collimator (MLC)-based IMRT. An MLC is a field shaping 
device that consists of a large number of highly absorbing tungsten leaves 
(20-80 on each side of the treatment field), which can be moved indivually 
under computer control in order to create a large variety of field openings 
(figure 1.2). MLC-based IMRT can be delivered rotationally as intensity-
modulated arc therapy (IMAT) [16] or using multiple static beams, either 
dynamically [17] or in step-and-shoot mode [18] depending on whether 
or not the patient is irradiated during the movement of the leaves. 
Both the physical aspects and clinical implementation of IMRT have been 
reviewed extensively [11,19-22]. At GUH, IMRT treatment planning is 
based on class solutions and involves direct MLC aperture optimization 
[23]. Planning starts from a template beam set, characterized by each 
beam’s isocentre, gantry, table and collimator angles, linear accelerator, 
radiation modality and energy. The target volumes and the organs at risk 
(OARs) are delineated on CT, which also provides the appropriate grid 
size and resolution, and voxel attenuation properties for accurate dose 
calculation. For every template beam, a set of initial beam segments is 
created by the in-house developed anatomy-based segmentation tool 
(ABST) developed by De Gersem et al. [24]. The weight and shape (MLC 
leaf positions) of each segment is then optimized by the in-house 
developed segment outline and weight adapting tool (SOWAT). The 
optimization uses a bio-physical objective function [25]. Several SOWAT 
cycles are performed until the criteria for plan acceptance are fulfilled. 
The final beam segments and corresponding weights are combined into a 
prescription that is suitable for transfer to the linear accelerator. 
To allow accurate patient positioning, the patient is sent to the simulator 
before the start of treatment. With this X-ray device, transmission images 
of the patient can be generated and compared to digitally reconstructed 
radiographs (DRRs) created by the treatment planning software. During 
simulation, water-resistant positioning marks are applied onto the 
patient’s skin. During treatment, these marks are used for accurate patient 
set-up at the linear accelerator.  
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1.4 Biological imaging 
Despite their many benefits (e.g. high spatial resolution), anatomical 
imaging techniques are inherently deficient in visualizing tumor biology 
as they can only reveal spatial changes in physical properties [26]. 
Therefore, many research efforts have recently been invested in cellular 
and molecular biology, computer technology and (bio)chemistry [2]. This 
has resulted in advanced biological imaging techniques, mainly based on 
positron emission tomography (PET), single photon emission computed 
tomography (SPECT), functional MRI (fMRI) and magnetic resonance 
spectroscopic imaging (MRSI), which are capable of revealing spatial 
biology distributions [27,28]. These new imaging techniques have also 
been described as ‘molecular’ imaging (for the in vivo characterization 
and measurement of biological processes at the cellular and molecular 
level [29]) or ‘functional’ imaging (for example, for the measurement of 
cerebral blood flow change with fMRI [30]). The general term ‘biological’ 
imaging has been adopted for all techniques that provide complementary 
biological information to the standard anatomical imaging techniques 
[31]. 
1.4.1 PET and SPECT 
PET imaging was developed by Ter-Pogossian et al. in the mid-1970s [32]. 
In PET imaging, a positron-emitting radionuclide is tagged to a molecule 
that is taken up selectively by certain types of tissue. Such radiolabeled 
molecules are called tracers.  Each emitted positron will annihilate with 
an electron from the surroundings, resulting in the production of two 511 
keV annihilation photons emitted in almost opposite directions. These 
coincident photons can be detected externally. After computerized 
reconstruction, tomographic images are obtained. The principle of PET 
imaging is illustrated in figure 1.3. The most frequently used 
radionuclides are fluorine-18 (18F), carbon-11 (11C) and oxygen-15 (15O). In 
SPECT imaging, tomographic images are reconstructed based on the 
external detection of individual photons, emitted by tracers labelled with 
gamma-emitting radionuclides such as technetium-99m (99mTc), indium-
11 (11In) or iodine-123 (123I). 
For some of the isotopes suitable for PET imaging, which have short half-
lives (e.g. 20.4 min for 11C, 2.0 min for 15O), an on-site cyclotron is 
required for the production of these isotopes as well as special synthesis 
facilities. Compared to PET, the synthesis of SPECT tracers is generally 
less expensive. Because collimation is required for the detection of single 
SPECT photons, the spatial resolution of PET is better than that of SPECT, 
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but clearly worse than CT or MRI. The temporal resolution of both PET 
and SPECT is poor. Both imaging techniques offer interesting 
opportunities for tumor detection [2], although their sensitivity and 
specificity are strongly tracer- and disease site-dependent, amongst other 
factors [33]. As they intend to provide complementary information 
(biological versus anatomical), PET or SPECT images differ 
fundamentally from CT or MRI images with regard to their use.  
 
Figure 1.3. In PET imaging, a positron emitted by a radioisotope annihilates with an electron, 
resulting in the production of two annihilation photons, which can be detected externally 
(image taken from physicsworld.com). 
The most widely used PET tracer is 2-[18F]fluoro-2-deoxy-D-glucose 
(FDG) [34]. FDG is transported in a cell like glucose itself and is then 
transformed into FDG-6-phosphate. The presence of 18F in position 2 
causes the FDG-6-phosphate to remain unmetabolized [35]. Therefore, it 
will accumulate within the cell at a speed proportional to glucose need. 
FDG-PET imaging will thus highlight regions of increased glucose 
metabolism. Tumor cells show an increased rate of glucose consumption, 
due to an increase of glycolytic enzymes and the high number of glucose 
transporters expressed on malignant cells [27]. However, in addition to 
changes in tumor metabolism, FDG uptake is influenced by other factors 
such as tumor burden, blood flow, hypoxia and inflammation. Indeed, 
hypoxic tumors are known to have increased glucose metabolism, as have 
macrophages that invade neoplastic tissues [36]. Additionally, some 
tumor types are not highly metabolic, e.g. prostate tumors, or may be 
masked by high uptake of FDG, e.g. in the brain. To overcome these 
limitations of FDG, it is important to identify the entire tumor profile 
using additional anatomical and biological imaging information. 
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Because of their complementarity, multi-modality imaging techniques 
have been developed by combining anatomical and biological imaging 
modalities. Integrated SPECT/CT and PET/CT scanners were introduced 
clinically in 1998 and 2001, respectively [37]. Using such combined 
equipment, many of the limitations associated with separate CT and PET 
or SPECT imaging are overcome, like problems with reproducible patient 
positioning and immobilisation, and co-registration of the two image data 
sets. Multi-modality imaging provides an anatomical reference frame for 
the biologically detected lesions, which strongly improves the specificity 
compared to mono-modality biological imaging [38]. Additionally, CT 
data may be used for the PET or SPECT attenuation correction to increase 
both the imaging accuracy and speed, enabling a more efficient use of 
radiopharmaceuticals as well as an increased patient throughput. Figure 
1.4 shows a clinical FDG-PET/CT imaging example. A Philips Gemini 16-
slice PET/CT scanner came into operation at GUH in September 2004.   
 
Figure 1.4. Clinical FDG-PET/CT investigation of the head and neck region: CT (left), PET 
(middle) and fused (right) sagittal images. B: normal FDG uptake in the brain; T: FDG 
uptake in the tumor in the base of tongue. 
1.4.2 fMRI and MRSI 
Apart from their ability to provide anatomical information, MRI 
techniques are capable of visualizing certain biological tumor properties. 
For instance, fMRI can be used to map changes in brain activity, based on 
the increase in blood flow to the local vasculature that accompanies 
neural activity in the brain [39]. One of the recent advances in fMRI is 
dynamic contrast-enhanced MRI (DCE-MRI), which was developed in the 
mid-1990s to yield information on the microenvironment of tumors and 
normal tissues, e.g. vascularity, blood flow and permeability [40]. 
MRSI allows the detection of biochemically important compounds other 
than water or fat molecules. The peaks in the individual MR spectra 
reflect the relative concentration of chemicals within each spatial location. 
Differences in the levels of cellular metabolites between tumors and 
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normal tissues are thus exploited. While both the temporal and spatial 
resolution of MRSI are worse than that of conventional MRI, both 
imaging techniques show a comparable sensitivity. The specificity of 
MRSI is better than that of conventional MRI [6]. 
1.5 Biologically conformal radiation therapy 
The use of biological imaging for RT can serve three different goals: 1) 
improvement of the diagnostic and staging accuracy, 2) guidance of 
target volume definition and dose prescription, and 3) evaluation of 
therapeutic response [26]. Within the scope of this thesis, only the 
potential application of biological imaging for RT treatment planning by 
improved target volume definition and dose prescription is considered. 
1.5.1 Tumor biology and radioresistance 
Using advanced biological imaging techniques, information can be 
obtained about tumor metabolism, proliferation, oxygenation and 
vascularization, and specific disease markers [31]. At first order, 
biological imaging may aid in visualizing tumor burden and clonogen 
density in order to identify the ‘real’ target volume consisting of 
malignant cells. To achieve tumor control, these cells need to be irradiated 
to a therapeutic dose. Moreover, hypoxic regions within tumors are 
associated with increased radioresistance [41]. As the development of 
blood supply is crucial to tumor growth, tumor vascularization or 
angiogenesis has been linked to radioresistance as well [42]. There has 
also been debate to the extent of the contribution of apoptosis to the 
control of human tumors by RT [43]. Additionally, rapid cell proliferation 
has been identified as a resistance mechanism in fractionated RT [44]. 
Table 1.1. Short-list of radiotracers for tumor biology characterization. 
Radiotracer Full name Characterization 
18F-FDG 18F-fluorodeoxyglucose Glucose metabolism 
18F-FLT 18F-fluorothymidine DNA synthesis (proliferation) 
11C-MET 11C-methionine Protein synthesis 
60Cu-ATSM Cu(II)-diacetyl-bis-N-(4)-methylthiosemicarbazone Hypoxia 
18F-FMISO 18F-fluoromisonidazole Hypoxia 
Radiolabeled Annexin V  Apoptosis 
Radiolabeled  αvβ3 integrin antagonists  Angiogenesis 
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The molecular pathways associated with the above-mentioned tumoral 
properties are under intense investigation. One of the main goals is to 
develop adequate biological imaging techniques and to continue the 
search for optimal tracers in order to visualize the main radiobiological 
properties of tumors. An overview of the most commonly studied 
radiotracers used for tumor characterization, including their present 
status (disappointing, potential or promising), is provided by 
Apisarnthanarax and Chao [2]. Table 1.1 presents a short-list. 
1.5.2 Biological imaging for target volume definition in RT 
RT aims to deliver the required therapeutic dose of ionizing radiation to 
tumor tissue, while minimizing the irradiation of normal tissue. 
Obviously, precise target volume definition is essential to this process. 
The nomenclature was standardized in ICRU report 62 [45], by 
introducing the concepts of gross tumor volume (GTV) for the known 
tumor, clinical target volume (CTV) for the GTV plus suspected 
microscopic spread, and planning target volume (PTV) for the CTV plus 
the marginal volumes necessary to account for setup variations and organ 
and patient motion. 
While the GTV describes the part of the cancer that can be directly 
imaged or palpated, the delineation of the CTV depends heavily on a 
priori knowledge of the behaviour of a given tumor. The PTV is a 
construct that helps to ensure that the desired dose distribution can be 
anatomically achieved within the CTV [46]. Because of the high 
conformity, set-up errors and tumor motion during treatment may have 
more severe dosimetric consequences for IMRT compared to conventional 
RT. Therefore, IMRT makes high demands on accurate PTV definition 
[20]. 
Biological imaging may add essential information to CT and MRI with 
significant consequences on GTV and CTV delineation, by providing 
information on the tumor’s microenvironment and metastasis to regional 
lymph nodes as well as to distant sites [2]. In this way, marginal misses 
and the irradiation of normal tissues can be reduced. Recently, several 
reviews have been dedicated to the impact of biological imaging on target 
volume definition for different tracers and modalities, and different 
disease sites. The use of FDG-PET imaging was reviewed for non-small 
cell lung cancer [47], for head and neck cancer [48], and for multiple 
disease sites including head and neck, brain, lung, esophagus, cervix and 
rectum tumors, and lymphomas [49,50]. Other PET tracers are included in 
reviews on head and neck cancer [51] and multiple disease sites [52,53]. 
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Newbold et al. have reviewed the application of PET, SPECT and NMR to 
RT treatment planning of head and neck cancer [54]. 
The golden standard for target volume definition is pathologic 
examination. However, to date only Daisne et al. have compared CT, MRI 
and PET-based delineations of the primary tumor with pathologic 
specimens, for 9 pharyngolaryngeal squamous cell carcinoma patients 
[55]. They found the FDG-PET based GTV to be smaller than both the CT 
and MRI-based GTVs, and to correspond better to the macroscopic tumor 
specimen. Similar validation studies should be carried out to evaluate the 
use of other tracers, other biological imaging modalities and other disease 
sites for target volume definition in RT. 
1.5.3 Biological imaging for dose prescription in RT:  dose 
painting 
Treatment plan optimization for external beam radiation is traditionally 
based on the assumption of a uniform biology distribution within the 
target volume and correspondingly aims at achieving a geometrically 
conformal dose distribution. In reality, the spatial distribution of 
biological properties within most tumors is far from homogeneous [56]. 
This distribution is visualized by biological imaging techniques, 
providing 3D maps of radiobiologically relevant tumor properties. It 
appears obvious not to limit the use of biological images to improving the 
accuracy of target volume definition in RT, but to use them to identify the 
most radioresistant subregions within tumors and target these regions 
with a higher radiation dose. 
In 2000, Ling et al. introduced the term ‘dose painting’ (in 2D, ‘dose 
sculpting’ in 3D) for prescribing, planning and delivering an increased 
radiation dose to one or more radioresistant tumor subvolumes. Figure 
1.5 schematically illustrates their proposed concept of treating a biological 
target volume (BTV) derived from biological imaging information. The 
BTV can be delineated either by visual interpretation of the biological 
images or by automatic segmentation techniques. The threshold for 
automatic segmentation can be a certain intensity level of the biological 
image signal, a percentage of the maximal intensity or a percentage of the 
source-to-background ratio. In 2001, Chao et al. demonstrated the 
feasibility of 60Cu-ATSM-PET guided dose painting for a head and neck 
cancer patient [57]. The dose to the hypoxic tumor subvolume could be 
escalated to 80 Gy in 35 fractions without compromising normal tissue 
sparing of the parotid glands and the spinal cord. 
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Figure 1.5. Introduction of the biological target volume (BTV) concept by Ling et al. [31]. The 
BTV is defined by combining biological imaging data, which for example identify regions of 
low oxygenation (from 18F-misonizadole PET imaging), high tumor burden (from 
choline/citrate ratio NMR imaging) and high proliferation (from 124I-iododeoxyuridine PET 
imaging). The BTV may be used to improve dose targeting to certain regions of the 
anatomical PTV. 
At GUH, FDG-PET guided dose painting was used to treat 41 head and 
neck cancer patients enrolled in a phase I clinical trial between 2003 and 
2005. The total treatment consisted of 32 fractions and was divided in two 
phases. During the escalation phase (fractions 1-10), a boost dose was 
planned to PTVPET, which was assumed to be the most radioresistant 
subvolume within the PTV. Two escalation dose levels were applied: 2.5 
Gy per fraction (level I; 23 patients) and 3 Gy per fraction (level II; 18 
patients). The BTV was automatically segmented based on the source-to-
background ratio following the method of Daisne et al. [58]. During 
fractions 11-32, standard IMRT was applied. Madani et al. have reported 
on the planning results and toxicity [59]. At dose level I, two cases of 
dose-limiting toxicity occurred (grade 4 dermitis and grade 4 dysphagia). 
A chemotherapy-related death at dose level II halted the study. Complete 
response was observed in 86% and 81% of the evaluated patients at dose 
levels I and II, respectively. Of 9 loco-regional recurrences, the site of 
relapse was located within the BTV for 4 patients. The maximum 
tolerated dose was not reached at the investigated dose levels. 
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The problem with discrete volumes like the BTV is that they are binary: 
voxels are either inside or outside the volume. In real patients, however, 
biological tumor characteristics present themselves at a variety of levels. 
It therefore seems natural to use the entire spatially heterogeneous 
distribution of biological information for RT treatment planning. By 
directly prescribing dose as a function of biological image intensities 
within each patient voxel, truly biologically conformal radiation therapy 
(BCRT) can be achieved. Bentzen has proposed to name this principle 
‘dose painting-by-numbers’, after the ‘painting-by-numbers’ activities for 
children (figure 1.6) [60]. 
 
Figure 1.6. ‘Painting-by-numbers’ illustration from the collection of toy company 
Ravensburger®. 
1.6 Dose calculation algorithms 
Accurate calculation of the patient dose distribution is essential to the 
IMRT (and BCRT, which is hypothetically an improved version of IMRT 
taking into account the heterogeneity of biological properties inside the 
tumor) treatment planning and delivery process. The calculated dose is 
used to compute the objective function value steering the optimization 
process, and to evaluate the clinical acceptability of the final treatment 
plan. However, dose calculation speed is in competition with accuracy. 
For complex optimization problems with complex objective functions, 
thousands of optimization iterations are necessary. Hence, 
approximations are often incorporated in the dose calculation algorithm 
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used by the optimization engine, to allow the optimization to be 
completed within an acceptable time frame. For the final dose 
computation used for treatment plan evaluation, speed issues are 
obviously less important, and high accuracy is essential. 
For external photon beam RT, the general problem of predicting the 
absorbed dose delivered to an individual patient consists of two separate 
components. Firstly, the radiation fluence incident upon the patient 
geometry needs to be determined. Secondly, the absorbed dose (absorbed 
energy per unit of mass) needs to be determined from that incident 
fluence as a function of position within the patient. IMRT dose calculation 
algorithms have been separated into four categories by the IMRT 
Collaborative Working Group [20]: correction-based (1) broad beam and 
(2) pencil beam (PB) algorithms, and model-based (3) kernel-based and 
(4) Monte Carlo (MC) algorithms. The correction-based algorithms first 
compute dose to a homogeneous water phantom, before applying various 
correction strategies to account for source-to-skin distance and 
heterogeneities within the patient. Model-based algorithms, on the other 
hand, compute dose directly within the patient geometry [61]. 
1.6.1  Broad beam algorithms 
Designed for radiation fields with a simple, smoothly varying fluence 
profile (open, blocked or wedged beams), broad beam algorithms are 
generally not recommended for use in IMRT [62]. Broad beam algorithms 
parametrize dose distributions in a homogeneous water phantom as a 
function of field size, depth, off-axis distance and source-to-surface 
distance based on measurements. For patient dose calculations, the 
specific treatment conditions are first applied in water, and then corrected 
for the patient anatomy. If used, heterogeneity corrections are based upon 
density-scaling equivalent path-length (EPL) methods. 
1.6.2  Pencil beam algorithms 
To reconstitute dose distributions in a homogeneous phantom, PB 
algorithms use energy deposition kernels in a water phantom derived 
from MC calculations [63] or measurements [64,65]. Figure 1.7 shows a 
pencil kernel, which describes the energy deposition from a 
monodirectional beam in a semi-infinite medium. Pencil kernels are 
obtained by pre-convolving point kernels over the depth dimension, 
which offers significant speed advantages for PB compared to kernel-
based algorithms. While PB algorithms can account for beam fluence 
modulations and irregular field shapes, they use radiological path length 
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scaling methods to account for heterogeneities and patient contours [66]. 
Because of their high calculation speed, PB algorithms are the most 
commonly used dose calculation algorithms for IMRT [62].  
 
Figure 1.7. Irradiation geometry (arrow) and isodose curves (full lines) for a pencil kernel 
[61]. 
1.6.3 Kernel-based algorithms 
Kernel-based algorithms, often called convolution/superposition (CS) 
algorithms, separate the effects of primary photons incident upon the 
patient from the effects of secondary radiations generated by interactions 
of the primary photons within the patient. Firstly, the total energy 
released per unit mass (TERMA) from primary photon interactions within 
the patient is computed. To yield the total dose distribution, pre-
computed secondary energy spread kernels are then convolved with the 
TERMA [67-69]. Such a point kernel is illustrated in figure 1.8. While the 
TERMA calculations account for tissue heterogeneities, radiological path 
length methods are typically used to scale the secondary energy spread 
kernels. Compared to PB, CS algorithms are much more accurate in 
heterogeneous geometries but they are relatively slow [70,71]. Therefore, 
they are usually only applied to compute the final dose distribution at the 
end of optimization.  
 
Figure 1.8. Irradiation geometry (arrow) and isodose curves (full lines) for a point kernel [61]. 
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1.6.4  Monte Carlo algorithms 
MC dose calculations simulate individual photon and electron tracks 
through the accelerator treatment head, the MLC and the patient. Along 
its track, a particle may interact with the medium through which it 
passes. Using a random number generator and cross section data for the 
different types of interactions, the program samples the distance to the 
next interaction for a particle at a given position and with a given speed 
in a given direction. After propagating the particle to the interaction 
location, the type of interaction that will take place is sampled. For each 
simulated interaction, the difference in energy between the incoming and 
outgoing particle(s) is calculated. By adding the contributions from all 
interactions taking place within a patient voxel and taking into account 
the voxel’s mass, the total dose can be calculated. 
As MC algorithms simulate stochastic processes, statistical uncertainties 
are inherently associated with the results. This statistical noise decreases 
with the square root of the calculation time, but is independent of the 
number of simulated beams, which is a distinct advantage for IMRT dose 
calculations [62]. Full Monte Carlo algorithms are considered the most 
accurate dose calculation algorithms as they directly account for tissue 
heterogeneities. Additionally, scatter and leakage effects are directly 
taken into account by transportation of individual particles through the 
MLC.  
1.6.5 Dose calculation algorithms at GUH 
At GUH, a broad beam algorithm is routinely applied during IMRT 
optimization [25]. Because the effect of a single MLC leaf movement on 
the value of the objective function needs to be evaluated thousands of 
times during the entire optimization process, a very fast algorithm is 
required. For lung cancer patients, a CS algorithm (Pinnacle, Philips 
Medical Systems, Best, The Netherlands) is used in between optimization 
cycles and for the final dose calculation because of the heterogeneous 
geometry (tumor-lung).  The final dose calculation for all IMAT treatment 
plans is also performed using Pinnacle’s CS algorithm. For research 
purposes, the PB and CS algorithms of Helax-TMS (Nucletron, 
Veenendaal, The Netherlands) are available at GUH too. At Ghent 
University an accurate Monte Carlo dose engine, MCDE, was developed 
by Reynaert et al. for IMRT patient dose calculations [72]. However, the 
present calculation times are too high for clinical use. Details on MCDE 
are provided in the next section. 
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1.7 Monte Carlo Dose Engine 
1.7.1  The EGSnrc code 
Four general purpose MC codes are commonly used for external photon 
beam RT dose calculations: EGS [73,74], MCNP [75,76], PENELOPE [77] 
and GEANT [78]. EGS and PENELOPE simulate the coupled transport of 
photons and electrons, while MCNP and GEANT can also take into 
account other particles such as protons or neutrons. Generally, photon 
transport modeling is quite similar in all four systems, although different 
cross section data are used. Important differences, however, are 
encountered in electron transport modeling, which strongly influences 
the speed and accuracy of the codes [79]. 
Much attention has been paid to the electron transport in EGS (Electron-
Gamma Shower). In 2000, the EGSnrc code was released [74,80]. 
Compared to its precursor EGS4 [73], an improved multiple scattering 
theory was implemented, and the parameter reduced electron stepping 
algorithm (PRESTA) was replaced by PRESTA-II [81]. These adaptations 
improved the accuracy of angular deflection calculations for electrons, 
eliminated previous restrictions on the minimal and maximal electron 
path length, and provided an exact boundary-crossing algorithm by using 
single elastic collisions of electrons. The EGSnrc code has been extensively 
benchmarked and is widely used. Individual user codes can be created in 
MORTRAN, a preprocessor of Fortran77, and connected to the EGSnrc 
core in a pre-compilation step. 
1.7.2 Linear accelerator modeling using BEAMnrc 
Accurate patient dose calculations can only be performed when the 
treatment beams are accurately modeled. An excellent review on this 
subject was written by Verhaegen and Seuntjens [82]. BEAMnrc is an 
EGSnrc user code dedicated to the 3D simulation of RT treatment units 
[83]. Each linear accelerator used for external photon beam RT essentially 
has a modular construction. The technical specifications of the 
components differ from one manufacturer to another; the order of the 
components may differ as well. Figure 1.9 shows a schematic drawing of 
the treatment head of the Elekta SLiplus linear accelerator installed at 
GUH. 
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Figure 1.9. Modular construction of the treatment head of the Elekta SLiplus linear 
accelerator at GUH. 
All component types are pre-programmed in BEAMnrc as component 
modules (CMs). Users can build their own accelerator model by selecting 
the required CMs. The dimensions, materials and transport parameters of 
each CM have to be defined in an input file but no programming efforts 
are required. BEAMnrc can be used to determine so-called phase-space 
files in a scoring plane at the end of a CM, e.g. at the exit of the linear 
accelerator treatment head. A phase-space file contains all necessary 
parameters (location, direction, energy, charge etc.) of particles that pass 
through the plane. Phase-space files can be used as input for further 
BEAMnrc simulations or for dose calculations within a patient or a 
phantom. BEAMnrc was used to model the treatment head of the Elekta 
SLiplus linear accelerator at GUH in detail [84,85]. 
1.7.3  Dose calculation using DOSXYZnrc 
DOSXYZnrc is an EGSnrc user code dedicated to the calculation of dose 
distributions within a phantom consisting of rectangular voxels [86]. 
Different source types can be selected, including individual beams and 
full phase-space files generated by a BEAMnrc simulation. A specific 
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material composition and mass density value can be assigned to each 
voxel, in which the energy deposition is scored. Voxel dimensions are 
independently variable in all 3 directions. DOSXYZnrc also allows the 
calculation of dose distributions within a phantom that is derived from a 
CT dataset. For this purpose, the stand-alone program CTCREATE was 
developed. Using CTCREATE, a CT data set can be converted into the 
appropriate voxel geometry for DOSXYZnrc. Material and mass density 
data are derived from the Hounsfield number within each voxel. Several 
CT data set formats are supported, including DICOM. 
1.7.4  MCDE and the PHANTOM component module 
In principle, the BEAMnrc/DOSXYZnrc system can be used for IMRT 
patient dose calculations. However, separate BEAMnrc and DOSXYZnrc 
calculations would be required for each IMRT treatment beam. In the end, 
the resulting dose maps would need to be summed taking into account 
the individual beam weights. This procedure is rather cumbersome, 
inefficient and demands a lot of user interactions. To solve these issues, 
MCDE was developed by Reynaert et al. [72]. MCDE was essentially 
created by reprogramming DOSXYZnrc as a CM within BEAMnrc: the 
PHANTOM CM. The excellent photon and electron transport algorithms 
and other characteristics of the EGSnrc code are thus preserved. 
Moreover, MCDE uses no additional variance reduction techniques or 
approximations that reduce the accuracy. 
The components within the upper part of the treatment head (from the 
target up to the mirror) are independent of an individual patient’s beam 
setup. Therefore, a BEAMnrc simulation is first performed to score a 
phase-space file just below the mirror. Next, MCDE is used to transport 
particles extracted from this phase-space file through the MLC, the jaws, 
the exit window and the PHANTOM. MCDE thus handles the beam 
modifiers and the patient in one process. All beam and patient data are 
included in a single BEAMnrc input file. Although still possible, it is no 
longer necessary to save a phase-space file for each individual beam after 
the exit window of the linear accelerator.   
A DICOM interface allows the user to import all necessary beam and 
patient data from another treatment planning system (TPS): beam angles, 
shapes and weights; isocenter data, CT images and anatomical contours. 
A separate scoring grid is superimposed on the geometry grid to limit the 
number of scoring voxels. To minimize volume averaging effects, 
spherical scoring voxels were implemented. The desired voxel radius and 
inter-voxel distance can be defined by the user. While MCDE is able to 
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simulate all beams in a single process, requiring only one input file, the 
output consists of separate 3D dose distribution files for each beam to 
facilitate beam weight optimization without requiring additional MC 
simulations. 
At Ghent University, MC calculations are performed on a Linux PC 
cluster consisting of 1 server and 34 nodes (2.4 GHz Intel Pentium IV dual 
processors with 2 Gb RAM). In house-created scripts split each MCDE job 
into a number of sub-jobs. Each sub-job runs on a separate cluster node 
and uses a different part of the phase space file. As MCDE applies no 
variance reduction techniques, calculation times are high. A typical 
patient calculation, aiming at a relative uncertainty on the estimated dose 
below 2% within the PTV, takes 6-8 hours.  MCDE is therefore not 
suitable for routine clinical use, e.g. as the dose calculation algorithm 
used at each iteration of the IMRT optimization engine. On the other 
hand, a very high level of accuracy can be achieved when MCDE is used 
to compute IMRT patient dose distributions. This makes it an excellent 
tool for benchmarking the performance of other dose calculation 
algorithms within patients, where measurements are difficult or even 
impossible. 
1.8 Dose calculation accuracy 
1.8.1  Requirements on dose calculation accuracy in RT 
Because of variations in tumor and normal tissue response, it is difficult 
to quantify the impact of geometric and dosimetric uncertainties in a 
clinical setting. Figure 1.10 illustrates the sigmoidal dependence of the 
tumor control probability (TCP) and the normal tissue complication 
probability (NTCP) on the radiation dose. In the steep part of the curves, 
a dose error of 5% may lead to a change in TCP of 10 to 20% and to an 
even larger change (20 to 30%) in NTCP [87,88]. Clinical effects have been 
noticed for dose errors of 7% [89]. Accurate dose calculation is thus 
required. 
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Figure 1.10. Dose dependence of tumor control probability (TCP) and normal tissue 
complication probability (NTCP). 
A large number of steps are involved between the dose prescription and 
the actual dose delivery in RT. During this complex process, each step 
introduces a certain amount of uncertainty, accumulating in an overall 
uncertainty on the absolute dose delivered to the patient. An overview of 
estimated uncertainties accompanying different steps within the dose 
determination process can be found in table 1.2. Excluding the dose 
calculation step, an overall uncertainty (one standard deviation) of 4.3% is 
obtained. This overall uncertainty can possibly be reduced down to 2.5% 
in the near future, due to improvements in imaging and radiation 
technology. When 2% to 3% errors in dose computation are included in 
the present estimate, the total uncertainty becomes about 5%. 
Table 1.2. Present and future estimates of uncertainty (one standard deviation) on the 
absolute patient dose for a complete RT treatment procedure using MV photons [87]. 
Source of uncertainty Uncertainty             
at present (%) 
Uncertainty        
in the future (%) 
Dose at the calibration point in water 2.5 1.0 
Additional uncertainty for other points 0.6 0.3 
Beam monitor stability 1.0 0.5 
Beam flatness 1.5 0.5 
Patient data 1.5 1.0 
Patient set-up and organ motion 2.5 2.0 
Overall (excl. dose calculation) 4.3 2.5 
Dose calculation algorithm (multiple levels) 1.0 / 2.0 / 3.0 / 5.0 1.0 / 2.0 / 3.0 
TOTAL 4.4 / 4.7 / 5.2 / 6.6 2.7 / 3.2 / 3.9 
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Increasing dose calculation accuracy will reduce the overall uncertainty in 
the delivered dose. But due to the significant contributions of several 
other factors, the use of extremely accurate dose calculation methods will 
not automatically lead to extremely low uncertainties in clinical dose 
delivery. Considering future technological improvements, however, the 
importance of dose calculation accuracy will increase. At present, it is 
generally believed that dose calculation accuracy in RT should be within 2 
- 3% (one standard deviation) [88]. 
1.8.2 Monte Carlo dose calculation accuracy 
For MC calculations, the degree of accuracy that can be achieved is 
determined mainly by the following factors [90]: 1) how accurately the 
treatment beams are modeled with respect to energy and directional 
distribution; 2) the accuracy of the cross section data used to simulate the 
various interactions between ionizing radiation and matter; 3) how 
accurately the patient geometry and tissue properties relevant to the 
radiation interactions are modeled; and 4) the statistical uncertainties 
inherently associated with MC simulations.  
The modeling of external RT photon beams has been reviewed in detail 
by Verhaegen and Seuntjens [82]. Rogers et al. have described the 
accuracy obtainable with EGS [91]. Additionally, Rogers and Bielajew 
have discussed the accuracy of the available cross section data [92]. 
Within the scope of this thesis, the following paragraphs address some 
patient-related issues in MC (heterogeneities, CT conversion and 
conversion to dose to water) as well as the stochastic nature of MC in 
more detail. 
1.8.2.1 Electron disequilibrium 
Loss of electron equilibrium occurs when there is an imbalance between 
the number of electrons entering and leaving a small region of dosimetric 
interest, i.e. between the number of absorbed and produced electrons. As 
the attenuation of the photon beam cannot be neglected with respect to 
the electron range, only transient electron equilibrium can be achieved for 
external MV photon beam RT [87]. Dose calculation is greatly simplified 
in the presence of (transient) electron equilibrium, since no detailed 
tracking of electron trajectories is required. Unfortunately, electron 
equilibrium is lost within patients at the beam edges and in the presence 
of tissue inhomogeneities. 
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Figure 1.11. Illustration of the occurrence of electron disequilibrium at the beam edge (a) and 
at the interface between lower and higher density tissues (b) for a schematic lung cancer case 
[93]. 
Loss of electron equilibrium causes a dosimetric blurring of the beam 
edges as scattered electrons originating inside the beam deposit energy 
outside the beam’s aperture. The effect increases as the electron range 
increases, i.e. as the energy of the photon beam increases or as the mass 
density of the tissue decreases. For extremely small or highly irregular 
treatment fields, commonly encountered in IMRT, even transient electron 
equilibrium may be completely inexistent. Moreover, at the interface 
between tissues with different mass density values, the number of 
electrons that leave the higher density tissue and deposit energy within 
the lower density tissue is higher than the number of electrons doing the 
opposite. This causes a regional overdosage within the lower density 
tissue close to the interface. Figure 1.11 illustrates both situations of 
electron disequilibrium for a schematic lung cancer case. 
To perform accurate dose calculations within regions of electron 
disequilibrium, precise modeling of secondary electron transport is 
required. With regard to IMRT patient dose calculations, lung cancer and 
head and neck cancer cases are particularly challenging, due to the 
presence of tumor tissue close to or within low density tissue like the 
lungs or air cavities like the sinuses. Even sophisticated analytical dose 
calculation algorithms like CS may lead to deviations larger than 10% 
from measurements at lung-tissue or bone-tissue interfaces and in 
rebuild-up regions behind air cavities [94-97]. As secondary electron 
transport is modeled most accurately by MC codes like EGSnrc, they can 
be used for accurate patient dose calculations provided that patient 
geometry modeling and tissue characterization are performed 
adequately. 
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1.8.2.2 CT conversion 
The patient geometry is usually derived from CT data. In this way, a 
rectangular voxel geometry with adequate spatial resolution is readily 
obtained. A CT number H, expressed in Hounsfield units (HU), is 
associated with each image voxel. The CT number is related to the linear 
attenuation coefficient µ of the material within the voxel as follows: 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
−= 11000
water
H
µ
µ . 
To model the attenuation of a primary photon beam in a medium other 
than water, conventional dose calculation algorithms apply tissue 
heterogeneity corrections. Because the correlation between the correction 
factors and tissue electron density is well known, CT scanners are usually 
calibrated in terms of electron density [98]. The effect of electron density 
on photon dose calculations has recently been assessed by Seco and Evans 
[99]. For RT beams with photon energies between 0.1 and 10 MeV, 
Compton scattering is the dominant interaction process within human 
tissues. The probability for Compton interaction is directly proportional 
to the electron density of the tissue. At CT imaging energies, however, the 
importance of the photo-electric and Rayleigh scattering strongly 
increases, especially within tissues with a high effective atomic number 
like bone. Therefore, it is advisable to use the highest available energy on 
the CT scanner for RT treatment planning. Although an increased tube 
potential slightly worsens the contrast of the resulting image, the 
contrast-to-noise ratio still improves thanks to a decrease in noise from 
the larger number of photons that is produced [100]. 
Unlike conventional dose calculation algorithms, MC dose engines 
require values for the mass density and the elemental material 
composition within each patient voxel. From these data, the probabilities 
of different interactions are derived using tabulated cross section 
information. Schneider et al. showed that human tissues cannot be 
uniquely resolved in terms of mass density and elemental composition by 
means of their CT number, especially in the range of soft tissues between 
0 and 100 HU [101].  However, they did not further investigate the 
dosimetrical effect of this limitation. Values for the mass density can be 
derived from the CT number in a continuous way [102]. To correlate the 
CT number with the elemental composition of tissues, the CT number 
scale is often divided into a discrete number of subsets [103-106]. 
Typically, six or less different media are defined, e.g. air, lung, fat, 
muscle, cartilage and bone (figure 1.12). Verhaegen and Devic have 
Chapter 1: Introduction 
 25
shown that the misassignment of media can lead to large errors in patient 
dose calculations (up to 10% for MV photons) [107]. 
Figure 1.12. Division of the CT number scale into 6 tissue subsets initially implemented in 
MCDE.  
Alternatively, some MC codes directly convert CT numbers into 
interaction probabilities, e.g. the electron code VMC [108] and its photon 
extension XVMC [109]. The main advantage of this approach is that there 
is no need to specify any boundaries separating tissue subsets. However, 
due to the complexity of the interaction processes some approximations 
have to be introduced. Moreover, the implementation into existing MC 
software is not straightforward. 
1.8.2.3  Conversion of dose to medium to dose to water. 
Whereas most conventional dose calculation algorithms for external 
photon beam RT report dose to water, MC calculates dose to medium. To 
compare MC results with results obtained by conventional systems, the 
MC dose distributions must thus be converted to dose to water. 
Additionally, dosimetry calibration protocols are generally based on 
absorbed dose to water standards. Although it would be possible to 
convert measurements and conventional dose results to dose to medium, 
the most important reason for converting dose to medium to dose to 
water is that TCP and NTCP data are usually given in terms of dose to 
water and it will take a lot of time and effort before biological data can be 
made available in terms of dose to medium. Liu and Keall have 
elaborated on this issue in a point-counterpoint discussion [110]. 
Siebers et al. have proposed a method to convert dose to medium to dose 
to water by applying Bragg–Gray cavity theory [111]. A single correction 
factor is used for each material (except for air) throughout the field for a 
given photon energy. Compared to an on-line (at each energy deposition 
event during the MC simulations) conversion of dose to medium to dose 
to water, their post-processing method was shown to be of equal value. 
The conversion factor for a certain material can be computed as the ratio 
of the water and medium mass stopping powers at an effective electron 
energy of 1 MeV. The difference between the conversion factors of soft 
and bone tissues easily exceeds 10%. Again, this illustrates the importance 
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of accurate patient and tissue property modeling for accurate MC dose 
calculations. 
1.8.2.4 The stochastic nature of Monte Carlo 
Unlike analytical dose calculation algorithms, MC is a stochastic method 
providing an average dose value and a value for the statistical uncertainty 
(σ) on the average dose within each scoring voxel. The statistical variance 
(σ2) is inversely proportional to the number of energy deposition events 
scored within the voxel. Therefore, an increase of the total number of 
simulated histories, a decrease of the voxel size or a decrease of the mass 
density assigned to the voxel all result in an increase of the statistical 
variance. For an IMRT treatment plan delivered to a certain patient 
geometry with a fixed voxel size, the statistical variance on the resulting 
dose distribution can only be reduced by increasing the MC simulation 
time. Severe noise is inevitably encountered within air cavities, as the 
mass density of air is about one thousand times smaller than that of soft 
tissues. In clinical practice, air may make up a significant portion of the 
PTV, e.g. in case of ethmoid sinus cancer (figure 1.13). 
 
Figure 1.13. Transversal CT image of an ethmoid sinus cancer patient. The anatomical 
contours of the PTV (red), skin (blue), retinas (orange), optic nerves (green) and optic chiasm 
(cyan) are shown. The PTV contains a significant amount of air. 
The statistical noise not only causes a degradation of the vizualisation of 
dose distributions [112], but may also mislead the optimization engine or 
lead to erroneous evaluation of clinical treatment plans. Several authors 
have studied the effect of statistical uncertainties on the evaluation of 
dose distributions [113,114] and radiobiological dose indices [115], as well 
as their impact on the inverse treatment planning process [116,117]. 
Moreover, denoising techniques have been developed to remove the 
effect of statistical uncertainties on dose-volume histograms (DVHs) 
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[118,119] or entire 3D dose distributions [112,120-124]. Denoising can 
decrease MC simulation times by a factor of ten, at the cost of accuracy 
[122,125]. 
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Chapter  2  
Objectives and outline 
2.1 Objectives and outline 
Considering the recent progress in biological imaging techniques, the first 
objective of this thesis was to implement BCRT at GUH. A constrained 
linear relationship was established between the biological image signal 
intensity and the desired dose within each patient voxel. The practical 
implementation involved the development of a new tool to generate 
initial beam segments based on biological imaging information, and an 
extension of the objective function. Finally, new ways for evaluating 
intentionally non-homogeneous dose distributions were developed to 
assess the obtained biological conformity. Details on the implementation 
can be found in Publication 1: “Implementation of biologically conformal 
radiation therapy (BCRT) in an algorithmic segmentation-based inverse 
planning approach” (p. 45). 
The next objective of this thesis was to validate the feasibility of BCRT 
treatment planning and to compare the plan characteristics of dose 
painting and dose painting-by-numbers. Because of the existing FDG-PET 
based dose painting phase I clinical trial at GUH [1], an FDG-PET based 
dose painting-by-numbers planning study was performed on 15 head and 
neck cancer patients. Since the majority of recurrences occurs within the 
high-dose regions, head and neck tumors are eligible for focused dose 
escalation [2-4]. Moreover, motion is conveniently limited within the head 
and neck region and is reduced by means of immobilization masks. As in 
the phase I clinical trial, two levels of dose escalation were investigated: 
2.5 and 3 Gy per fraction. Treatment plans from BCRT and dose painting 
were compared through an extensive set of clinically important dose-
volume parameters for both targets and organs at risk. The results of this 
study are reported in  Publication 2: “[18F]fluoro-deoxy-glucose positron 
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emission tomography ([18F]FDG-PET) voxel intensity-based intensity-
modulated radiation therapy (IMRT) for head and neck cancer” (p. 59). 
Experiments involving phantom measurements have already shown that 
MC calculations are clearly superior to conventional dose calculation 
algorithms near low density materials and around air cavities [5-9]. 
However, there is a lack of data evaluating the performance of highly 
developed analytical dose calculation algorithms compared to MC 
computations in a clinical setting. Due to the presence of electronic 
disequilibrium, the calculation of patient dose distributions for lung 
cancer makes great demands on dose calculation systems. Therefore, the 
third objective of this thesis was to evaluate the accuracy of MC, CS and 
PB algorithms for lung cancer patient dose calculations. Two IMRT 
treatment plans (using either 6 MV or 18 MV photons) were created for 
each of ten lung cancer patients. MCDE, two commercial CS 
implementations and one commercial PB algorithm were used to 
recompute the final dose distribution for each treatment plan. The 
resulting dose distributions were compared through an extensive set of 
clinically important dose-volume parameters for both targets and organs 
at risk. The results are presented in Publication 3: “Accuracy of patient 
dose calculation for lung IMRT: A comparison of Monte Carlo, 
convolution/superposition, and pencil beam computations” (p. 79). 
The comparison of MC and CS algorithms for lung cancer lead to another 
interesting clinical application. At GUH, 18 MV photons are generally 
used for IMRT treatment of lung cancer. This practice has originated from 
experience with the IMRT optimization software, which was able to select 
both 6 MV and 18 MV photons using a CS dose calculation algorithm. 
However, to minimize lateral electronic disequilibrium and to reduce the 
irradiated volume of normal lung, low-energy photons have been advised 
for radiotherapy of lung cancer [10]. The fourth objective of this thesis 
therefore was to evaluate whether 6 MV photon beams result in better 
IMRT treatment plans for lung cancer than 18 MV photon beams. For this 
purpose, target dose coverage and organ at risk sparing were investigated 
by comparing 6 MV and 18 MV dose distributions computed by MCDE 
and a commercial CS algorithm for ten IMRT lung cancer patients. The 
results of this study are reported in Publication 4: “Comparison of 6 MV 
and 18 MV photons for IMRT treatment of lung cancer” (p. 101). 
The conversion of CT numbers into material properties is one of the main 
factors that determine the accuracy of MC patient dose calculations. The 
fifth objective of this thesis was to develop a CT conversion scheme 
suitable for photons and electrons, and to evaluate the proposed CT 
conversion scheme in a European multi-center study. Firstly, the 
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attenuation and energy deposition properties of human tissues and their 
constituent elements were studied. The proposed CT conversion method 
is based on the stoichiometric calibration method of Schneider et al. [11] 
and makes use of dosimetrically equivalent tissue subsets. It was 
validated using virtual MC slab phantoms and a real CT phantom 
containing different inserts. Finally, the investigation was focused 
towards the clinical evaluation of patient treatment plans. Attention was 
paid to the conversion from dose to medium to dose to water in order to 
assess the magnitude of errors that may arise with the conversion if the 
wrong material composition is assigned. The CT conversion study is 
presented in Publication 5: “Conversion of CT numbers into tissue 
parameters for Monte Carlo dose calculations: a multi-centre study” 
(p.115). 
Due to the stochastic nature of MC, statistical uncertainties are inherently 
associated with the resulting dose distributions. The amount of noise 
decreases as the simulation time increases. From a practical point of view 
it is thus important to determine the optimum, i.e. minimum, number of 
simulated histories at which a clinical treatment plan can still be 
evaluated adequately. Therefore, the sixth objective of this thesis was to 
develop uncertainty-based stopping criteria for MC patient dose 
calculations. Upper limits on both the relative and absolute statistical 
uncertainties within each patient voxel were implemented into MCDE. 
Calculations were performed taking into account the PTV only, or the 
PTV and a set of critical organs. Both approaches were compared for 
three clinical treatment plans. The evaluation of the observed dose 
differences can be found in Publication 6: “Evaluation of uncertainty-
based stopping criteria for Monte Carlo calculations of intensity-
modulated radiotherapy and arc therapy patient dose distributions” (p. 
147). 
The final objective of this thesis was to investigate the impact of MC on 
IMRT optimization. MC dose distributions were integrated into the 
iterative IMRT optimization process at GUH to evaluate whether 
treatment plans obtained using conventional dose calculation algorithms 
could be further improved. Two different methods were developed to 
incorporate the MC dose distributions. The influence of large air cavities 
on the outcome of the optimization process was illustrated for a paranasal 
sinus cancer case. The results of this study are presented in Publication 7: 
“The influence of air cavities within the PTV on Monte Carlo based IMRT 
optimization” (p. 165). 
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In conclusion, the overall objective of this thesis was to improve RT by 
incorporating biological imaging information into the IMRT treatment 
planning process and by using MC as a benchmark for RT dose 
calculations. For this purpose, suitable software applications were 
developed, implemented in the clinic and evaluated. 
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Abstract 
The development of new biological imaging technologies offers the opportunity to further 
individualize radiotherapy. Biologically conformal radiation therapy (BCRT) implies the use of 
the spatial distribution of one or more radiobiological parameters to guide the IMRT dose 
prescription. Our aim was to implement BCRT in an algorithmic segmentation-based planning 
approach. A biology-based segmentation tool was developed to generate initial beam segments 
that reflect the biological signal intensity pattern. The weights and shapes of the initial segments 
are optimized by means of an objective function that minimizes the root mean square deviation 
between the actual and intended dose values within the PTV. As proof of principle, [18F]FDG-
PET-guided BCRT plans for two different levels of dose escalation were created for an 
oropharyngeal cancer patient. Both plans proved to be dosimetrically feasible without violating 
the planning constraints for the expanded spinal cord and the contralateral parotid gland as 
organs at risk. The obtained biological conformity was better for the first (2.5 Gy per fraction) 
than for the second (3 Gy per fraction) dose escalation level. 
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1. Introduction 
The development of radiation therapy has always relied strongly on the 
available imaging technologies. Anatomical imaging techniques such as 
computed tomography (CT), magnetic resonance imaging (MRI) and 
ultrasound (US) can visualize spatial changes in physical properties 
within patients. Additionally, tumour biology plays an important role in 
the diagnosis, treatment decision-making and the assessment of 
therapeutic response (Xing et al 2006). Recent advances in biological 
imaging techniques, mainly based on positron emission tomography 
(PET), single photon emission tomography (SPECT) and magnetic 
resonance spectroscopy (MRS), aim at revealing the spatial biology 
distribution within patients (Van de Wiele 2006, Verhey et al 2006). 
Highly structured dose distributions can be delivered using 
intensity modulated radiation therapy (IMRT). In current clinical practice, 
IMRT optimization is based on the assumption of a uniform biology 
distribution within each target volume and aims at achieving 
geometrically conformal dose distributions. However, the use of 
biological imaging in radiotherapy treatment planning has become 
increasingly popular. In the first instance, biological images can aid in the 
delineation of target volumes, which are subsequently planned to receive 
a uniform dose. However, by using the entire spatially heterogeneous 
distribution of biological information to create the IMRT treatment plan, 
truly biologically conformal dose distributions can be delivered (Ling et al 
2000). The biologically conformal radiation therapy (BCRT) treatment 
planning process involves several steps, from the registration of 
anatomical and biological images over the quantification of the biological 
image signal and definition of the relationship between signal intensity 
and prescription dose to the optimization of the treatment plan. 
Several authors have described the implementation of BCRT into 
the inverse treatment planning process (Xing et al 2002, Alber et al 2003, 
Das et al 2004, Yang and Xing 2005). At our institution, IMRT treatment 
plans are created by optimizing the weights and shapes of initially 
generated beam segments. Our aim was to implement BCRT in this 
algorithmic segmentation-based inverse planning approach. This note 
describes the development of a new tool to generate initial beam 
segments based on biological imaging information and the changes that 
were made to the objective function. As proof of principle, an exemplary 
patient case of [18F]fluoro-deoxy-glucose PET (FDG-PET)-guided BCRT 
for oropharyngeal cancer is presented. 
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2. Methods 
2.1. A bound-constrained linear model 
Although it is an essential step in the BCRT planning process, translating 
the available biological imaging information into the most desirable dose 
distribution within a tumour is not at all obvious. Radiobiological models 
can generate this dose distribution by maximizing the tumour control 
probability value, provided all necessary biological parameters are 
known (Xing et al 2006, pp 194–5). However, as our knowledge on 
radiobiological parameters is limited and they are hard to extract from the 
available biological images, a more practical approach seems to be the 
best option at present (Xing et al 2006, p 191). Several authors have 
suggested the use of a linear relationship between the prescribed 
radiation dose and the quantified biological signal (S), which is assumed 
to represent the level of metabolic abnormality, in every image voxel 
(Xing et al 2002, Alber et al 2003, Das et al 2004). For our study, we assume 
the following dose prescription within the planning target volume (PTV): 
)( lowhigh
lowhigh
low
lowpresc DDSS
SS
DD −
−
−
+=  for Slow ≤ S ≤ Shigh (1) 
Thus, the prescription dose Dpresc is escalated linearly between Dlow and 
Dhigh, respectively corresponding to Slow and Shigh. The values of Slow, Shigh, 
Dlow and Dhigh can be chosen freely. Additionally, Dpresc = Dlow for voxels 
within the target volume where S ≤ Slow, while Dpresc = Dhigh for voxels 
within the target volume where S ≥ Shigh. 
2.2. BCRT treatment planning: an algorithmic segmentation-based inverse 
approach 
At our institution, IMRT treatment planning is based on class solutions 
and involves direct multi-leaf collimator (MLC) aperture optimization. 
Figure 1 illustrates the BCRT planning strategy. We start from a template 
beam set, characterized by each beam’s isocentre, gantry, table and 
collimator angles, linear accelerator, radiation modality and energy. 
Delineation of target volumes and organs at risk (OARs) on anatomical 
images results in a set of PTV and OAR contours. Anatomical imaging 
also provides the appropriate grid size and resolution, and voxel 
attenuation properties for accurate dose calculation. For every template 
beam, a set of initial beam segments is created by in-house developed 
software. To implement BCRT, the anatomy-based segmentation tool 
(ABST) developed by De Gersem et al (2001a) was replaced by a new 
biology-based segmentation tool (BBST). BBST generates beam segments 
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based on the anatomical contours, the biological imaging signal intensity 
values and the 4 × 4 rigid transformation matrix that characterizes the 
fusion of the anatomical and biological images. Once the initial set of 
segments is created, both segment weights and shapes (MLC leaf 
positions) are optimized by the in-house developed segment outline and 
weight adapting tool (SOWAT) (De Gersem et al 2001b). The optimization 
uses a bio-physical objective function, which was modified to implement 
BCRT. Several SOWAT cycles are performed until the plan acceptance 
criteria are fulfilled. The final beam segments and corresponding weights 
are then combined into a prescription that is suitable for transfer to the 
linear accelerator. The next paragraphs describe BBST and the 
modification of the objective function in detail. 
 
Figure 1. The BCRT planning strategy at Ghent University Hospital. Starting from a template 
beam set, the biology-based segmentation tool creates initial beam segments. The weights 
and MLC shapes of these segments are further optimized by maximizing a bio-physical 
objective function. The final prescription is sent to the linear accelerator. 
2.3. Biology-based segmentation tool 
To implement BCRT, the available biological imaging information is used 
to create initial beam segments. Like ABST, BBST uses one or more PTVs, 
OARs, the skin contours and a template beam as input. Additionally, 
BBST requires the biological imaging signal intensity information and the 
4 × 4 transformation matrix that describes the rotations and translations 
needed for the rigid anatomical–biological image fusion. A detailed 
description of ABST has been given by De Gersem et al (2001a). The next 
paragraphs focus on the new aspects of segmentation involved in BBST; 
parts of the algorithm that are also performed by ABST are reproduced 
only in brief. 
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First, a two-dimensional ‘segmentation grid’ is created in the 
template beam’s isocentric plane. This is the plane through the isocentre 
and perpendicular to the central axis. The pixel size of the grid is 1 × 1 
mm2 and all pixel values are initialized to zero. All target volumes are 
centrally projected from the source point onto this grid. To account for 
penumbra, a user-defined expansion margin is applied to each PTV 
projection. The segmentation grid pixel values inside each PTV projection 
are all set to the same positive value. By projecting the biological imaging 
information onto the segmentation grid, the pixel values within each PTV 
projection are differentiated: for every pixel inside a PTV projection, a 
weighted function of the signal intensity values S is integrated along each 
rayline emanating from the source: 
( ) dsSSS
PTV
low∫ ⎥⎦⎤⎢⎣⎡ −+ −
21 1'1'  (2) 
with S’ = Slow if S ≤ Slow and S’ = Shigh if S ≥ Shigh; otherwise S’ = S. As 
voxels for which the signal S ≤ Slow should receive the same dose (i.e. 
Dlow) as voxels for which S = Slow, and as voxels for which S ≥ Shigh should 
receive the same dose (i.e. Dhigh) as voxels for which S = Shigh, these voxels 
should be taken into account equally during the segment generation, 
hence the introduction of S’. S’ is integrated after multiplication by a 
dimensionless weighting function. Several weighting functions have been 
investigated, including linear, polynomial and exponential functions of 
S’(Slow)-1. The objective function was assessed after one optimization 
cycle, and maximal values were found for the quadratic weighting 
function presented in equation (2). The integration is constrained to 
voxels inside the target volume; ds is the line element along the rayline. 
For each pixel the result is normalized by division of the integral by the 
total pathlength within the PTV along the rayline. Additionally, the user 
is allowed to enter an importance factor for a global scaling of the 
biological contribution to the segmentation grid. Its default value is set to 
1. As the result is added to the corresponding grid value, the 
segmentation grid pixels reflect the biological image signal within each 
PTV projection. 
BBST’s second step involves the central projection of all OARs from 
the source point onto the segmentation grid. A user-defined expansion 
margin is applied to each OAR projection to achieve good sparing. The 
grid values inside each OAR projection are all set to the same, negative 
value. After this, all positive pixel values inside the segmentation grid are 
divided by (1+D), where D is the distance in cm of the pixel to the nearest 
contour point of an expanded OAR projection. This will result in the 
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creation of segments close to and conformally avoiding the OARs, which 
allows for homogeneous irradiation of a target that surrounds a critical 
organ with a rotational technique (Brahme et al 1982). To account for 
patient attenuation, all positive pixel values inside the segmentation grid 
are also divided by (1 + d), where d is the distance in cm of the pixel to the 
entry point through the patient’s surface along the rayline emanating 
from the source point. 
Finally, beam segments can be determined from the iso-value lines 
of the created anatomical–biological segmentation grid. By selecting a 
minimal beam segment area (defined in the isocentric plane) and an area 
multiplication factor, the user can control the total number of beam 
segments created. 
2.4. Optimization of segment weights and shapes: objective function 
SOWAT (De Gersem et al 2001b) optimizes both segment weights and leaf 
positions. The planning goals are expressed through an objective 
function, which is maximized during the optimization. Its mathematical 
expression consists of two major parts. The biological part includes 
tumour control probability and normal tissue complication probability 
factors,  while the physical part is entirely target-related and refers to 
target inhomogeneity and prescription dose values. The objective 
function has been described in detail by De Gersem et al (2001b). 
BCRT optimization requires the minimization of the difference 
between the actual (Dp) and intended (Dpresc) dose values in all dose 
calculation points p (n in total) that are randomly seeded within the target 
structure of interest. Therefore, the following term was added to the 
physical part of the objective function: 
⎥⎥⎦
⎤
⎢⎢⎣
⎡
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The summation index i runs through all target structures involved in the 
BCRT optimization. Fi is a user-defined importance factor, which is used 
to identify the level of priority of BCRT optimization within target i over 
other target structures or other planning goals expressed by the objective 
function. (Dmean)i and (Ddev)i are the mean dose and the root mean square 
deviation between the actual and intended dose values within target 
volume i, respectively: 
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The optimization employs a variant of the algorithm developed by Brent 
(1973) to maximize the objective function. By definition of (3), the 
derivative of the BCRT term with respect to Ddev/Dmean is a linearly 
descending function of this ratio. Thus, the larger Ddev/Dmean, the larger 
the force exerted by the optimization algorithm to reduce the value of this 
ratio will be. 
2.5. Treatment plan evaluation 
The new segmentation tool and the extension of the objective function can 
be evaluated by comparing the dose distribution of the resulting 
treatment plans with the prescribed BCRT dose pattern. For this purpose, 
a quality factor QF was introduced. For every point p within the PTV the 
obtained-over-intended dose ratio Qp = Dp/Dpresc is calculated. This 
information can be visualized in a Q-volume histogram (QVH), by 
display of the partial PTV volume for which Q is greater than or equal to 
each abscissa value. Ideally such a curve would drop down steeply at Q = 
1. QF is defined as the average absolute deviation of Q to 1 within the 
PTV: 
∑ −=
p
pQn
QF 11 .  (5) 
3. Example: [18F]FDG-PET-guided BCRT for oropharyngeal cancer 
As proof of principle, a patient with a squamous cell carcinoma arising 
from the oropharynx was considered. Planning CT images were fused 
with [18F]FDG-PET images. Both sets of images were acquired using a 
thermoplastic mask to immobilize the patient. To escalate the dose within 
the PTV, two BCRT treatment plans were created with Dhigh-values of 2.5 
and 3 Gy per fraction (Gy/fx); Dlow was 2.16 Gy/fx. The escalation phase 
consisted of 10 fractions, while the total treatment consisted of 32 
fractions. Thus, the total PTV prescription dose ranged from 69.12 Gy to 
72.52 Gy, and from 69.12 Gy to 77.52 Gy for the 2.5 Gy/fx and 3 Gy/fx dose 
escalation levels, respectively. As an optimization constraint, the relative 
volume of the 5 mm-expanded spinal cord receiving more than 1.56 Gy/fx 
(V>1.56 Gy/fx) had to be less than 5%. Additionally, sparing of the 
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contralateral parotid gland was attempted. Therefore, the median dose 
Dmed within the spared parotid had to be less than 0.84 Gy/fx. 
Apart from the difference in Dhigh-value, the same segment 
generation and optimization settings were used to create both plans. 
Three optimization cycles were performed and both final treatment plans 
required a minimum number of 2 monitor units (MUs) per segment and 
per fraction. To minimize the influence of PET signal noise on Slow and 
Shigh, the dose was escalated between 25% and 100% of the 95th percentile 
value of the PET signal intensity values within the PTV. BBST was 
performed using a minimal beam segment area of 0.8 cm2 and an area 
multiplication factor of 2.5. The importance factor for BCRT optimization 
of the PTV was equal to 3.5. The importance factors of the PTV for the 
other physical terms of the objective function, which aim to achieve a 
homogeneous target dose, were set to 0 to avoid any conflicts during 
optimization. The other forces driving the optimization were the 
biological terms of the objective function that aimed at sparing the 
expanded spinal cord and the contralateral parotid gland. Their 
importance factors were set to 1. 
 
Table 1. Summary of treatment planning results for the 2.5 Gy per fraction (Gy/fx) plan, the 
original 3 Gy/fx plan and the additionally created 3 Gy/fx plans. 
 2.5 Gy/fx 
3 Gy/fx 
original 
plan 
3 Gy/fx 
more 
segments
3 Gy/fx 
changed 
importance
3 Gy/fx  more 
segments and 
changed 
importance 
3 Gy/fx    
using 
ABST 
Initial no. of segments 86 86 121 - - 88 
Final no. of segments 55 54 58 58 55 51 
QF (%) 1.8 3.4 3.4 3.1 3.0 3.4 
Expanded spinal cord 
V>1.56Gy/fx (%) 
0.3 0.0 0.0 1.7 1.8 0.0 
Spared parotid gland 
D50 (Gy/fx) 
0.66 0.66 0.67 0.76 0.69 0.68 
Total no. of MUs/fx 523 686 676 760 761 661 
Average no. of MUs/fx 
per segment 9.5 12.7 11.7 13.1 13.8 13.0 
 
Table 1 summarizes the planning results. Initially, 86 beam 
segments were created by BBST. The final plans consisted of 55 (2.5 Gy/fx) 
and 54 (3 Gy/fx) beam segments and delivered a total number of 523 (2.5 
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Gy/fx) and 686 (3 Gy/fx) MUs/fx, respectively. Thus, on average 9.5 (2.5 
Gy/fx) and 12.7 (3 Gy/fx) MUs/fx were delivered per segment. Figures 2 
and 3 illustrate the resulting dose distribution superimposed on the 
original PET images for Dhigh = 2.5 Gy/fx. Dose–volume histograms 
(DVHs) of the PTV, the expanded spinal cord and the spared parotid 
gland are shown in figure 4 for both escalation steps. The planning 
constraints were fulfilled: the V>1.56 Gy/fx-value for the expanded spinal 
cord was 0.3% (2.5 Gy/fx) and 0.0% (3 Gy/fx), while the median dose 
within the spared parotid gland was 0.66 Gy/fx for both escalation steps. 
Figure 5 shows the QVHs of the PTV for both escalation steps. The QF-
value was 1.8% for Dhigh = 2.5 Gy/fx, and 3.4% for Dhigh = 3 Gy/fx. By 
increasing Dhigh, the dose gradients required within the PTV become 
steeper, while their maximal steepness is limited by the penumbra width 
of the delivered beam segments. This depends on the design of the linear 
accelerator’s treatment head and on the field shape of the individual 
segments. 
 
To see whether the QF-value of the 3 Gy/fx plan could be improved 
by taking into account more initial beam segments, an additional 
treatment plan was generated. All parameters were the same as for the 
original 3 Gy/fx plan, except for the area multiplication factor which was 
decreased from 2.5 to 1.5. The results are summarized in table 1. Initially, 
121 beam segments were generated by BBST. However, after optimization 
only 58 segments were retained for the final plan, which is comparable to 
the final number of segments (54) of the original 3 Gy/fx plan. The V>1.56 
Gy/fx-value for the expanded spinal cord was 0.0% for the plan with more 
segments, while the median dose within the spared parotid gland was 
0.67 Gy/fx. The QF-value was equal to 3.4%. It is clear that the original 3 
Gy/fx plan could not be improved by creating more initial beam 
segments. 
Figure 4 shows a larger separation between the DVHs of the PTV 
and of the expanded spinal cord for the 3 Gy/fx plan than for the 2.5 Gy/fx 
plan. To investigate whether the QF-value of the 3 Gy/fx plan could be 
improved by allowing a higher dose to be delivered to the expanded 
spinal cord, two additional treatment plans were generated.  Starting 
from the original 3 Gy/fx plan and from the above-mentioned 3 Gy/fx 
plan with more initial beam segments, an additional optimization cycle 
was performed with changed importance factors. While the importance 
factor of the expanded spinal cord in the objective function was changed 
from 1 to 0.1, the importance factor of the BCRT term was strongly 
increased from 3.5 to 35. This resulted in modified plans, consisting of 58 
(changed importance) and 55 (more segments and changed importance) 
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beam segments, respectively. The planning results are summarized in 
table 1. V>1.56 Gy/fx was raised to 1.7% (changed importance) and 1.8% 
(more segments and changed importance), while the median dose 
delivered to the contralateral parotid gland was raised to 0.76 Gy/fx 
(changed importance) and 0.69 Gy/fx (more segments and changed 
importance). However, even with these extreme settings QF could only be 
improved slightly to 3.1% (changed importance) and 3.0% (more 
segments and changed importance), respectively. It is clear that the 3 
Gy/fx plans could not be greatly improved by allowing the dose delivered 
to the spinal cord to increase (within tolerance). 
 
Figure 2. [18F]FDG-PET-guided BCRT dose distribution superimposed on the original PET 
images for Dhigh = 2.5 Gy per fraction, shown for 2 transverse planes (left: 1.8 cm above the 
isocentre, right: 1.2 cm below the isocentre). The 1.6, 1.8, 2.1, 2.2, 2.3, 2.4 and 2.5 Gy per 
fraction isodose lines are indicated in orange. The contours of the PTV (red), the expanded 
spinal cord (cyan) and the spared parotid gland (yellow) are shown. 
 
Figure 3. [18F]FDG-PET-guided BCRT dose distribution superimposed on the original PET 
images for Dhigh = 2.5 Gy per fraction, shown for 2 sagittal planes (left: 0.3 cm to the left of the 
isocentre, right: 4 cm to the left of the isocentre). The 1.6, 1.8, 2.1, 2.2, 2.3, 2.4 and 2.5 Gy per 
fraction isodose lines are indicated in orange. The contours of the PTV (red) and the 
expanded spinal cord (cyan) are shown. 
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Figure 4. Dose–volume histograms of the PTV, the expanded spinal cord and the spared 
parotid gland for both escalation steps (2.5 and 3 Gy per fraction). The crosses represent the 
planning constraints. 
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Figure 5. Q-volume histograms of the PTV for both escalation steps (2.5 and 3 Gy per 
fraction). 
To investigate the influence of using BBST instead of ABST, a fourth 
additional treatment plan was generated. All parameters were the same 
as for the original 3 Gy/fx plan, except for the fact that ABST was used to 
create initial beam segments instead of including the biological part of the 
segmentation grid. This resulted in the generation of 88 initial beam 
segments, of which 51 segments were retained for the final plan. The 
results are summarized in table 1. QF was equal to 3.4%, while V>1.56 Gy/fx 
for the expanded spinal cord was equal to 0.0% and the median dose 
within the spared parotid gland was 0.68 Gy/fx. For this patient the use of 
ABST instead of BBST did not result in a worse BCRT treatment plan after 
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the same number of optimization cycles, but this is unlikely to hold true 
for all possible patient cases. Although the use of SOWAT clearly 
minimizes the dependence of the final treatment plan on the initially 
created beam segments, we still consider BBST preferable to create initial 
beam segments for BCRT due to its capability of incorporating biological 
imaging data into the segmentation grid. 
Only one patient case was presented in this note as proof of 
principle. In a separate planning study BCRT plans (for dose escalation 
levels of 2.5 and 3 Gy/fx) were compared to so-called PET contour-based 
plans, in which a boost dose of 2.5 Gy/fx was prescribed homogeneously 
to an automatically delineated PET lesion inside the PTV, for 15 patients 
(Vanderstraeten et al 2006). Thus, the PET contour-based plans did not 
use BBST nor the BCRT term of the objective function. According to a 
paired, two tailed t-test for those 15 patients the BCRT 3 Gy/fx plans had 
significantly more beam segments than the BCRT 2.5 Gy/fx plans (49 ± 6 
(1σ) versus 46 ± 4), which in their turn had significantly more beam 
segments than the contour-based plans (41 ± 7). The total number of 
MUs/fx was not significantly different between the contour-based (466 ± 
57) and the BCRT 2.5 Gy/fx (503 ± 26) plans, but was obviously 
significantly higher for the BCRT 3 Gy/fx plans (645 ± 37) than for the 
BCRT 2.5 Gy/fx plans. The average number of MUs/fx per segment was 
not significantly different between the contour-based (11.7 ± 2.0) and the 
BCRT 2.5 Gy/fx (11.1 ± 1.2) plans, but was significantly higher for the 
BCRT 3 Gy/fx plans (13.3 ± 1.2) than for the BCRT 2.5 Gy/fx plans. 
In the future similar planning studies must be performed for other 
tumour sites to confirm the feasibility of BCRT dose escalation and to 
evaluate its effect on the dose delivered to the organs at risk in order to 
facilitate the clinical implementation of the BCRT technique proposed in 
this note. The quality of the final treatment plan is guarded by SOWAT. 
4. Conclusions 
The development of new biological imaging technologies offers the 
opportunity to further individualize radiotherapy. Biologically conformal 
radiation therapy (BCRT) implies the use of the spatial distribution of one 
or more radiobiological parameters to guide the IMRT dose prescription. 
By developing a biology-based segmentation tool and extending the 
objective function, BCRT could be implemented in an algorithmic 
segmentation-based inverse planning approach. By projecting the 
biological imaging information onto the isocentric plane of each template 
beam, BBST creates initial beam segments that reflect the biological signal 
intensity pattern. The weights and shapes of the initial segments are 
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optimized using the new objective function, which minimizes the root 
mean square deviation between the actual and intended dose values 
within the PTV. BCRT plans for two different dose escalation steps were 
used to demonstrate the feasibility of [18F]FDG-PET-guided BCRT for 
oropharyngeal cancer. The obtained biological conformity was better for 
the first (2.5 Gy per fraction) than for the second (3 Gy per fraction) dose 
escalation level. 
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Abstract 
Background and purpose: Focused dose escalation may improve local control in head and neck 
cancer. Planning results of [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-
PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) were compared with 
those of PET contour-based IMRT. 
Patients and methods: PET contour-based IMRT aims to deliver a homogeneous boost dose to a 
PET-based subvolume of the planning target volume (PTV), called PTVPET. The present PET 
voxel intensity-based planning study aims to prescribe the boost dose directly as a function of 
PET voxel intensity values, while leaving the dose distribution outside the PTV unchanged. 
Two escalation steps (2.5 and 3 Gy/fraction) were performed for 15 patients. 
Results: PTVPET was irradiated with a homogeneous dose in the contour-based approach. In the 
voxel intensity-based approach, one or more sharp dose peaks were created inside the PTV, 
following the distribution of PET voxel intensity values. 
Conclusions: While PET voxel intensity-based IMRT had a large effect on the dose distribution 
within the PTV, only small effects were observed on the dose distribution outside this PTV and 
on the dose delivered to the organs at risk. Therefore both methods are alternatives for boosting 
subvolumes inside a selected PTV. 
Keywords: [18F]FDG-PET; Voxel intensity; IMRT; Optimization; Head and neck cancer 
Biologically conformal RT and Monte Carlo dose calculations in the clinic 
 60
 Highly structured dose distributions can be delivered using intensity-
modulated radiation therapy (IMRT), which serves two purposes. Firstly, 
IMRT can reduce toxicity by allowing a selective reduction of the dose to 
organs at risk (OARs). With regard to head and neck cancer, results of 
case series indeed suggest that conformal avoidance of radiosensitive 
structures like parotid or lacrimal glands, optic or auditory pathways has 
resulted in less morbidity [8,23,33]. Secondly, by reducing the dose to 
critical organs relative to the tumour prescription dose, IMRT techniques 
also allow dose escalation with the aim to improve local control. The 
target for dose escalation is mainly the gross tumour volume (GTV) [7,15]. 
Since [18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-
PET) exhibits a higher accuracy for GTV delineation than magnetic 
resonance imaging (MRI) or computed tomography (CT) [13], it is the 
preferred modality for defining the boost volume. In a phase I trial that is 
currently conducted at our institution, the boost dose is prescribed 
medianly to an automatically delineated PET-lesion [12]. The resulting 
dose distributions were used as a reference for the present planning 
study, in which the boost dose was not prescribed to a contoured volume 
but directly as a function of PET voxel intensity values. The rationale for 
testing this approach is explained in the Discussion section. The purpose 
of our study was to investigate the feasibility of creating PET voxel 
intensity-based IMRT dose distributions in head and neck tumours for 
different levels of dose escalation, without compromising the planning 
constraints set for the OARs. Therefore, we have compared the dosimetric 
characteristics of conventional PET contour-based dose escalation with 
PET voxel intensity-based planning for 15 patients and two different 
escalation steps (2.5 and 3 Gy/fraction). 
 
Materials and methods 
Lay-out of the study 
At Ghent University Hospital (GUH), IMRT is routinely performed 
to treat patients with laryngopharyngeal cancer. The total treatment 
consists of 32 fractions (fx). Multiple dose levels are delivered in a 
simultaneous integrated boost (SIB) approach [46]. Planning CT and PET 
scans are performed for each patient. Both are acquired in treatment 
position using a thermoplastic mask for immobilization and are fused 
manually using Pinnacle (Philips Medical Systems, Best, The 
Netherlands) [11]. GTVPET is automatically segmented based on the 
source-to-background ratio following the method of Daisne et al. [12]. 
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GTVCT is delineated based on the planning CT, supplemented with 
information from physical examination and complementary diagnostic 
imaging data (CT and/or MRI), but not PET. Lymph node regions (LNRs) 
are contoured seperately based on the guidelines of Grégoire et al. [27]. A 
primary CTV (pCTV) containing the microscopic extension locally around 
GTVCT is delineated manually based on the idea of compartmental 
tumour spread [24,29]. If necessary, this pCTV is extended manually to 
encompass GTVPET. All CTV subvolumes (pCTV and all separate LNRs) 
are grouped according to the prescription dose levels in CTV69+PET, CTV66, 
CTV62 and CTV56. The grouping criteria are presented in Table 1. 
Table 1. Fraction (fx) dose prescription levels for the PET contour-based phase I trial during 
the escalation phase and for both escalation steps of the PET voxel intensity-based planning 
study.  
 Description SIB(cb)250 
(cGy/fx) 
SIB(vib)216-250 
(cGy/fx) 
SIB(vib)216-300 
(cGy/fx) 
PTVPET PET lesion 250   
PTV69+PET Macroscopic tumour + margin for 
microscopic disease 
 216 - 250 216 - 300 
PTV69 PTV69+PET - PTVPET 216   
PTV66 Resected lymph node regions (LNRs) 
with capsular rupture 
206 206 206 
PTV62 Resected LNRs containing invaded 
lymph nodes without capsular rupture 
194 194 194 
PTV56 Elective LNRs 175 175 175 
PTV names and abbreviations are defined in the Lay-out of the study section. Fraction dose 
intervals are denoted with a hyphen. 
 
 
Figure 1. Illustration of a possible PTV configuration. Each PTV index refers to the total 
prescription dose in Gray. PTVPET is the PTV based on the automatically delineated PET-
lesion. In this figure, it consists out of two separate subvolumes. For optimization purposes, 
each PTV stays away at least 6 mm from each PTV with a higher prescription dose and 
excludes a 6 mm-wide build-up region. 
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Planning target volumes (PTVs) are constructed by expanding each CTV 
with a 3 mm-margin to account for patient motion and set-up errors 
during treatment. PTVPET is created by expanding GTVPET with a 3 mm-
margin. Moreover, each PTV is adjusted to avoid conflicts during 
optimization as we prioritize the highest dose prescription levels: for x>y, 
PTVy is made to exclude PTVx after expansion with a 6 mm-margin. All 
PTV’s also exclude a 6 mm-wide build-up region. The procedures are 
described in detail elsewhere [20]. Fig. 1 schematically illustrates a 
possible PTV configuration. 
The total treatment is divided in two phases of 10 and 22 fractions, 
respectively. During the escalation phase (fractions 1–10), the above-
mentioned phase I trial prescribes a median dose of 250 cGy/fraction 
(cGy/fx) to PTVPET, while PTV69 medianly receives 216 cGy/fx. During 
the second phase (fractions 11–32), 216 cGy/fx is delivered to the entire 
PTV69+PET volume. This contour-based (cb) SIB technique will further be 
denoted as SIB(cb)250, referring to the PTVPET escalation dose. For this 
paper, the dose distribution obtained by SIB(cb)250 during the escalation 
phase is used as the reference for a planning study in which PTVPET was 
not used but in which the dose escalation was based directly on the PET 
voxel intensity values within PTV69+PET. As the prescribed dose levels 
within PTV69+PET range between 216 and 250 cGy/fx or 300 cGy/fx, these 
planning studies are further denoted as SIB(vib)216–250 and SIB(vib)216–300 
(vib stands for voxel intensity-based). Table 1 summarizes the 
prescription dose levels. Fig. 2 illustrates the principle of PET voxel 
intensity-based IMRT. 
Planning objectives 
For PET voxel intensity-based IMRT, the relationship between the 
wanted dose distribution and the voxel intensities (I) within PTV69+PET has 
to be defined. Given the lack of detailed knowledge on the radiobiological 
meaning of the magnitude of the PET voxel intensities, we chose to 
implement a proportional relationship between voxel intensity and 
prescribed dose. This was also proposed by Das et al. [14]. Within 
PTV69+PET, dose values increase linearly with voxel intensity between Dlow 
and Dhigh, respectively, corresponding to Ilow and Ihigh, and the prescribed 
dose DI becomes: 
)( lowhigh
lowhigh
low
lowI DDII
II
DD −
−
−
+=  (1) 
The prescribed dose within PTV69+PET voxels where I≤Ilow is Dlow, while 
Dhigh is the prescribed dose within PTV69+PET voxels where I≥Ihigh. To 
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minimize the influence of PET signal noise on Ilow and Ihigh, the dose was 
escalated between 25 and 100% of the 95th percentile PET voxel intensity 
value within PTV69+PET (I95%): Ilow=0.25×I95%, Ihigh=I95%. 
PET voxel intensity-based plans were made for 15 patients of the 
phase I trial (four hypopharynx, five oropharynx, six larynx). For PTV56, 
PTV62 and PTV66, the partial volume receiving less than 95% of the pre-set 
median dose (V<95%) had to be less than 5%. For every patient the 
following set of OARs was delineated: spinal cord, brainstem, parotid 
glands and mandible. The spinal cord and the brainstem were expanded 
with margins of 5 and 3 mm, respectively. The partial volume of the 
expanded spinal cord receiving more than 50 Gy (V>50Gy) should not 
exceed 5%. For 10 out of the 15 patients sparing of the contralateral 
parotid gland was attempted (four left, six right) [4,42]. The median dose 
Dmed within the spared parotid had to be less than 27 Gy. A 
surroundings-structure (surr) was created to avoid overdosage within 
otherwise unspecified tissues; it contains all points more than 20 mm 
away from PTV56 and more than 30 mm away from PTV69 [20]. 
 
Figure 2. PET voxel intensity-based IMRT. (A) Anatomical PTV-definition is based on 
clinical examination, PET, CT and MRI imaging. (B) PET provides radiobiological data in the 
form of an intensity value within each image voxel that is proportional to a radiobiological 
parameter. (C) Fusing results in an image where each image voxel has a Hounsfield value (for 
computation of absorbed dose) and PET intensity value (for intra-tumour guidance of the 
dose distribution). (D) The PET voxel intensity-based IMRT optimization algorithm creates a 
spatial dose variation within the anatomical PTV (E), as a function of the voxel intensity 
values in the PET image. Abbreviations are defined in the Lay-out of the study and Planning 
objectives sections. 
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Modification to IMRT planning tools 
IMRT treatment planning at GUH is based on class solutions and 
involves direct multi-leaf collimator (MLC) aperture optimization. In brief 
we start from a template beam set, which is characterized by each beam’s 
isocenter, gantry, table and collimator angles, linear accelerator, radiation 
modality and energy. For every template beam initial beam segments are 
created by an in-house developed anatomy-based segmentation tool 
(ABST) based on one or more target structures, taking into account the 
presence of critical structures and the distance to the skin [17]. Once the 
initial set of segments is created, both segment weights and MLC leaf 
positions are optimized by the segment outline and weight adapting tool 
(SOWAT) [18]. The optimization uses a bio-physical objective function 
[18]. 
To implement the bound-constrained linear model of formula (1) 
into the IMRT planning strategy at GUH, two modifications were made to 
the planning tools. Firstly, ABST was adapted into a segmentation tool 
that also supports biological imaging information, called biology-based 
segmentation tool (BBST): by projecting voxel intensity data onto a 
combined anatomical-biological segmentation grid, the biological 
imaging information is already taken into account during the creation of 
the initial beam segments. Secondly, the bio-physical objective function of 
SOWAT was modified to minimize the difference between the actual (D) 
and intended dose distribution. The physical part of the objective 
function was extended by a term that minimizes the root mean square 
deviation between D and DI in all dose calculation points within the 
target structure of interest (in this case PTV69+PET). 
Dose reporting and evaluation 
For PTV69+PET, the resulting dose distribution was compared to the 
intended voxel intensity-based dose pattern; therefore, a quality factor QF 
was introduced. In every point p that is randomly seeded within 
PTV69+PET (n points in total), the obtained-over-intended dose ratio Qp = 
Dp/(DI)p is calculated. This information can be visualized in a Q-volume 
histogram (QVH), by displaying the partial PTV69+PET volume for which Q 
is greater than or equal to each abscis value. Ideally such a curve would 
drop down steeply at Q = 1. QF is defined as the mean absolute deviation 
of Q to 1 within PTV69+PET: 
∑ −=
p
pQn
QF 11   (2) 
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Dose-volume histograms (DVHs) and QVHs were computed for all 
individual patients. To compile the resulting curves over the whole 
patient group, the mean and the standard error of the mean (SEM) of the 
partial volume were calculated from the individual fraction dose-
distributions for dose levels between 0 and 3.3 Gy in steps of 0.02 Gy for 
the DVHs and from the individual Q-distributions for Q-values between 0 
and 1.2 in steps of 0.005 for the QVHs. 
For each PTV the minimal, median and maximal dose levels (Dmin, 
Dmed and Dmax), and V<95% were evaluated. Dmin and Dmax are represented 
by the 98th and second dose percentile, respectively [46]. For the 
expanded spinal cord V>50Gy and Dmax were calculated, while for the 
parotid glands Dmed and V>27Gy are reported. For the spared parotid Dmean 
was calculated as well. V>60Gy and Dmax are reported for the mandible. For 
the expanded spinal cord and the mandible, Dmax is also represented by 
the second dose percentile. Average dose-volumes values are reported as 
95% confidence intervals; the half width of each interval is calculated as 
SEM × t14,0.05, where t14,0.05 represents the two-tailed t-value of the 
Student’s t-distribution with 14 degrees of freedom for a probability of 
5%. For all statistical comparisons a paired Student’s t-test was used. All 
tests were two-tailed; P-values below 5% are considered significant. 
 
Results 
The 95% confidence intervals for the average PTV69+PET and PTVPET 
volumes were 194 ± 38 and 26 ± 10 cc, respectively. The volume of PTVPET 
was 13 ± 4% of the volume of PTV69+PET. The largest PTV69+PET volume 
recorded was 286 cc, while the smallest volume was 66 cc. For PTVPET 
these volumes were 63 and 4 cc, respectively. The partial volume of 
PTV69+PET with PET intensity values I≥Ilow was 94 ± 33 cc or 52 ± 17% of 
the volume of PTV69+PET. For Ihigh, this volume was 10 ± 2 cc or 5 ± 0% of 
the volume of PTV69+PET, by definition of Ihigh as the 95th percentile 
intensity value within PTV69+PET. Thus, the voxel intensity-based dose 
escalation was performed over 85 ± 32 cc or 47 ± 17% of the volume of 
PTV69+PET. 
Fig. 3 shows the compiled dose-volume histograms for the PET 
contour-based SIB plans (SIB(cb)250) and the PET voxel intensity-based 
SIB plans for both escalation steps (SIB(vib)216–250 and SIB(vib)216–300). The 
clinically relevant dose–volume characteristics are reported in Table 2. 
For all patients the OAR planning dose objectives stated in the Planning 
objectives section were reached. However, there was a significant 
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difference between the Dmax-values delivered to the expanded spinal cord 
by SIB(cb)250 and SIB(vib)216–250. Both the maximal dose and V>50Gy differed 
significantly between both PET voxel intensity-based plans. Additionally, 
the median dose within the spared parotid gland was significantly higher 
for SIB(vib)216–300 than for SIB(vib)216–250, while V>27Gy was significantly 
higher for SIB(vib)216–300 than for SIB(cb)250. Whereas V>60Gy within the 
mandible was not significantly different between both PET voxel 
intensity-based planning studies, its value was significantly lower for the 
PET contour-based SIB plans. Both V>60Gy and Dmax within the mandible 
were significantly higher for SIB(vib)216–300 than for SIB(cb)250. 
 
 
Fig. 3. Comparison of the compiled dose-volume histograms for (a): SIB(cb)250 (grey) and 
SIB(vib)216–250 (black), and (b): SIB(vib)216–300 (grey) and SIB(vib)216–250 (black). For each 
structure, the mean relative volume (solid line) ± the SEM (dotted lines) is represented. SD = 
3.87 × SEM. The single dots represent the target underdosage limitations and OAR planning 
constraints stated in the Planning objectives section. PTV names are defined in the Lay-out 
of the study section and in Table 1. The DVHs for PTV66 and PTV62 are compiled from the six 
and four patients, respectively, for whom these target dose levels were prescribed. In 10 
patients sparing of a parotid gland was attempted; their data are compiled into the spared 
parotid DVH. The spinal cord DVH is shown for the 5 mm-expanded structure. 
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Table 2. Clinically relevant dose-volume statistics for SIB(cb)250, SIB(vib)216–250, SIB(vib)216–300. 
PTV names are defined in Lay-out of the study and in Table 1. All fraction dose characteristics 
were rescaled, i.e. multiplied by 32, because in IMRT treatments that consist of two consecutive 
phases, the 1st phase is planned to the total number of fractions in order to secure enough 
sparing of the OARs to make the planning of the 2nd phase technically possible. By rescaling, 
the critical absolute dose levels for the expanded spinal cord and parotid gland stated in 
Planning objectives can be maintained. Dmin and Dmax are represented by the 98th and 2nd dose 
percentile, respectively. The spinal cord data is reported for the 5 mm-expanded structure. The 
average dose–volume characteristics are presented as 95% confidence intervals. For all statistical 
comparisons, a paired Student’s t-testwas used; P-values < 5% (bold) are considered significant. 
a For SIB(vib) V<0.95 × 69Gy was considered instead of V<95%. 
 SIB(cb)250 
(a) 
P-value 
(a)-(b) 
SIB(vib)216-250 
(b) 
P-value 
(b)-(c) 
SIB(vib)216-300 
(c) 
P-value 
(a)-(c) 
PTVPET 
Dmin (Gy) 77.3 ± 0.7 < 0.001 71.3 ± 1.2 < 0.001 75.5 ± 2.9 0.177 
Dmed (Gy) 79.6 ± 0.1 < 0.001 75.5 ± 1.0 < 0.001 84.9 ± 2.3 < 0.001 
Dmax (Gy) 80.9 ± 0.2 0.554 80.8 ± 0.5 < 0.001 97.2 ± 1.1 < 0.001 
PTV69+PET 
Dmin (Gy) 65.2 ± 0.4 < 0.001 67.0 ± 0.5 0.001 66.5 ± 0.7 0.003 
Dmed (Gy) 71.0 ± 1.2 0.402 70.3 ± 0.9 0.010 72.2 ± 2.2 0.421 
Dmax (Gy) 80.3 ± 0.3 < 0.001 78.5 ± 0.2 < 0.001 91.6 ± 0.6 < 0.001 
V<95%a (%) 3.2 ± 1.0 < 0.001 0.5 ± 0.2 < 0.001 1.2 ± 0.5 0.003 
PTV69 
Dmin (Gy) 64.8 ± 0.5 < 0.001 66.7 ± 0.5 0.001 66.2 ± 0.7 0.001 
Dmed (Gy) 69.3 ± 0.3 0.228 69.9 ± 0.8 0.024 71.3 ± 2.1 0.068 
Dmax (Gy) 74.1 ± 1.0 0.140 72.7 ± 1.6 0.001 77.3 ± 4.0 0.130 
V<95%* (%) 4.7 ± 1.2 < 0.001 0.7 ± 0.3 0.004 2.0 ± 1.1 0.003 
PTV66 
Dmin (Gy) 62.5 ± 2.0 0.984 62.5 ± 0.7 0.480 62.6 ± 0.7 0.898 
Dmed (Gy) 65.9 ± 0.2 0.824 65.9 ± 0.1 0.347 65.9 ± 0.1 0.581 
Dmax (Gy) 68.1 ± 0.9 0.937 68.1 ± 0.6 0.112 68.4 ± 0.8 0.574 
V<95% (%) 2.9 ± 4.0 0.718 2.2 ± 1.6 0.898 2.2 ± 1.1 0.648 
PTV62 
Dmin (Gy) 59.4 ± 1.3 0.141 58.8 ± 0.7 0.829 58.8 ± 1.3 0.219 
Dmed (Gy) 61.9 ± 0.1 0.039 62.0 ± 0.0 0.529 62.1 ± 0.2 0.148 
Dmax (Gy) 63.9 ± 0.7 0.184 65.3 ± 2.4 0.416 65.8 ± 3.3 0.187 
V<95% (%) 1.5 ± 2.0 0.208 2.2 ± 1.1 0.434 2.5 ± 2.4 0.172 
PTV56 
Dmin (Gy) 52.3 ± 0.6 0.191 52.5 ± 0.5 0.154 52.7 ± 0.3 0.063 
Dmed (Gy) 56.1 ± 0.1 0.053 56.0 ± 0.1 0.044 56.0 ± 0.0 0.013 
Dmax (Gy) 60.5 ± 0.8 0.577 60.7 ± 0.6 0.001 60.1 ± 0.7 0.367 
V<95% (%) 4.0 ± 1.3 0.150 3.4 ± 0.9 0.669 3.3 ± 0.7 0.106 
Spinal cord 
V>50Gy (%) 0.3 ± 0.3 0.051 0.7 ± 0.4 0.004 0.2 ± 0.3 0.706 
Dmax (Gy) 44.4 ± 2.1 0.002 48.1 ± 0.8 < 0.001 46.2 ± 1.1 0.098 
Spared parotid gland 
Dmed (Gy) 18.1 ± 3.4 0.898 18.2 ± 2.5 0.044 19.1 ± 2.9 0.189 
Dmean (Gy) 21.9 ± 1.9 0.212 22.5 ± 1.7 0.197 22.8 ± 1.9 0.098 
V>27Gy (%) 37.2 ± 4.4 0.111 38.8 ± 3.2 0.183 39.8 ± 3.7 0.013 
Unspared parotid gland(s) 
Dmed (Gy) 54.1 ± 4.0 0.206 55.6 ± 4.6 0.479 56.1 ± 4.4 0.119 
V>27Gy (%) 86.6 ± 8.7 0.223 88.4 ± 8.8 0.520 88.0 ± 8.7 0.351 
Mandible 
V>60Gy (%) 15.8 ± 10.1 0.005 19.0 ± 11.0 0.417 18.6 ± 11.4 0.031 
Dmax (Gy) 64.6 ± 3.0 0.127 65.8 ± 3.3 0.076 66.8 ± 4.0 0.030 
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The target underdosage limitation was not always respected. For 
SIB(vib)216–250 the V<95%-values within PTV56 were 5.6 and 5.3% for two 
patients; for SIB(vib)216–300 this value was 5.0% for one patient. In all other 
PTVs, the underdosage constraint was met for all patients. For SIB(cb)250, 
V<95% was higher than 5% for one patient within PTVPET (5.5%), for eight 
patients within PTV69 (5.0, 5.5, 5.9, 5.9, 6.1, 6.1, 6.7 and 8.6%), for two 
patients within PTV66 (6.1 and 9.2%) and for six patients within PTV56 
(5.5, 5.8, 5.9, 6.1, 6.4 and 8.6%). Due to the differences in escalation 
strategy, comparing the dose–volume characteristics of SIB(cb)250, 
SIB(vib)216–250 and SIB(vib)216–300 showed significant differences for PTVPET, 
PTV69+PET and PTV69. Additionally, the median dose within PTV62 was 
significantly different between SIB(cb)250 and SIB(vib)216–250, while both 
the median and maximal dose within PTV56 were significantly different 
between SIB(vib)216–250 and SIB(vib)216–300. Dmed within PTV56 was also 
significantly different between SIB(vib)216–300 and SIB(cb)250. 
For individual patients, substantial differences between the 
performance of each planning approach on the fields of target coverage 
and OAR sparing were observed. However, there was no patient for 
which either the voxel intensity-based or contour-based approach could 
provide superior results similarly on both fields: voxel intensity-based 
IMRT tends to perform better within the target structures, while contour-
based IMRT tends to realize better OAR sparing. 
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Figure 4. Compiled Q-volume histograms for SIB(vib)216–250 and SIB(vib)216–300 (PTV69+PET) and 
for SIB(cb)250 (PTVPET and PTV69). The mean relative volume (solid line) ± the SEM (dotted 
lines) is represented. SD = 3.87 × SEM. PTV names are defined in the Lay-out of the study 
section and in Table 1. Note the scale on the Q-axis (0.9–1.1). 
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Fig. 5. Fraction dose (Gy/fx) distribution of SIB(vib)216–250 for one patient case, superimposed 
on the original PET voxel intensity data. The bold blue line contours PTV69+PET. 
Abbreviations are defined in the Lay-out of the study section. (a) Transverse slice. (b) Sagittal 
slice. (c) Coronal slice. 
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To evaluate the difference between the intended dose distribution 
and the obtained dose values within PTV69+PET, Fig. 4 shows the compiled 
QVHs for SIB(vib)216–250 and SIB(vib)216–300. Fig. 5 illustrates the fraction 
dose distribution resulting from the PET voxel intensity-based 
optimization superimposed on the original PET voxel intensity data for 
one patient case. Q-values can be determined for SIB(cb)250 as well: for 
each voxel within an optimization target structure Q can be calculated as 
the ratio of the obtained over the homogeneously prescribed dose; the 
compiled QVHs of PTVPET and PTV69 are also shown in Fig. 4. The 95% 
confidence interval for the average QF-value for SIB(vib)216–250 was 1.6 ± 
0.1%; for SIB(vib)216–300 it was 3.1 ± 0.4%. The lowest value for SIB(vib)216–
250 was 1.2%, while the highest value was 2.0%. For SIB(vib)216–300 these 
values were 2.2 and 4.3%, respectively. For SIB(cb)250 the mean QF-value 
within PTVPET was 0.9 ± 0.3%, with values ranging between 0.3 and 1.6%. 
Within PTV69 QF was 2.6 ± 0.5%; the minimum value was 1.3%, while the 
maximum value was 4.6%. Apart from the comparison of the average QF-
value between PTV69 for SIB(cb)250 and PTV69CPET for SIB(vib)216–250 (P = 
0.220), paired t-tests showed all mean QF-values to be significantly 
different (P ≤ 0.001). However, when the QF-values for SIB(cb)250 were 
averaged over PTVPET and PTV69, there was no significant difference with 
the mean QF-value of SIB(vib)216–250 (P = 0.122). 
 
Discussion 
For head and neck cancer, IMRT can be used to lower the dose to 
selected organs at risk outside the PTV, thereby opening a window for 
dose escalation [25,36,37]. If the surrounding organs are not dose-limiting, 
the maximal dose escalation becomes restricted by the presence of dose-
limiting structures within the PTV, such as cartilage, connective tissues, 
nerve tissues, bone, the swallowing apparatus or the lymphatic system 
[19]. We therefore hypothesize that, in this situation, a dose escalation 
should be focused to small subvolumes of the PTV. This hypothesis is 
supported by theoretical considerations, suggesting that focused dose 
escalation may improve local control [38]. Furthermore, the feasibility and 
safety of dose escalation to small volumes has been demonstrated for 
certain tumour sites using brachytherapy boosts [21,41], stereotactic 
surgery boosts [43] and IMRT SIB techniques. These techniques deliver a 
high dose to the GTV and a lower dose to subclinical disease with 
acceptable toxicity if the boost volume is kept small [46]. 
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To improve local control by reducing the occurrence of loco-
regional relapses within the high-dose regions, we may need to identify 
the most radioresistant regions inside the tumour [7]. It appears obvious 
to direct foci of dose escalation towards these regions. New biological 
imaging techniques, mainly based on PET, MRI and magnetic resonance 
spectroscopy (MRS) imaging, may be used to create three-dimensional 
maps of radiobiologically relevant parameters [6,35,44]. These maps can 
be fused with high-resolution CT and MRI images and used for treatment 
design and optimization with a small-volume, focused dose escalation 
strategy. Imaging techniques that can be used to map radiation resistant 
regions using specific tracers for hypoxia, proliferation or intrinsic 
radioresistance are still the subject of intense research. Recent 
publications have addressed the increased importance of PET in 
radiotherapy [28]. Results have been reported on the use of [18F]FDG-PET 
for target volume definition in the treatment planning process of non-
small cell lung cancer [22,30,32], thoracic lymphoma [34] and esophageal 
carcinoma [45], the use of 18F-fluoromisonidazole PET to assess hypoxia 
in human soft tissue tumours [2] and the use of 11C-methionine PET to 
delineate the tumour volume in pharyngolaryngeal squamous cell 
carcinoma and to address the salivary gland function after radiotherapy 
[5,26]. At present, [18F]FDG-PET is routinely available and is—at first 
order—of interest for focused dose escalation. For pharyngolaryngeal 
squamous cell carcinoma, [18F]FDG-PET defines a much smaller target 
volume than CT or MRI imaging, and comparison with macroscopic 
surgical specimens has shown PET to be the most accurate modality for 
GTV definition [13]. Inside a contoured PTV, the GTV is known to be the 
region in which local control is most difficult to achieve. 
Although care should be taken as FDG-PET may not detect highly 
hypoxic/necrotic centers in tumours, evidence that FDG-avid regions of 
the tumour are of increased radioresistance is provided by in vitro and in 
vivo studies correlating cellular or regional FDG uptake with hypoxia. 
Clavo et al. [9,10] as well as Burgman et al. [3] have reported increased 
cellular uptake of FDG under hypoxic conditions in vitro. Positive 
correlation of FDG uptake and hypoxia was also observed in vivo by 
Dearling et al. [16], who reported increased FDG uptake in the hypoxic 
regions of the tumour compared to the normoxic regions. Using Dunning 
prostate tumours implanted in nude mice, Pugachev et al. observed that 
FDG uptake was highly correlated with regions of intense pimonidazole 
staining, the latter being a tracer of hypoxia [39]. In human patients, 
Rajendran et al. observed highly significant positive pixel-by-pixel 
correlations between PET images of FDG uptake and of the tracer of 
hypoxia [18F]fluoromisonidazole, with the value of the correlation 
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coefficient being highest for head and neck tumours [40]. Hypoxia-
inducible factor 1-alpha (HIF-1alpha) may be involved in the mechanism 
of increased FDG uptake in hypoxic regions by increasing the expression 
levels of the glucose transporters Glut-1, Glut-3, and hexokinase-II (HK-
II) that carry FDG in the cells [47]. 
The proportionality of the intensity-dose relationship in the PET 
voxel intensity-based planning studies is based on the assumption that 
voxels with a higher PET intensity require a higher dose. This technique 
hypothetically offers the possibility of improved local control by focusing 
dose to the most radiation resistant regions within the tumour. Of course, 
decisive answers can only be provided after extensive evaluation of 
clinical results. Individual tumour data showing that regions with the 
highest FDG uptake are the most radioresistant are inexistent, but indirect 
evidence has been given by Kitagawa et al. [31] and Allal et al. [1], who 
reported that head and neck cancer patients who show a high pre-
radiotherapy uptake of FDG in the tumour are characterized by worse 
local control than the patients with a lower uptake. A linear relationship 
is merely the most straightforward way of expressing the demand for a 
monotonically increasing function, since the function relating PET-
activity to tumour proliferation rate and radiosensitivity is currently 
unknown. The same relationship is used by Das et al. [14] for lung cancer. 
When defining Ilow and Ihigh, our main concern was to prevent the 
noisy background signal from affecting the escalation dose prescription, 
while maintaining a maximal range for dose escalation. With regard to 
the choice of Ihigh, the 95th percentile value of the PET voxel intensities 
within PTV69+PET was therefore considered instead of the maximal 
intensity value. Looking at the PET intensity maps in a number of 
patients, we chose Ilow = 0.25 × Ihigh as this seemed to do well in 
eliminating most background noise. However, we need to emphasize the 
arbitrariness of this decision. An equally arbitrary choice would have 
been to take a separate percentile value for Ilow, as was done for example 
by Das et al. [14], who took the 25th and 75th percentile PET activity 
values within the PTV as Ilow and Ihigh. In this case dose is always 
escalated over exactly 50% of the PTV volume, while Ilow = 0.25 × Ihigh will 
focus dose escalation to smaller volumes in case of more pronounced 
intensity peaks. Although it is clear that the volume for dose escalation 
depends strongly on the choice of Ilow, it is uncertain which is the better 
option. Moreover, in both cases the PTV volume plays a role in 
determining the volume for dose escalation, while we actually want to 
achieve independency of the voxel intensity-based dose escalation from 
manually delineated target structures. For most of the patients in our 
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study low PET intensity values represent the majority of the target 
volume: their PET images are characterized by one or more relatively 
high but narrow intensity peaks. 
To evaluate the impact of voxel intensity-based IMRT, SIB(cb)250 
planning results were compared with those for SIB(vib)216–250. From Fig. 3 
the difference in dosimetric characteristics is apparent. SIB(cb) aims to 
achieve homogeneous dose distributions within PTVPET and PTV69. The 
dose distribution within PTV69+PET is inevitably inhomogeneous, since the 
dose values vary between both intended median dose levels. In contrast, 
the planning dose objective in the SIB(vib) approach was to obtain a 
boost-dose distribution that directly reflects PET voxel intensity values 
within PTV69+PET, resulting in intended inhomogeneous dose distributions 
within both substructures PTVPET and PTV69. This intended 
inhomogeneity is fundamentally different from the inevitable 
inhomogeneity within PTV69+PET for SIB(cb). The shape of the compiled 
PTV69+PET DVH in Fig. 3 for SIB(vib) illustrates that the distribution of 
PET voxel intensities throughout PTV69+PET is highly non-linear; 
otherwise, the relative PTV69+PET volume would decrease linearly as a 
function of dose between Dlow and Dhigh due to the implemented 
proportional voxel intensity-dose relationship. Table 2 reports a 
significant difference between the V<95%-values within PTV69+PET and 
PTV69 of SIB(cb)250, SIB(vib)216–250 and SIB(vib)216–300. Indeed, the voxel 
intensity-based IMRT optimization algorithm inherently limits 
underdosage by minimizing the difference between actual and intended 
dose values in each voxel within PTV69+PET. The clinical importance of this 
difference in V<95%-value is unknown. In any case, the voxel intensity-
based approach is more suitable to create peak-dose regions inside 
PTV69+PET compared to the contour-based approach. 
The comparison between SIB(vib)216–250 and SIB(vib)216–300 illustrates 
the dosimetric changes accompanying a higher dose escalation level. By 
increasing Dhigh, steeper dose gradients are imposed on PTV69+PET. This 
more complex prescribed dose pattern results in significantly more 
underdosage within PTV69+PET and PTV69. Moreover, Fig. 4 clearly shows 
that the agreement between the prescribed dose pattern and the obtained 
dose distribution becomes significantly worse if Dhigh is raised. The 
maximal steepness of deliverable dose gradients is limited by the 
penumbra width of the beam segments. This depends on the design of the 
linear accelerator’s treatment head and on the field shape of the 
individual MLC segments. 
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Voxel intensity-based IMRT optimization results in a dose 
distribution that is modulated within PTV69+PET. Therefore patient motion 
may seriously affect the tumour dose. However, motion is usually limited 
in head and neck tumours. Moreover, for the treatment of head and neck 
cancer patients at GUH all images needed for the planning are acquired 
in treatment position, while a thermoplastic mask is used to immobilize 
the patient. The purpose of the current treatment planning study was to 
evaluate the dosimetric characteristics of voxel intensity-based IMRT 
plans. Therefore, motion issues are not addressed in-depth in this paper. 
However, it remains important to notice not only possible treatment 
problems due to patient motion, but also due to shrinkage of the tumour 
volume during treatment. Solutions for the last problem can only be 
provided by non-rigid coregistration of pre- and during-treatment 
images, which enables us to track the location of the image voxels. This 
may result in tumour regression models, which can be taken into account 
by the optimization engine as well. 
In conclusion, PET voxel intensity-based IMRT may aid to improve 
local control in head and neck cancer by focusing dose escalation to the 
most radioresistant subvolumes within the tumour. The hypothesis that 
tumour regions with the highest FDG uptake are the most radioresistant 
can only be confirmed by clinical results; this paper provides the 
necessary planning technology and a comprehensive set of patient data as 
an important and necessary step in the process of clinical implementation. 
The dosimetric characteristics of the contour-based and voxel intensity-
based simultaneous integrated boost plans differ fundamentally. While 
the voxel intensity-based strategy has a large effect on the dose 
distribution inside PTV69+PET, only small effects were observed on the 
dose distribution outside PTV69+PET and on the dose delivered to the 
organs at risk. For all patients both the contour-based and voxel intensity-
based plans comply with the planning constraints set for the organs at 
risk, and are therefore considered clinically acceptable. Thus, both 
methods are alternatives for boosting subvolumes inside a selected PTV. 
Acknowledgements 
Wim Duthoy and Barbara Vanderstraeten are Research Assistants 
of the Research Foundation—Flanders (FWO—Vlaanderen). The project 
‘Conformal Radiotherapy Ghent University Hospital’ is supported by the 
Belgische Federatie tegen Kanker (grants 51AC8904, FBC2003/2006 and 
ZKB2747) and by grants from the Research Foundation—Flanders 
(G.0183.03), Ghent University (GOA 12050401, BOF 01112300, 011VO497, 
011B3300), and the Centrum voor Studie en Behandeling van 
Gezwelziekten. 
Chapter 4: FDG-PET voxel intensity-based IMRT for head and neck cancer 
 75
References 
[1] Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of 
outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]Fluoro-
2-Deoxy-D-Glucose. Int J Radiat Oncol Biol Phys 2004;59:1295–300. 
[2] Bentzen L, Keiding S, Nordsmark M, et al. Tumour oxygenation assessed by 18F-
fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. 
Radiother Oncol 2003;67:339–44. 
[3] Burgman P, O’Donoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake 
in MCF7 cells. J Nucl Med 2001;42:170–5. 
[4] Bussels B, Maes A, Hermans R, Nuyts S, Weltens C, Van den Bogaert W. Recurrences after 
conformal parotid-sparing radiotherapy for head and neck cancer. Radiother Oncol 2004;72:119–
27. 
[5] Buus S, Grau C, Munk OL, Bender D, Jensen K, Keiding S. 11C-methionine PET, a novel 
method for measuring regional salivary gland function after radiotherapy of head and neck 
cancer. Radiother Oncol 2004;73:289–96. 
[6] Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumour 
resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol 
Phys 2001;49:1171–82. 
[7] Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure in patients 
receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol 
Phys 2003;55:312–21. 
[8] Claus F, De Gersem W, De Wagter C, et al. An implementation strategy for IMRT of ethmoid 
sinus cancer with bilateral sparing of the optic pathways. Int J Radiat Oncol Biol Phys 
2001;51:318–31. 
[9] Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is 
increased by hypoxia. J Nucl Med 1995;36:1625–32. 
[10] Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-
methionine, and FDG in cultured cancer cells. J Nucl Med 1996;37:502–6. 
[11] Daisne JF, Sibomana M, Bol A, Cosnard G, Lonneux M, Grégoire V. Evaluation of a 
multimodality image (CT, MRI and PET) coregistration procedure on phantom and head and 
neck cancer patients: accuracy, reproducibility and consistency. Radiother Oncol 2003;69:237–45. 
[12] Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Grégoire V. Tri-dimensional 
automatic segmentation of PET volumes based on measured source-to-background ratios: 
influence of reconstruction algorithms. Radiother Oncol 2003;69:247–50. 
[13] Daisne JF, Duprez T, Weynand B, et al. Tumour volume in pharyngolaryngeal squamous 
cell carcinoma: comparison at CT, MR Imaging, and FDG PET and validation with surgical 
specimen. Radiology 2004;233:93–100. 
[14] Das SK, Miften MM, Zhou S, et al. Feasibility of optimizing the dose distribution in lung 
tumours using fluorine-18-fluorodeoxyglucose positron emission tomography and single 
photon emission computed tomography guided dose prescriptions. Med Phys 2004;31:1452–61. 
[15] Dawson L, Anzai Y, Marsh L, et al. Patterns of loco-regional recurrence following parotid-
sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. 
Int J Radiat Oncol Biol Phys 2000;46:1117–26. 
[16] Dearling JL, Flynn AA, Sutcliffe-Goulden J, et al. Analysis of the regional uptake of 
radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med 2004;45:101–7. 
Biologically conformal RT and Monte Carlo dose calculations in the clinic 
 76
[17] De Gersem W, Claus F, De Wagter C, De Neve W. An anatomy-based beam segmentation 
tool for intensity-modulated radiation therapy and its application to head-and-neck cancer. Int J 
Radiat Oncol Biol Phys 2001;51:849–59. 
[18] De Gersem W, Claus F, De Wagter C, Van Duyse B, De Neve W. Leaf position optimization 
for step-and-shoot IMRT. Int J Radiat Oncol Biol Phys 2001;51:1371–88. 
[19] De Neve W, Duthoy W. Intensity-modulated radiation therapy for head and neck cancer. 
Expert Rev Anticancer Ther 2004;4:425–34. 
[20] De Neve W, Wu Y, Ezzell G. Practical IMRT planning. In: Bortfeld T, Schmidt-Ullrich R, De 
Neve W, Wazer DE, editors. Image-Guided IMRT. Berlin: Springer; 2006. p. 49–54. 
[21] DeNittis AS, Liu L, Rosenthal DI, Machtay M. Nasopharyngeal carcinoma treated with 
external radiotherapy, brachytherapy and concurrent/adjuvant chemotherapy. Am J Clin Oncol 
2002;25:93–5. 
[22] De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a 
dedicated combinded PET-CT-simulator of patients with non-small cell lung cancer on dose 
limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol 
2005;77:5–10. 
[23] Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume and function 
relationships in parotid salivary glands following conformal and intensity-modulated 
irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999;45:577–87. 
[24] Eisbruch A, Foote R, O’Sullivan B, Beitler JJ, Vikram B. Intensity-modulated radiation 
therapy for head and neck cancer: emphasis on the selection and delineation of the targets. 
Semin Radiat Oncol 2002;12:238–49. 
[25] Feng M, Jabbari S, Lin A, et al. Predictive factors of locoregional recurrences following 
parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. 
Radiother Oncol 2005;77:32–8. 
[26] Geets X, Daisne JF, Grégoire V, Hamoir M, Lonneux M. Role of 11-C-methionine positron 
emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous 
cell carcinoma: comparison with FDG-PET and CT. Radiother Oncol 2004;71:267–73. 
[27] Grégoire V, Coche E, Cosnard G, Hamoir M, Reychler H. Selection and delineation of 
lymph node target volumes in head and neck conformal radiotherapy. Proposal for 
standardizing terminology and procedure based on the surgical experience. Radiother Oncol 
2000;56:135–50. 
[28] Grégoire V. Is there any future in radiotherapy planning without the use of PET: unraveling 
the myth. Radiother Oncol 2004;73:261–3. 
[29] Harnsberger HR, Willey RC. Handbook of head and neck imaging. 2nd ed. St Louis, MO: 
Mosby; 1995. 
[30] Holloway CL, Robinson D, Murray B, et al. Results of a phase I study to dose escalate using 
intensity modulated radiotherapy guided by combined PET/CT imaging with induction 
chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 2004;73:285–7. 
[31] Kitagawa Y, Sano K, Nishizawa S, et al. FDG-PET for prediction of tumour aggressiveness 
and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J 
Nucl Med 2003;30:63–71. 
[32] Lavrenkov K, Partridge M, Cook G, Brada M. Positron emission tomography for target 
volume definition in the treatment of non-small cell lung cancer. Radiother Oncol 2005;77:1–4. 
[33] Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of 
nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 
2002;53:12–22. 
Chapter 4: FDG-PET voxel intensity-based IMRT for head and neck cancer 
 77
[34] Lee YK, Cook G, Flower MA, et al. Addition of 18F-FDG-PET scans to radiotherapy 
planning of thoracic lymphoma. Radiother Oncol 2004;73:277–83. 
[35] Ling C, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): 
biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551–60. 
[36] Longobardi B, De Martin E, Fiorino C, et al. Comparing 3DCRT and inversely optimized 
IMRT planning for head and neck cancer: equivalence between step-and-shoot and sliding 
window techniques. Radiother Oncol 2005;77:148–56. 
[37] Miles EA, Clark CH, Guerrero Urbano MT, et al. The impact of introducing intensity 
modulated radiotherapy into routine clinical practice. Radiother Oncol 2005;77:241–6. 
[38] Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the 
design of fractionation strategies for intensity-modulated radiation therapy of head and neck 
cancers. Int J Radiat Oncol Biol Phys 2000;46:619–30. 
[39] Pugachev A, Ruan S, Carlin S, et al. Dependence of FDG uptake on tumor 
microenvironment. Int J Radiat Oncol Biol Phys 2005; 62:545–53. 
[40] Rajendran JG, Mankoff DA, O’Sullivan F, et al. Hypoxia and glucose metabolism in 
malignant tumors. Evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron 
emission tomography imaging. Clin Cancer Res 2004;10:2245–52. 
[41] Rudoltz MS, Perkins RS, Luthmann RW, et al. High-dose-rate brachytherapy for primary 
carcinomas of the oral cavity and oropharynx. Laryngoscope 1999;109:1967–73. 
[42] Saarilahti K, Kouri M, Collan J, et al. Intensity modulated radiotherapy for head and neck 
cancer: evidence for preserved salivary gland function. Radiother Oncol 2005;74:251–8. 
[43] Tate DJ, Adler JR, Chang SD, et al. Stereotactic radiosurgical boost following radiotherapy 
in primary nasopharyngeal carcinoma: impact on local control. Int J Radiat Oncol Biol Phys 
1999;45:915–21. 
[44] Van de Wiele C, Lahorte C, Oyen W, et al. Nuclear medicine imaging to predict response to 
radiotherapy: a review. Int J Radiat Oncol Biol Phys 2003;55:5–15. 
[45] Vrieze O, Haustermans K, De Wever W, et al. Is there a role for FGD-PET in radiotherapy 
planning in esophageal carcinoma? Radiother Oncol 2004;73:269–75. 
[46] Wu Q, Mohan R, Morris M, Lauve A, Schmidt-Ullrich R. Simultaneous integrated boost 
intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell 
carcinomas. I: dosimetric results. Int J Radiat Oncol Biol Phys 2003;56:573–85. 
[47] Zhao S, Kuge Y, Mochizuki T, et al. Biologic correlates of intratumoral heterogeneity in 18F-
FDG distribution with regional expression of glucose transporters and hexokinase-II in 
experimental tumor. J Nucl Med 2005;46:675–82. 

Chapter 5: Accuracy of patient dose calculation for lung IMRT 
 79
Chapter  5  
Publication 3: 
Accuracy of patient dose calculation for lung IMRT:  
A comparison of Monte Carlo, convolution/super-
position, and pencil beam computations 
Barbara Vanderstraeten1,2, Nick Reynaert1, Indira Madani2, Leen 
Paelinck2, Carlos De Wagter2, Werner De Gersem2, Wilfried De Neve2, 
Hubert Thierens1 
1 Department of Medical Physics, Ghent University, Gent, Belgium 
2 Department of Radiotherapy, Ghent University Hospital, Gent, Belgium 
Medical Physics 2006;33:3149-3158 
 
Abstract 
The accuracy of dose computation within the lungs depends strongly on the performance of the 
calculation algorithm in regions of electronic disequilibrium that arise near tissue 
inhomogeneities with large density variations. There is a lack of data evaluating the 
performance of highly developed analytical dose calculation algorithms compared to Monte 
Carlo computations in a clinical setting. We compared full Monte Carlo calculations (performed 
by our Monte Carlo dose engine MCDE) with two different commercial 
convolution/superposition (CS) implementations (Pinnacle-CS and Helax-TMS’s collapsed cone 
model Helax-CC) and one pencil beam algorithm (Helax-TMS’s pencil beam model Helax-PB) 
for 10 intensity modulated radiation therapy (IMRT) lung cancer patients. Treatment plans were 
created for two photon beam qualities (6 and 18 MV). For each dose calculation algorithm, 
patient, and beam quality, the following set of clinically relevant dose-volume values was 
reported: (i) minimal, median, and maximal dose (Dmin, D50, and Dmax) for the gross tumor and 
planning target volumes (GTV and PTV); (ii) the volume of the lungs (excluding the GTV) 
receiving at least 20 and 30 Gy (V20 and V30) and the mean lung dose; (iii) the 33rd percentile 
dose (D33) and Dmax delivered to the heart and the expanded esophagus; and (iv) Dmax for the 
expanded spinal cord. Statistical analysis was performed by means of one-way analysis of 
variance for repeated measurements and Tukey pairwise comparison of means. Pinnacle-CS 
showed an excellent agreement with MCDE within the target structures, whereas the best 
correspondence for the organs at risk (OARs) was found between Helax-CC and MCDE. Results 
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from Helax-PB were unsatisfying for both targets and OARs. Additionally, individual patient 
results were analyzed. Within the target structures, deviations above 5% were found in one 
patient for the comparison of MCDE and Helax-CC, while all differences between MCDE and 
Pinnacle-CS were below 5%. For both Pinnacle-CS and Helax-CC, deviations from MCDE above 
5% were found within the OARs: within the lungs for two (6 MV) and six (18 MV) patients for 
Pinnacle-CS, and within other OARs for two patients for Helax-CC (for Dmax of the heart and D33 
of the expanded esophagus) but only for 6 MV. For one patient, all four algorithms were used to 
recompute the dose after replacing all computed tomography voxels within the patient’s skin 
contour by water. This made all differences above 5% between MCDE and the other dose 
calculation algorithms disappear. Thus, the observed deviations mainly arose from differences 
in particle transport modeling within the lungs, and the commissioning of the algorithms was 
adequately performed (or the commissioning was less important for this type of treatment). In 
conclusion, not one pair of the dose calculation algorithms we investigated could provide 
results that were consistent within 5% for all 10 patients for the set of clinically relevant dose-
volume indices studied. As the results from both CS algorithms differed significantly, care 
should be taken when evaluating treatment plans as the choice of dose calculation algorithm 
may influence clinical results. Full Monte Carlo provides a great benchmarking tool for 
evaluating the performance of other algorithms for patient dose computations. 
Key words: Monte Carlo, convolution/superposition, pencil beam, lung cancer, intensity 
modulated radiation therapy (IMRT) 
 
I. INTRODUCTION 
The level of refinement of dose calculation algorithms used for clinical 
radiotherapy treatment planning has increased highly over the past 
decades. The accuracy of patient dose predictions has continuously 
improved by moving from simple scatter- and inhomogeneity corrections 
over pencil beam algorithms to point kernel-based convolution/ 
superposition (CS) methods. Calculating dose distributions for lung 
cancer makes great demands on computational engines, as regions of 
electronic disequilibrium arise in the presence of tissue inhomogeneities, 
for example, at the tumor-lung interface. Due to the steep slopes of tumor 
control probability (TCP) and normal tissue complication probability 
(NTCP) curves, a dose error of 5% may lead to a change in TCP of 10 to 
20% and to an even larger change in NTCP.1,2 Therefore, we must 
obviously try to avoid any (systematic) differences between the planned 
and delivered dose distributions. 
By explicitly modeling the particle transport, full Monte Carlo (MC) 
simulations are expected to result in the highest dose calculation 
accuracy. Experiments involving phantom measurements have already 
shown that MC calculations are clearly superior to conventional systems, 
including CS algorithms, near low density materials and around air 
cavities.3–7 For pencil beam algorithms, deviations from MC calculations 
and measurements larger than 10% have been reported. All of these 
experiments study the effect of a single beam on a large air or lung cavity. 
Transferring these results to a clinical setting is not at all obvious. 
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Therefore, it is important to evaluate the accuracy of dose calculation 
algorithms directly within their ultimate field of application: the 
computation of patient dose distributions for clinical treatment plans. 
This will enable us to evaluate their performance for a variety of tissue 
inhomogeneity shapes and sizes, as well as for a large number of small 
and irregularly shaped beam segments for a combination of beam 
incidences. 
Several studies have compared MC computations with pencil beam 
calculations for clinical cases, especially demonstrating the latter’s 
shortcomings in regions with tissue heterogeneities.8–14 Data on the 
comparison of MC with CS algorithms are more scarce15–17 and to our 
knowledge no such study has been devoted to intensity modulated 
radiation therapy (IMRT) for lung cancer yet. By reducing the dose to 
critical organs relative to the tumor prescription dose, IMRT techniques 
allow dose escalation with the aim to improve local control. However, the 
use of a large number of irregularly shaped segments implies the need for 
an accurate dose calculation algorithm. The purpose of the present study 
was to compare full MC calculations of patient dose distributions with 
results from two different commercial CS implementations and one pencil 
beam algorithm for 10 clinical lung IMRT cases for two photon beam 
qualities (6 and 18 MV). This also allowed for a comparison between both 
CS algorithms. 
 
II. MATERIALS AND METHODS 
A. Patients and IMRT treatment planning 
Ten non-small-cell lung cancer patients with various tumor 
locations were randomly selected for this study. For each patient, a 
median dose of 70 Gy was prescribed to the planning target volume 
(PTV). This PTV results from a 5-mm-wide isotropic expansion of the 
clinical target volume (CTV), which is derived from the macroscopic 
gross tumor volume (GTV). To deal with conflicting dose objectives 
during the optimization, a 6-mm-wide expansion of all organs at risk 
(OARs) is excluded from the PTV.18 The lungs, heart, esophagus, and 
spinal cord were delineated as OARs. The lungs include both the 
ipsilateral and contralateral lung, but they exclude the GTV. The 
esophagus was expanded by a 3-mm-wide isotropic margin, while the 
spinal cord was expanded by a 5-mm-wide isotropic margin. Treatment 
planning objectives for the OARs were formulated as follows. For the 
lungs, V20 and V30 should not exceed 30 and 20%, respectively, while the 
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mean lung dose (MLD) should not exceed 27 Gy. Vx is the relative lung 
volume (percentage) that receives at least x Gy. For the heart, the maximal 
dose (Dmax) should not exceed 62 Gy, while D33, D67, and the minimal dose 
(Dmin) should not exceed 55 Gy, 50 Gy, and 40 Gy, respectively. A dose of 
at least Dx is received by x% of the OAR’s volume. Dmax and Dmin are 
represented by D2 and D98.19 For the expanded esophagus Dmax, D33, D67, 
and Dmin should not exceed 68 Gy, 60 Gy, 54 Gy, and 50 Gy, respectively. 
For the expanded spinal cord, Dmax should not exceed 50 Gy. 
For each patient, two IMRT treatment plans were created with 
photon beam qualities of 6 MV and 18 MV. A class solution of nine non-
coplanar beams with a single isocenter was applied. A combination of 
GRATIS (Sherouse Systems, Inc, Chapel Hill, NC, USA) and in-house 
developed software was used for planning. For every template beam, 
initial beam segments were created by the anatomy-based segmentation 
tool (ABST), taking into account the presence of OARs and the distance to 
the skin.20 Segment weights and multileaf collimator (MLC) leaf positions 
were optimized by the segment outline and weight adapting tool 
(SOWAT); the optimization uses a biophysical cost function.21 Dose 
computation between optimization cycles was performed by Pinnacle 
version 6.2b (Philips Medical Systems, Best, The Netherlands). The 6 MV 
and 18 MV plans were optimized independently. 
B. Dose calculation algorithms 
Four different calculation algorithms were used to recompute the 
final dose for all plans. MCDE (Monte Carlo dose engine) is an accurate 
MC code for IMRT dose computations. Based on the 
BEAMnrc/DOSXYZnrc system,22 MCDE uses the most recent EGSnrc 
electron transport algorithms.23 Reynaert et al.24 have described the 
working of MCDE. The commissioning of the 6 MV and 18 MV photon 
beams of the Elekta SLiplus linear accelerator at Ghent University 
Hospital has been reported in detail elsewhere,25,26 including data on the 
comparison of simulations and measurements. The MLC was modeled 
using BEAMnrc’s MLCE component module (CM), which takes into 
account the tongue-and-groove design of the MLC as well as the air gap 
between the leaves. A phase space file scored below the mirror is used as 
input in MCDE. By having DOSXYZnrc reprogrammed as an additional 
CM, MCDE handles the beam modifiers and the patient in one process. 
Pinnacle version 6.2b and Helax-TMS version 6.1A (Nucletron, 
Veenendaal, The Netherlands) are two commercial treatment planning 
systems which incorporate CS algorithms. These algorithms convolve the 
energy released by a photon per unit mass with energy deposition 
kernels.27 For inhomogeneous media, the energy deposition kernels are 
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scaled with density. Pinnacle’s CS model (Pinnacle-CS) is based on the 
work of Mackie et al. and Papanikolaou et al.28–30 Just like Pinnacle-CS, 
Helax-TMS’s collapsed cone model (Helax-CC) involves point kernels,31 
while its simpler pencil beam model (Helax-PB) is based on pencil 
kernels.32 We did not introduce bias by including the algorithm used by 
the optimization engine (Pinnacle-CS) in our comparison, as we directly 
compared the resulting dose distributions with each other and did not 
evaluate their individual compatibility with the planning objectives. 
Beam and computed tomography (CT) data for all plans were 
interchanged between MCDE, Pinnacle-CS, Helax-CC, and Helax-PB 
through a DICOM interface. A common scoring grid with an equal 
spacing of 5 mm in the x, y, and z directions was used. For each MCDE 
calculation, 25 million particles were transported through the patient-
dependent part of the linac head and the patient geometry. To convert CT 
numbers into elemental composition data, six material bins were 
introduced (air, lung, adipose, muscle, cartilage, and cortical bone), while 
the mass density was calibrated continuously against the CT number. 
Each MCDE scoring voxel had a radius of 2 mm.33 The resulting dose 
grids were converted from dose-to-medium to dose-to-water.34 As the 
same set of commissioning measurements was used to customize the 
beams for clinical use for both Pinnacle and Helax-TMS, a fair comparison 
could be made. 
To eliminate the effect of differences in particle transport modeling 
within the patient, additional computations for each of the dose 
calculation algorithms and for both energies were performed for one 
patient after setting all CT voxels within the skin contour to water 
(density=1 g/cm3). 
C. Dose reporting and evaluation 
For each patient, dose-volume histograms (DVHs) were created 
with the PLUNC   software (Plan UNC, University of North Carolina) for 
the dose distributions of both the 6 MV and 18 MV plans calculated by all 
four-dose calculation algorithms for the following structures: GTV, PTV, 
lungs, heart, expanded esophagus, and expanded spinal cord. Individual 
dose-volume points were also recorded. Dmin, D50, and Dmax were 
evaluated for the GTV and PTV. For the lungs, V30, V20, and MLD were 
reported. D33 and Dmax were evaluated for the expanded esophagus and 
for the heart. Dmax was recorded for the expanded spinal cord. In the case 
of steep DVHs, volume points (Vx) have a greater variability than dose 
points (Dx). Therefore, comparison of dose engines should preferably be 
based directly on dose point differences and not on the extrapolation of 
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volume point differences. For the lungs, however, we report values of V30 
and V20 because of their importance in clinical treatment plan evaluation; 
typically, the relevant part of the DVH is reasonably flat. 
To detect systematic differences between the dose calculation 
algorithms, one-way analysis of variance (ANOVA) for repeated 
measurements35 was performed for each dose-volume point, structure, 
and beam energy combination. Tukey’s method was used to perform 
pairwise comparison of means. P values below 5% were considered 
significant. Although the ANOVA method efficiently allows us to gain 
insight in systematic deviations, it is questionable whether all patients can 
be considered random samples from the same population, considering 
their differences in anatomy, tumor location, and tumor size. Therefore, 
and due to the limited number of patients in our study, it is essential to 
evaluate differences observed in individual patients as well. For this 
purpose, relative dose-volume differences (percentage) between the 
results from the different dose calculation algorithms were computed for 
each patient, dose-volume point, structure, and beam energy 
combination. Whenever relative dose-volume differences are reported, 
this is done by dividing the absolute difference by the prescription dose 
(70 Gy) for target structures or by the maximally tolerable value indicated 
by the treatment planning objectives for the OARs. 
 
III. RESULTS 
A. ANOVA and pairwise comparison of means 
Tables I and II show the results of the statistical analysis for the 6 
MV and 18 MV plans, respectively. Each table row corresponds to a 
certain dose-volume point for a certain target or OAR. The p value of the 
one-way ANOVA for repeated measurements (for the same dose-volume 
point for all 10 patients) is reported. For all six possible pairs of dose 
calculation algorithms, the mean value (averaged over all patients) of the 
relative difference in dose-volume value between each pair is presented, 
as well as the corresponding p value according to Tukey’s multiple 
comparison procedure. P values below 5% are printed in bold. 
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For 6 MV (Table I), there are significant differences between at least 
two of the dose calculation algorithms for all dose-volume points. When 
comparing MCDE to the other three algorithms, Pinnacle-CS certainly 
shows the best correspondence within the target structures (within 2% for 
all dose-volume points), although MCDE reports significantly higher 
Dmax-values (+1.5% for the GTV and +1.7% for the PTV). Helax-CC and 
Helax-PB both deviate significantly from MCDE within the target 
structures, but in opposite directions: Helax-PB reports higher doses than 
MCDE (up to +3.2% for PTV-Dmin), while Helax-CC reports lower dose 
values (up to −3.1% for PTV-Dmax). As expected due to the 
correspondence between MCDE and Pinnacle-CS within the targets, 
Pinnacle-CS also reports significantly higher doses than Helax-CC (up to 
+3.1% for PTV-Dmin), and significantly lower doses than Helax-PB (up to 
−4.4% for PTV-Dmax). Consequently, both Helax algorithms differ 
significantly for all target dose-volume points (up to 5.9% for PTV-Dmin). 
TABLE I. Results of the statistical analysis for 6 MV. For each target or OAR and for every 
dose-volume point, one-way ANOVA for repeated measurements was performed. For each 
pair of dose calculation algorithms studied, results of the pairwise comparison of means 
according to Tukey’s method are reported. Significant p values (<5%) are printed in bold. 
 
   MCDE            
- Pinnacle-CS 
MCDE             
– Helax-CC 
MCDE            
– Helax-PB 
Pinnacle-CS   
– Helax-CC 
Pinnacle-CS    
– Helax-PB 
Helax-CC        
– Helax-PB 
6 MV  
p-
value 
ANO-
VA 
Mean 
Rel. 
Diff. 
(%) p 
Mean 
Rel. 
Diff. 
(%) p 
Mean 
Rel. 
Diff. 
(%) p 
Mean 
Rel. 
Diff. 
(%) p 
Mean 
Rel. 
Diff. 
(%) p 
Mean 
Rel. 
Diff. 
(%) p 
Targets 
GTV Dmin 0.001 -0.60 0.547 0.49 0.701 -1.45 0.014 1.09 0.092 -0.85 0.251 -1.94 0.001 
 D50 0.000 0.19 0.954 1.69 0.000 -0.49 0.542 1.50 0.001 -0.68 0.263 -2.18 0.000 
 Dmax 0.000 1.54 0.002 2.82 0.000 -0.24 0.928 1.27 0.012 -1.78 0.000 -3.06 0.000 
PTV Dmin 0.000 -0.47 0.918 2.63 0.005 -3.24 0.001 3.10 0.001 -2.77 0.003 -5.87 0.000 
 D50 0.000 0.13 0.986 1.96 0.000 -1.99 0.000 1.83 0.000 -2.12 0.000 -3.95 0.000 
 Dmax 0.000 1.71 0.018 3.06 0.000 -2.70 0.000 1.35 0.082 -4.41 0.000 -5.76 0.000 
Organs at risk 
Lungs V30 0.000 1.84 0.138 -0.12 0.999 -2.53 0.021 -1.96 0.103 -4.37 0.000 -2.41 0.030 
 V20 0.000 2.89 0.000 -0.29 0.968 0.51 0.846 -3.17 0.000 -2.37 0.003 0.80 0.588 
 MLD 0.000 3.05 0.000 1.06 0.011 -1.46 0.000 -1.99 0.000 -4.51 0.000 -2.52 0.000 
Heart D33 0.000 1.20 0.002 -0.06 0.997 -1.11 0.005 -1.27 0.001 -2.31 0.000 -1.04 0.008 
 Dmax 0.036 0.86 0.755 0.33 0.980 -1.71 0.217 -0.53 0.928 -2.57 0.026 -2.04 0.105 
D33 0.022 -0.07 1.000 1.19 0.670 -2.26 0.155 1.26 0.629 -2.19 0.175 -3.45 0.011 Expanded 
esophagus Dmax 0.000 0.69 0.612 1.45 0.063 -2.22 0.002 0.76 0.532 -2.90 0.000 -3.66 0.000 
Dmax 0.000 2.48 0.001 0.46 0.869 -0.43 0.894 -2.01 0.011 -2.91 0.000 -0.89 0.465 Expanded 
spinal cord               
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  On the other hand, the statistical analysis indicates an excellent 
correspondence between MCDE and Helax-CC for the organs at risk 
(within 1.5% for all dose-volume points), although there is a small but 
significant underestimation of MLD by Helax-CC (−1.1%). Pinnacle-CS 
strongly underestimates the dose to critical structures compared to 
MCDE and Helax-CC, in particular for the lungs (−2.9% for V20 and −3.1% 
for MLD), the heart (−1.2% for D33), and the expanded spinal cord (−2.5% 
for Dmax). Helax-PB, on the other hand, has a tendency to overestimate the 
dose delivered to the organs at risk compared to MCDE (up to +2.5% for 
lungs-V30) and Helax-CC (up to +3.7% for expanded esophagus-Dmax), 
although for some dose-volume points its reported values show good 
correspondence, for example, V20 for the lungs (−0.5% compared to 
MCDE and −0.8% compared to Helax-CC) and Dmax for the expanded 
spinal cord (+0.4% compared to MCDE and +0.9% compared to Helax-
CC). Unsurprisingly, the dose-volume values of Helax-PB are 
significantly higher than those of Pinnacle-CS (up to +4.5% for MLD). 
TABLE II. Results of the statistical analysis for 18 MV. For each target or OAR and for every 
dose-volume point, one-way ANOVA for repeated measurements was performed. For each 
pair of dose calculation algorithms studied, results of the pairwise comparison of means 
according to Tukey’s method are reported. Significant p values (<5%) are printed in bold. 
   MCDE            
- Pinnacle-CS 
MCDE             
– Helax-CC 
MCDE            
– Helax-PB 
Pinnacle-CS   
– Helax-CC 
Pinnacle-CS    
– Helax-PB 
Helax-CC        
– Helax-PB 
6 MV  
p-
value 
ANO-
VA 
Mean 
Rel. 
Diff. 
(%) p 
Mean 
Rel. 
Diff. 
(%) p 
Mean 
Rel. 
Diff. 
(%) p 
Mean 
Rel. 
Diff. 
(%) p 
Mean 
Rel. 
Diff. 
(%) p 
Mean 
Rel. 
Diff. 
(%) p 
Targets 
GTV Dmin 0.000 -2.18 0.000 0.65 0.238 -1.56 0.000 2.83 0.000 0.63 0.265 -2.20 0.000 
 D50 0.000 -1.08 0.014 2.25 0.000 -0.58 0.320 3.33 0.000 0.50 0.454 -2.83 0.000 
 Dmax 0.000 0.71 0.878 3.32 0.007 -3.31 0.007 2.61 0.044 -4.02 0.001 -6.64 0.000 
PTV Dmin 0.000 -0.92 0.583 0.86 0.635 -3.72 0.000 1.79 0.082 -2.80 0.002 -4.58 0.000 
 D50 0.000 -1.03 0.067 2.03 0.000 -2.66 0.000 3.07 0.000 -1.63 0.001 -4.70 0.000 
 Dmax 0.000 0.90 0.863 3.35 0.032 -7.95 0.000 2.44 0.169 -8.85 0.000 -11.30 0.000 
Organs at risk 
Lungs V30 0.000 2.81 0.000 0.25 0.969 0.19 0.986 -2.56 0.000 -2.62 0.000 -0.06 0.999 
 V20 0.000 8.05 0.000 0.38 0.992 4.40 0.013 -7.67 0.000 -3.65 0.049 4.02 0.026 
 MLD 0.000 3.73 0.000 1.20 0.053 -0.87 0.238 -2.52 0.000 -4.59 0.000 -2.07 0.000 
Heart D33 0.000 0.88 0.001 0.48 0.142 -0.29 0.539 -0.41 0.261 -1.18 0.000 -0.77 0.006 
 Dmax 0.149 1.02 0.469 0.66 0.783 -0.52 0.879 -0.37 0.952 -1.54 0.141 -1.17 0.348 
D33 0.014 0.59 0.800 0.58 0.804 -1.40 0.151 -0.01 1.000 -1.98 0.020 -1.98 0.020 Expanded 
esophagus Dmax 0.000 0.11 0.995 1.44 0.014 -2.30 0.000 1.33 0.026 -2.40 0.000 -3.73 0.000 
Dmax 0.001 2.14 0.000 0.89 0.227 0.88 0.233 -1.25 0.045 -1.26 0.044 -0.01 1.000 Expanded 
spinal cord               
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For 18 MV (Table II), only for Dmax of the heart is there no 
significant difference between all four dose calculation algorithms 
(p=0.149). Again, MCDE and Pinnacle-CS show the best correspondence 
within the target structures (within 1% for the dose-volume points within 
the PTV), although Pinnacle-CS reports significantly higher values of the 
minimal and median dose within the GTV (+2.2% and +1.1%, 
respectively). As with 6 MV, Helax-PB reports higher target dose values 
than MCDE (up to +8.0% for PTV-Dmax) and Pinnacle-CS (up to +8.9% for 
PTV-Dmax), while Helax-CC reports lower values (up to −3.4% for PTV-
Dmax compared to MCDE and up to −3.3% for PTV-D50 compared to 
Pinnacle-CS). Helax-PB and Helax-CC differ significantly for all dose-
volume points within the GTV (up to 6.6% for Dmax) and PTV (up to 11.3% 
for Dmax). 
Except for the maximal dose delivered to the expanded esophagus 
(p=0.014), the statistical analysis indicates an excellent agreement between 
MCDE and Helax-CC for all OAR dose-volume points (within 1.5%), 
whereas Pinnacle-CS again underestimates dose-volume values within 
most critical structures (up to −8.1% for lungs-V20 compared to MCDE). 
Helax-PB has a tendency to overestimate OAR doses compared to Helax-
CC (up to +3.7% for expanded esophagus-Dmax), although its results still 
agree well with those of MCDE (within 1.5%, except for lungs-V20 :−4.4% 
and expanded esophagus-Dmax: +2.3%). 
B. Individual patients 
Figure 1 summarizes the comparison results for individual patients. 
The upper-right corner of the matrix plot represents the 6 MV results, 
while the 18 MV results are shown in the lower-left corner. Each 
individual plot contains data on the relative dose-volume differences 
between the two dose calculation algorithms indicated by each plot’s row 
and column headers. Each bar within a plot corresponds to a certain dose-
volume point for a certain target or OAR, in the same order as found in 
Tables I and II. For every dose-volume point the patients were divided 
into three categories, where the absolute value of the relative difference 
was either below 2% (white), between 2% and 5% (light gray), or above 
5% (dark gray). 
For 6 MV, it is clear that the best correspondence between target 
dose-volume values can be found between MCDE and Pinnacle-CS, in 
agreement with the results of our statistical analysis. The difference 
between MCDE and Helax-CC is above 5% (9.0%) for only one patient 
(for Dmin of the PTV), which puts the obtained statistically significant 
differences into perspective. On the other hand, while our statistical 
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analysis indicates a good resemblance between MCDE and Helax-CC for 
the OAR dose-volume points, Fig. 1 shows two patient/dose-volume 
point combinations where the observed difference is above 5% (−6.1% for 
Dmax of the heart and +11.1% for D33 of the expanded esophagus). A 
similar situation can be found in Fig. 1 for the OAR differences between 
MCDE and Pinnacle-CS, with deviations of +6.1 and +5.3% occurring for 
V20 of the lungs. Helax-PB shows unacceptably great deviations from the 
other three dose calculation algorithms for both targets and OARs. For 18 
MV MCDE, Pinnacle-CS, and Helax-CC correspond very well with regard 
to the target structures. Only for one patient, a deviation larger than 5% 
occurred between MCDE and Helax-CC (+5.2% for Dmax of the PTV). For 
the OARs, the difference in dose-volume value between MCDE and 
Helax-CC is within 5% in all cases, while Pinnacle-CS clearly shows larger 
deviations: both for the comparison with MCDE and Helax-CC, 
differences above 5% are reported for 11 patient/dose-volume point 
combinations, mainly within the lungs. Again, Helax’s pencil beam 
algorithm is clearly inferior to the other CS algorithms and to MCDE. 
 
FIG. 1. Individual patient results for 6 MV (upper-right corner) and 18 MV (lower-left 
corner). For each pair of dose calculation algorithms and for each dose-volume point 
corresponding to a certain target or organ at risk, the number of patients for which the 
absolute value of the observed relative dose-volume difference was below 2% (white), 
between 2% and 5% (light gray), and above 5% (dark gray) is shown. 
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FIG. 2. Dose-volume histograms of the PTV and the lungs for patient number 4, computed by 
our MCDE, Pinnacle’s CS algorithm, and Helax-TMS’s collapsed cone and pencil beam 
algorithms: (a) for 6 MV, (b) for 6 MV and after replacing all CT voxels within the skin 
contour with water, (c) for 18 MV, and (d) for 18 MV and after replacing all CT voxels within 
the skin contour with water. 
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To illustrate the observed differences for individual patients, Fig. 2 
shows an exemplary set of DVHs (for patient number 4) of the PTV and of 
the lungs for all four dose calculation algorithms for 6 MV (a) and 18 MV 
(c). For 6 MV, both Helax-CC and Helax-PB deviate up to 3% from MCDE 
within the PTV, but in opposite directions, while the Pinnacle-CS curve 
stays within 1% from the MCDE curve. For the lungs, Pinnacle-CS 
underestimates the observed dose-volume values compared to MCDE (up 
to −5.3% for V20), while the deviations between Helax-PB and MCDE are 
more moderate (up to −4.0% for V20). The clinically relevant dose-volume 
values of Helax-CC correspond within 2% with those of MCDE within the 
lungs. For 18 MV, Pinnacle-CS still shows the best correspondence with 
MCDE within the PTV (up to +2.1% for Dmin), followed by Helax-CC (up 
to −3.9% for Dmax). Dmax within the PTV is overestimated by Helax-PB 
compared to MCDE by 5.6%. For the lungs, Pinnacle-CS underestimates 
V30 and V20 by 5.5 and 6.4%, respectively. Deviations between Helax-PB 
and MCDE are also over 4% (−4.4% for V30 and −4.3% for V20); while for 
Helax-CC, the clinically relevant dose-volume values again stay within 
2% of those reported by MCDE. 
C. Calculations in water 
All four dose calculation algorithms were used to recompute the 
dose for patient number 4 after replacing all CT voxels with water within 
the patient’s skin contour. The DVHs of the PTV and the lungs are shown 
in Fig. 2 for 6 MV (b) and 18 MV (d). For 6 MV both the Pinnacle-CS and 
Helax-CC curves now stay within 2% from the MCDE curve for the PTV, 
while the differences between MCDE and Helax-PB become slightly 
larger compared to the calculations in medium (up to +3.5% for Dmin). For 
the lungs, the deviations of Pinnacle-CS from MCDE for the clinically 
relevant dose-volume points greatly decrease compared to the 
calculations in medium (−0.7% instead of −5.3% for V20). The deviation 
between Helax-PB and MCDE for V20 is reduced to +3.1%. For 18 MV all 
algorithms agree within 2.2% with MCDE within the PTV for the 
calculations in water (+2.2% instead of +5.6% for the difference in Dmax 
between Helax-PB and MCDE). For the reported dose-volume points 
within the lungs, Pinnacle-CS differs much less from MCDE compared to 
the calculations in medium (−2.7% instead of −5.5% for V30 and −2.4% 
instead of −6.4% for V20). Deviations between Helax-PB and MCDE are 
reduced from −4.4% to −0.1% for V30 and from −4.3% to +1.9% for V20. 
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IV. DISCUSSION 
Both from the statistical analysis and the evaluation of individual 
patient cases, it is clear that large deviations occur between the different 
dose calculation algorithms. Therefore, substantial errors can be made 
when an insufficiently accurate dose computation engine is selected. For 
treatment planning of lung cancer, it is highly important to take into 
account differences in tissue density during dose computation and to 
model secondary electron transport accurately.36 If the lower attenuation 
of photon beams within lung tissue is not considered, the dose to tissues 
downstream will be underestimated. Furthermore, as the electron path 
length within lung amounts to several centimeters, the beam penumbra 
widens, exposing larger volumes of lung to significant doses and 
reducing the dose near the beam edge.37,38 Additionally, an imbalance 
between the number of produced and absorbed electrons arises near the 
interface between low and high density tissues, causing the dosage to 
build up.4,39,40 The electronic disequilibrium occurring in these cases will 
again cause an underestimation of the dose to the lung if its effect is not 
taken into account. Moreover, these effects are expected to become more 
pronounced for higher photon energies, smaller field sizes, and decreased 
lung densities.3,41,42 Both Helax-CC and Pinnacle-CS apply three-
dimensional (3D) density scaling of their kernels for inhomogeneous 
media,31 whereas Helax-PB only employs a one-dimensional 
inhomogeneity correction through depth scaling.32 Helax-CC also uses 
kernel tilting and accounts for beam hardening and off-axis softening,43,44 
like Pinnacle-CS. Electron transport is modeled most accurately in MCDE 
through the EGSnrc code.23 
Although measurement data may be helpful in establishing the 
ground truth between the four dose calculation algorithms, the accuracy 
of 3D gel dosimetry or radiochromic film in anthropomorphic phantoms 
is presently limited around 3%, which is comparable to the differences 
that were observed in our study. Research on establishing measurement 
protocols for dose verification of clinical (lung) cases is ongoing, and we 
may certainly benefit from experimental verification in the future. On the 
other hand, comparison with measurements has shown that MCDE 
performs excellently even for narrow offset fields.16 Details on the 
commissioning and validation of the 6 MV and 18 MV photon beams 
have been published as well.25,26 Moreover, none of the data presented in 
this paper indicate that any systematic errors may still be present when 
MCDE is used to perform patient dose calculations. The calculations in 
water that were performed for patient number 4 show that the observed 
differences mainly arise from differences in particle transport modeling 
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within the patient, as the observed deviations between MCDE and the 
other dose calculation algorithms strongly decreased compared to the 
calculations in medium. Because MCDE incorporates the most accurate 
electron transport of the four dose calculation algorithms, we believe it is 
safe to assume that MCDE is the system that is the closest to the ground 
truth in our study. 
By performing a one-way ANOVA for repeated measurements, we 
can detect systematic differences between dose calculation algorithms. 
Pairwise comparison of means is performed by averaging dose-volume 
differences between two algorithms over all patients. Consequently, if the 
difference between two algorithms is a large positive value for one 
patient and a large negative value for another patient, both values will 
cancel each other out in the final evaluation and will cause the test to 
conclude that there is no evidence of significant difference between both 
algorithms. However, such a situation would be unacceptable for clinical 
practice. An example can be found in our data set for D33 of the expanded 
esophagus comparing Pinnacle-CS to Helax-PB for 6 MV. On the other 
hand, if deviations are small but in the same direction (positive or 
negative) for all patients, the test may conclude that both algorithms 
differ significantly. At the same time, looking at individual patient results 
may show that all the observed differences are within 5%, which could 
certainly be considered acceptable for clinical use. An example of this can 
be seen in our data set for comparison between MCDE and Helax-CC 
within the target structures. While the statistical analysis is valuable for 
gaining initial insight in systematic differences, additional analysis of 
individual patient results remains indispensable for evaluating the 
practicability of the different dose calculation algorithms. In principle, if 
only one patient shows an unacceptably large deviation for one dose 
calculation algorithm, this algorithm is no longer suitable for clinical use 
(for this type of patient). 
From our data set, Pinnacle-CS could be considered the best CS 
algorithm for dose determination within the target structures, whereas 
Helax-CC yields better results for the OARs. As illustrated by Figs. 2(a) 
and 2(c), Helax-CC typically underestimates the dose to the PTV (and 
other target structures), while Pinnacle-CS has a tendency to 
underestimate the dose to the lungs. For individual patients, both 
algorithms show deviations over 5% from MCDE (except for Pinnacle-CS 
within the targets). As the algorithms behind the commercial treatment 
planning systems are not known in detail to the user, it is not so easy to 
explain the observed differences. To investigate this, it is advisable to 
distinguish effects related to differences in beam modeling from effects 
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related to the particle transport within the patient.45 For a proper 
comparison, an accurate beam model is required, which provides an 
excellent agreement between calculations and measurements in 
homogeneous phantoms. By recomputing the dose after setting all CT 
voxels within the skin contour to water for patient number 4 as an 
exemplary patient case, we could eliminate the influence of particle 
transport within the patient. The results are shown in Figs. 2(b) and 2(d). 
The DVHs of the different dose calculation algorithms clearly lay closer 
together for the calculations in water compared to those in medium. 
Analysis of the clinically relevant dose-volume values shows that all 
deviations above 5% between MCDE and the other dose calculation 
algorithms disappear, for example, the difference between Pinnacle-CS 
and MCDE for V20 within the lungs decreases from −5.3% to −0.7% for 6 
MV and from −6.4% to −2.4% for 18 MV. Thus, for this patient, the 
observed differences were mainly due to the modeling of the particle 
transport within the patient by the different dose calculation algorithms. 
The remaining differences are all clinically acceptable and are either due 
to slight discrepancies in the commissioning process or to differences in 
the beam model. Due to the relatively large fields involved in lung cancer 
treatments, the accuracy of the beam model is less important here than, 
for example, in cases of treatments of head and neck tumors close to or 
within the oral or nasal cavity. As the differences between the calculations 
in medium mainly arise from the modeling of secondary electron 
transport within the lungs, the deviations are the most striking within the 
PTV and the lungs and not so much within the other OARs. 
To maximize the accuracy while commissioning a treatment 
planning system, it is important to consider the specific field of 
application of future dose calculations. In the case of IMRT, which 
involves the use of a large number of small and irregularly shaped fields, 
one should attach great importance to the similarity between simulations 
and measurements for small offset fields, rather than focus on large 
central fields. Indeed, when commissioning a commercial treatment 
planning system, limitations of the beam model require a compromise, as 
it is generally not possible to achieve perfect agreement for both large and 
small fields, central and off-axis. Moreover, attention should be paid to 
the fact that the commissioning process should take place based on fields 
shaped by the MLC only, that is, with the jaws retracted. Again, this aims 
to mimic the clinical reality, because large parts of a highly irregular field 
contour will be created by the MLC leaves and not by the jaws. 
 
Biologically conformal RT and Monte Carlo dose calculations in the clinic 
 94
The treatment plan configuration (number of beams or beam 
segments, shapes and angles) may influence dose calculation errors in 
various ways. As IMRT typically combines a large number of beam 
angles (in our case, 9) as well as a large number of segments for each 
beam angle, the superposition of dose contributions from the individual 
beam segments may wipe out differences between dose calculation 
algorithms. Indeed, it has been stated that larger differences are observed 
when comparing individual fields.9 Therefore, 3D conformal treatment 
plans may be more crucial when it comes to evaluating the performance 
of the inhomogeneity correction of a certain dose calculation algorithm, 
because of the smaller number of treatment fields. On the other hand, the 
fact that IMRT beam segments will generally be smaller than 3D field 
shapes will potentially increase dose errors for IMRT. Larger errors may 
also arise for IMRT treatments due to increased MLC transmission in the 
presence of irregularly shaped beam segments. It is obvious that the type 
of treatment machine and the way in which leaf sequencing is performed 
also contribute to the entire treatment plan configuration; hence these 
factors may also influence the magnitude of dose errors. The way in 
which the treatment plan configuration affects the accuracy of dose 
calculation within inhomogeneous patient geometries is certainly worth 
further investigation. It is clear that care should be taken not to generalize 
the results presented in this paper toward other treatment configurations. 
Moreover, inhomogeneity effects are expected to become more 
distinct for higher photon energies. Figure 1 clearly illustrates the 
presence of more large deviations (over 5%) between the dose-volume 
values reported within the lungs for 18 MV than for 6 MV. Again, 
analysis of individual segments may allow us to study the influence of 
beam quality in more detail, as differences will become more pronounced. 
From the large variety in deviations observed for the same dose-
volume parameter in different patients, it follows that individual patient 
anatomy plays an important role. Together with a profound knowledge 
of the causes of the observed dose-volume differences between 
algorithms, extensive patient data sets may allow us to formulate 
guidelines concerning the appropriate dose calculation algorithm based 
on tumor location and size. If a particular anatomy is more “difficult” or 
“critical”, for example, because the tumor is located close to the edge of 
the lungs, a more accurate (but time-consuming) dose calculation 
algorithm could be recommended. Research focusing on individual 
segments may give us more insight into the strengths and weaknesses of 
different dose calculation algorithms. At the moment, dose engines like 
MCDE are not suitable for use in routine clinical practice, due to the 
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present limitations in computer power. Faster MC solutions, which 
include several approximations and simplifications to increase calculation 
speed, are commercially available. Like any other dose calculation 
algorithm, these practical MC codes need to be benchmarked before 
clinical use. Full MC provides a great tool for benchmarking the 
performance of other dose calculation algorithms within patients (where 
measurements are difficult or even impossible), as it models particle 
transport most accurately. 
 
V. CONCLUSIONS 
We compared full Monte Carlo calculations (performed by our 
Monte Carlo dose engine MCDE) with two different commercial CS 
implementations (Pinnacle-CS and Helax-TMS’s collapsed cone model 
Helax-CC) and one pencil beam algorithm (Helax-TMS’s pencil beam 
model Helax-PB) for 10 IMRT lung cancer patients and two photon beam 
qualities (6 and 18 MV). Statistical analysis was performed by means of 
one-way ANOVA for repeated measurements and pairwise comparison 
of means according to Tukey’s method. Pinnacle-CS showed an excellent 
correspondence with MCDE for dose evaluation within the target 
structures, whereas the best correspondence for the OARs was found 
between Helax-CC and MCDE. Results from Helax-PB were unsatisfying 
for both target and OARs. As the statistical analysis averages pairwise 
differences over all patients, it is valuable for gaining insight in systematic 
differences. However, additional analysis of individual patient results 
remains indispensable. 
Not one pair of the dose calculation algorithms we investigated 
could provide results that were consistent (within 5%) for all 10 patients 
for the set of clinically relevant dose-volume indices studied. This was 
even true for both CS algorithms: Pinnacle-CS and Helax-CC. The choice 
of dose calculation algorithm may thus influence treatment planning as 
well as clinical results. After setting all CT voxels within the skin contour 
to water for one patient, all differences above 5% between MCDE and the 
other dose calculation algorithms disappeared. Thus, the deviations 
observed for the calculations in medium mainly arose from the 
differences between the algorithms in secondary electron transport 
modeling within the lungs. As it directly models particle transport, full 
Monte Carlo provides a great benchmarking tool for evaluating the 
performance of other algorithms for patient dose computations. 
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Abstract 
Background and purpose: To compare 6 MV and 18 MV photon intensity modulated radiotherapy 
(IMRT) for non-small cell lung cancer. 
Materials and methods: Doses for a cohort of 10 patients, typical for our department, were 
computed with a commercially available convolution/superposition (CS) algorithm. Final dose 
computation was also performed with a dedicated IMRT Monte Carlo dose engine (MCDE). 
Results: CS plans showed higher D95% (Gy) for the GTV (68.13 vs 67.36, p = 0.004) and CTV (67.23 
vs 66.87, p = 0.028) with 18 than with 6 MV photons. MCDE computations demonstrated higher 
doses with 6 MV than 18 MV in D95% for the PTV (64.62 vs 63.64, p = 0.009), PTVoptim (65.48 vs 
64.83, p = 0.014) and CTV (66.22 vs 65.64, p = 0.027). Dose inhomogeneity was lower with 18 
than with 6 MV photons for GTV (0.08 vs 0.09, p = 0.007) and CTV (0.10 vs 0.11, p = 0.045) in CS 
but not MCDE plans. 6 MV photons significantly (D33%; p = 0.045) spared the esophagus in 
MCDE plans. Observed dose differences between lower and higher energy IMRT plans were 
dependent on the individual patient. 
Conclusions: Selection of photon energy depends on priority ranking of endpoints and 
individual patients. In the absence of highly accurate dose computation algorithms such as CS 
and MCDE, 6 MV photons may be the prudent choice. 
Keywords: Intensity modulated radiotherapy; Non-small cell lung cancer; Loss of electronic 
equilibrium 
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High-energy photons for treatment of deep targets improve dose 
uniformity and skin sparing. However, loss of electronic equilibrium may 
reduce target coverage. Furthermore, lateral scatter of high-energy 
electrons results in an extended path in low-density tissues such as the 
lung, causing increase of beam penumbra, larger volumes of lung 
irradiated and reduced target dose near the beam edge [15]. High-energy 
photons have a pronounced rebuild-up dose at lung–tissue, tissue–bone 
interfaces and behind air cavities [18,19,27]. With higher photon energy, 
smaller field sizes and decreased lung density this effect becomes more 
pronounced [1,17,23]. Thus, low-energy photons were advised for 
radiotherapy of lung cancer to minimize lateral electronic disequilibrium 
and to reduce the irradiated volume of the normal lung [13]. Protocol 91-
05 of Radiation Therapy Oncology Group (RTOG) has recommended the 
use of photons of energy in the range 4–12 MV for radiotherapy of non-
small cell lung cancer (NSCLC) [21]. 
Our current clinical practice still uses 18 MV photon beams for 
intensity modulated radiotherapy (IMRT) of lung cancer. This practice 
has originated from experience where the optimization tool was allowed 
to apply 6 MV as well as 18 MV photons, using a 
convolution/superposition (CS) dose engine. The use of 6 MV photons in 
patients with extended anteroposterior diameter may result in inadequate 
target coverage along the central axis and high dose in superficial 
structures. Photon beam energy is less critical when multiple beams are 
used [2]. There are data supporting the use of high-energy photons in 
particular clinical settings [28]. Moreover, the use of 18 MV in IMRT of 
lung cancer has been shown not to influence the quality of treatment 
plans [16]. 
The goal of the present study was to determine if 6 MV photon 
beams result in better treatment plans, as obtained with the CS algorithm 
than 18 MV beams. We evaluated the dose coverage of the targets and 
sparing of the organs at risk (OARs) in IMRT plans from 10 patients with 
inoperable NSCLC. We also compared final dose calculations with CS 
and the Monte Carlo dose engine (MCDE). 
 
Materials and methods 
Patient characteristics 
All patients, as characterized in Table 1, were scheduled for IMRT 
in accordance with the protocol adopted by the Radiotherapy Department 
Chapter 6: Comparison of 6 MV and 18 MV photons for lung IMRT 
 103
of the Ghent University Hospital. They underwent helical CT scanning 
throughout the thorax with 5 mm width between slices in a supine 
position under normal free breathing. 
 
Table 1. Patient characteristics 
Patient  Tumor  Target volume 
(cc) 
Number Age Gender  Side Location Histology T N M Stage  CTV PTV 
1 54 M  Right Middle 
lobe 
SCC 4 2 0 IIIB  136.62 292.36
2 70 M  Left Upper 
lobe 
SCC 3 2 0 IIIA  272.14 481.64
3 60 M  Right Middle 
lobe 
SCC 2 2 0 IIIA  115.35 248.05
4 70 M  Left Upper 
lobe 
Adeno 4 2 0 IIIB  185.32 354.15
5 67 M  Right Lower 
lobe 
SCC 2 0 0 IB  572.93 912.18
6 68 M  Left Upper 
lobe 
SCC 4 3 0 IIIB  69.03 228.88
7 76 F  Right Lower 
lobe 
Adeno 1 2 0 IIIA  96.06 205.11
8 57 M  Right Upper 
lobe 
SCC 2 2 0 IIIA  116.99 238.59
9 74 M  Left Hilum SCC 3 2 0 IIIA  108.74 229.27
10 69 M  Right Lower 
lobe 
SCC 4 0 0 IIIB  115.19 231.88
CTV, clinical target volume; PTV, planning target volume; M, male; F, female; SCC, squamous 
cell carcinoma; Adeno, adenocarcinoma. 
 
Target and OAR delineation and volumes 
The gross tumor volume (GTV), including the tumor and enlarged 
lymph nodes, was expanded by a 5 mm margin to yield the clinical target 
volume (CTV). In the case of nodal disease, adjacent intact lymph nodes 
were included in the CTV. A margin of 5 mm for upper and middle lobe 
tumors and 8 mm for tumors in the lower lobes was added to create the 
Planning Target Volume (PTV). PTV-fragmentation was performed to 
obtain the PTV without build-up (PTVwhbu), a part of the PTV beneath the 
skin resulting from subtraction of a 6-mm wide build-up region from the 
PTV [10]. Subtraction of expanded OARs from the PTVwhbu resulted in the 
optimization PTV (PTVoptim), a structure used in optimization.  
OARs include heart, esophagus, lungs (ipsilateral and contralateral 
without the GTV) and spinal cord. To obtain the respective planning risk 
volumes (PRVs), the esophagus was expanded by a 3-mm 
(esophagus_exp_3 mm) and the spinal cord by a 5-mm margin 
(spinal_cord_exp_5 mm); expansion was not applied to the lungs. 
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Treatment planning objectives 
A total dose of 70 Gy in 35 fractions of 2.0 Gy was prescribed to the 
PTV. Maximum dose of 50, 62 and 68 Gy was allowed to the spinal cord 
(PRV), heart, esophagus (PRV), respectively. D33% and D67% should not 
exceed 60 and 54 Gy, respectively, to the esophagus (PRV). Dose–volume 
constraints for the lungs were set as follows: V20 < 30%, V30 < 20% and 
mean lung dose <27 Gy. 
Treatment planning 
The algorithm and tools used for IMRT planning of lung tumors 
were described before [9]. Briefly, identical beam angles and conformal 
beam shapes were used for both the 6 MV and 18 MV plans. The beam 
configuration was based on a class solution of 9 non-coplanar beams with 
a single isocenter where every beam was adjusted for each individual 
patient to meet the set dose–volume constraints for OARs. These 
adjustments sometimes resulted in a change in the number of beams, 
beam shape, gantry, couch and collimator angles. For every conformal 
beam, initial multileaf collimator defined beam segments were generated 
from the beam’s eye view projections of the PTVs and OARs with an in-
house developed Anatomy Based Segmentation Tool (ABST) [3]. The 
conformal beams and segments were passed as multileaf collimated 
beams to the convolution/superposition dose engine at the Pinnacle 
planning system (version 6.2 b, Philips Medical Systems, Andover, MA), 
which returned beam and segment-specific 3-D dose distributions. Initial 
beam and segment weights for the optimization process were generated 
using an in-house developed segment weight optimization tool (SWOT) 
[4]. The full set of dose distributions was passed to the in-house 
developed segment outline and weight adapting tool (SOWAT) [5] for 
segment weight and leaf position optimization. Dose computations 
between optimization cycles were performed by the collapse cone 
convolution/superposition dose engine at the Pinnacle planning system. 
The dose fall-off of the beamlets that are used to account for leaf position 
changes during optimization is too steep to incorporate effectively 
changes in distant scatter. The weight optimization of SOWAT takes into 
account wide scatter as optimization uses dose distributions that are 
computed per segment by the Pinnacle planning system. The 
optimization algorithm involves a bio-physical objective function [5,7]. 
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When the treatment plan fulfilled the acceptance criteria, the 
CRASH (combine, reorder and step and shoot) tool resulted in a 
prescription file for the linear accelerator [6]. Six and 18 MV photons of 
the Elekta SLiplus linear accelerator were commissioned and validated 
previously [11,25]. 
MCDE was used for recomputation of the dose of the final plan 
[24]. For MCDE, DOSXYZnrc was reprogrammed as a component module 
within BEAMnrc [22]. Use of the DOSXYZnrc module allows one to 
combine the physical properties of the patients (e.g., the electron densities 
from the planning CTs) with the phase space files of the treatment 
machine generated by BEAMnrc. The result is a highly accurate dose 
engine that uses the electron transport algorithms of the EGSnrc Monte 
Carlo code. 
Dose reporting and evaluation 
We evaluated 2%, 95% and 98% dose levels (D2%, D95% and D98%) 
and dose inhomogeneity for the following target structures: the GTV, 
CTV, PTV and PTVoptim; D2%, D33%, and D67% were assessed for the heart, 
esophagus and esophagus_exp_3 mm; D2% for the spinal cord and 
spinal_cord_exp_5 mm; mean lung dose, V20 and V30 for the lungs. D2% 
and D98% are used as surrogate for dose maximum and dose minimum, 
respectively [10]. Dose inhomogeneity has been calculated as (D2% - 
D98%)/Dmedian. Two-tailed paired sample t-test was used for comparison of 
numerical data between the two energies. A value of p < 0.05 was 
considered statistically significant. 
 
Results 
Comparison of dose distributions 
Mean dose–volume parameters of the targets and OARs calculated for 6 
MV and 18 MV photons with the CS algorithm and MCDE are presented 
in Tables 2 and 3, respectively. The tables also show the statistical 
significance of the differences using a two-tailed paired sample t-test. It 
can be seen from Table 2 that the PTV was underdosed in CS plans when 
18 MV photons were used (p > 0.05 for D2%, D98% and D95%). Eighteen MV 
photons provided significantly higher D95% for the GTV and CTV 
comparing with 6 MV (p = 0.004 and 0.028 correspondently). However, 
this difference was not confirmed by MCDE computations (Table 3). 
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Table 2. Mean dose-volume parameters computed with the CS algorithm 
End point  18 MV  6 MV   
  Mean SD  Mean SD  p 
 Target        
D2% (Gy) GTV 72.64 0.88  72.92 1.58  0.422 
 CTV 72.73 0.82  72.97 1.47  0.491 
 PTV 72.61 0.74  72.84 1.37  0.479 
 PTVoptim 72.63 0.74  72.85 1.37  0.488 
         
D98% (Gy) GTV 66.80 3.34  66.30 2.40  0.252 
 CTV 65.62 5.69  65.37 4.72  0.527 
 PTV 62.92 5.94  63.37 5.13  0.296 
 PTVoptim 63.58 5.42  64.27 4.32  0.154 
         
D95% (Gy) GTV 68.13 1.39  67.36 1.44  0.004 
 CTV 67.23 3.00  66.87 2.83  0.028 
 PTV 64.49 5.30  64.83 4.48  0.372 
 PTVoptim 65.63 3.86  65.78 3.39  0.607 
         
Inhomogeneity GTV 0.08 0.05  0.09 0.06  0.007 
 CTV 0.10 0.09  0.11 0.09  0.045 
 PTV 0.14 0.09  0.14 0.09  0.576 
 PTVoptim 0.13 0.08  0.12 0.08  0.217 
         
 Organ at risk        
D2% (Gy) Heart 28.62 19.05  31.07 16.63  0.401 
 Esophagus 60.60 10.47  60.91 9.77  0.824 
 Esophagus_exp_3 mm 62.53 8.16  63.14 6.82  0.549 
 Spinal cord 30.18 12.97  26.59 13.63  0.313 
 Spinal cord_exp_5 mm 33.07 12.20  29.41 13.61  0.294 
         
D33% (Gy) Heart 11.49 12.21  9.66 11.82  0.423 
 Esophagus 41.59 16.48  39.50 18.84  0.129 
 Esophagus_exp_3 mm 40.99 17.00  38.96 19.41  0.161 
         
D67% (Gy) Heart 6.23 8.63  5.00 7.22  0.241 
 Esophagus 6.01 6.58  5.68 6.39  0.504 
 Esophagus_exp_3 mm 5.69 5.88  5.60 6.21  0.839 
         
V20 (%) Lungs 27.14 12.89  26.99 14.63  0.899 
         
V30 (%) Lungs 14.28 6.75  13.03 6.59  0.252 
         
Mean lung 
dose (Gy) Lungs 14.55 4.80 
 14.55 4.69  0.997 
SD, standard deviation; GTV, gross tumor volume; CTV, clinical target volume; PTV, planning 
target volume; PTVoptim, PTV for optimization; D2%, D67%, D95% and D98%, dose levels on the 
DVHs above which lay 2%, 67%, 95% and 98% of the contoured volume; V20, relative volume of 
the lung receiving at least 20 Gy; V30, relative volume of the lung receiving at least 30 Gy. 
Significant differences (p < 0.05) are in bold. 
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Table 3. Mean dose-volume parameters computed with Monte Carlo dose engine 
End point  18 MV  6 MV   
  Mean SD  Mean SD  p 
 Target        
D2% (Gy) GTV 73.17 1.21  73.98 1.43  0.053 
 CTV 73.33 1.12  74.13 1.49  0.093 
 PTV 73.22 1.14  74.03 1.38  0.067 
 PTVoptim 73.26 1.19  74.05 1.39  0.077 
         
D98% (Gy) GTV 65.18 3.46  65.74 3.01  0.116 
 CTV 64.03 5.96  64.90 4.87  0.071 
 PTV 62.31 6.25  63.27 5.47  0.015 
 PTVoptim 62.94 5.73  63.94 4.87  0.028 
         
D95% (Gy) GTV 66.56 1.71  67.00 1.87  0.258 
 CTV 65.64 3.42  66.22 3.61  0.027 
 PTV 63.64 5.78  64.62 4.99  0.009 
 PTVoptim 64.83 3.94  65.48 3.84  0.014 
         
Inhomogeneity GTV 0.11 0.05  0.12 0.06  0.642 
 CTV 0.13 0.09  0.13 0.09  0.434 
 PTV 0.16 0.09  0.15 0.09  0.081 
 PTVoptim 0.15 0.08  0.14 0.09  0.081 
         
 Organ at risk        
D2% (Gy) Heart 29.26 18.61  31.60 16.30  0.408 
 Esophagus 60.55 10.61  61.34 9.89  0.523 
 Esophagus_exp_3 mm 62.61 8.12  63.61 7.25  0.250 
 Spinal cord 31.41 12.67  27.89 13.50  0.310 
 Spinal cord_exp_5 mm 34.15 12.17  30.65 13.52  0.310 
         
D33% (Gy) Heart 12.03 11.98  10.36 11.61  0.452 
 Esophagus 42.49 16.54  39.72 18.64  0.045 
 Esophagus_exp_3 mm 41.83 16.91  39.43 19.37  0.116 
         
D67% (Gy) Heart 6.68 8.57  5.64 7.32  0.316 
 Esophagus 6.82 6.68  6.27 5.98  0.315 
 Esophagus_exp_3 mm 6.43 5.94  6.16 5.82  0.516 
         
V20 (%) Lungs 24.63 9.72  23.32 8.77  0.272 
         
V30 (%) Lungs 18.50 7.62  17.46 7.34  0.057 
         
Mean lung 
dose (Gy) Lungs 15.37 4.70 
 15.27 4.65  0.730 
SD, standard deviation; GTV, gross tumor volume; CTV, clinical target volume; PTV, planning 
target volume; PTVoptim, PTV for optimization; D2%, D67%, D95% and D98%, dose levels on the 
DVHs above which lay 2%, 67%, 95% and 98% of the contoured volume; V20, relative volume of 
the lung receiving at least 20 Gy; V30, relative volume of the lung receiving at least 30 Gy. 
Significant differences (p < 0.05) are in bold. 
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MCDE computations demonstrated superiority of 6 MV over 18 MV in 
dose coverage (D95% and D98%) of the PTV (p = 0.009 and 0.015) (Fig. 1), 
PTVoptim (p = 0.014 and 0.028) and D95% in the CTV (p = 0.027). Dose 
inhomogeneity in the PTV did not differ between the two energies for 
both the CS and MCDE calculations. Dose inhomogeneity in the GTV and 
CTV for CS but not for MCDE was lower with 18 MV than with 6 MV 
photons (Tables 2 and 3). There was no significant difference between 
both energies in sparing of the lungs – V20, V30 and mean lung dose did 
not exceed the set planning constraints (Table 2). In comparison with 
MCDE there was overestimation in V20 for individual patients whose 
plans did not meet lung dose–volume constraints (Fig. 2). V30 was at the 
border of significance (p = 0.057). Change of energy did not affect D33% for 
the esophagus in CS plans but MCDE revealed a significantly (p = 0.045) 
higher value for 18 MV photons. As can be seen from Tables 2 and 3 and 
Fig. 1, the differences between other target and OAR dose–volume 
parameters were smaller than uncertainty for the two energies and both 
computation algorithms. 
Dose distributions and tumor location 
We studied the influence of target location on dose coverage of the 
targets and OARs in individual patients (Table 1 and patient numbers in 
Figs. 1 and 2). All treatment planning objectives for the targets and all 
OARs with the lowest V20 and V30 were achieved for the two energies and 
for CS and MCDE in patients number 4 and 8 bearing a peripheral middle 
sized tumor in the left and right upper lobe, respectively. Though, all 
treatment plans of patient number 1 met dose–volume constraints. 
Treatment plans of 3 patients did not meet the lung dose–volume 
constraints V20 and/or V30. In patients number 5 and 7 with tumors in the 
lower lobe V20 exceeded the planning objectives for both energies and for 
the two calculation algorithms (Fig. 2). The index V30 was less than 20 Gy 
in CS plans for both energies in patient number 5 (data not shown). 
Patient number 6 had two separate tumor lesions located in the same lobe 
that resulted in irradiation of the large lung volume and thus making 
impossible to keep V20 (Fig. 2) and V30 (data not shown) below the set 
values. In the rest of patients with tumors located centrally or in the lower 
lobe, D2% exceeded the constraints for the heart (patient number 2, CS 
plans with 6 MV and 18 MV photons), esophagus and/or 
esophagus_exp_3 mm (patients number 3, 9, 10 in CS plans regardless the 
energy; patients number 2 and 9 with the two energies and patient 
number 10 MV with 18 MV photons in MCDE plans) (data not shown). 
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Fig. 1. Comparison of D95% in the PTV computed with MCDE (a) and with the CS algorithm 
(b) for 6 MV (abscissa) and 18 MV photons (ordinate). Each diamond represents data of an 
individual patient indicated by Arabic numbers. The dashed line indicates the line of 
identity. If the diamonds fall below the diagonal identity line then they show an advantage 
for the 6 MV plans, while if they lie above the diagonal identify line they show an advantage 
for the 18 MV plans. 
 
Fig. 2. Comparison of V20 computed with MCDE (a) and with the CS algorithm (b) for 6 MV 
(abscissa) and 18 MV photons (ordinate). Symbols represent data of an individual patient 
indicated by Arabic numbers. 
 
Discussion 
In this study, we compared IMRT treatment plans for a typical 
NSCLC cohort with middle to large size tumors with 6 MV and 18 MV 
photon beams. The observed differences in dose coverage of the targets 
and OARs between the 6 MV and 18 MV plans were insignificant except 
higher D95% for the CTV and GTV, lower inhomogeneity in the CTV and 
GTV and underdosage of PTV in 18 MV plans. PTV underdosage may be 
explained by differences in secondary electron transport in low density 
tissues caused by lower- and higher-energy photons. Loss of electronic 
equilibrium in the lungs results in enlarged beam penumbra and blurring 
of the dose at the beam edge, compromising dose homogeneity and 
irradiating larger volumes of the lung [12,20]. In case of conflict between 
the underdosage to the PTV and dose–volume constraints for OARs such 
as lungs and spinal cord, it is our policy to give priority to dose–volume 
constraints for OARs with the aim to achieve the prescribed dose in the 
CTV or GTV. 
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It appears that benefit from 6 MV photon beams may not be so 
obvious when different beam arrangements are applied. Beam 
configuration can influence the effects of electronic equilibrium and 
increase them with increase in number of beams that may favor higher 
energies, particularly in dose escalation [2]. To exclude influence of beam 
configuration, the same beam arrangements were used for higher and 
lower energy IMRT treatment plans. We did not find advantage of 6 MV 
over 18 MV photons in dose coverage of the targets. 
Any calculation algorithm used for dose computation in IMRT 
planning of lung cancer should take into account tissue density and 
secondary electron transport [8]. We wanted to evaluate the observed 
dose deviations between lower- and higher-energy treatment plans using 
MCDE for final dose calculations. A detailed comparison of different dose 
calculation algorithms, including CS and MCDE, for IMRT of lung cancer 
was published by Vanderstraeten et al. [24]. They described differences 
between MCDE and other algorithms putting forward MCDE as a 
benchmarking tool. For our treatment plans, MCDE generally favored 6 
MV photons while for CS 18 MV was better. Still, the observed deviations 
were quite small. MCDE calculations performed in the present study are 
based on the most accurate EGSnrc electron transport algorithms [14]. 
Possibly incomplete account for loss of electronic equilibrium in the lungs 
by the CS algorithm compared to MCDE has resulted in discrepancy 
between both calculations. Moreover, using the CS dose engine might 
have misled the optimization tool. Due to present limitations in computer 
power, MCDE calculations were only performed for recomputing the 
dose of the final plan. If MCDE computation had been used as start of 
optimization, the results might have been different from those observed. 
In absence of fast Monte Carlo algorithms, Monte Carlo may still be used 
to verify target coverage in case of applying other algorithms [26]. 
Our results are in agreement with the report of Liu et al. who did 
not find any noticeable difference in the quality of IMRT plans applying 6 
MV and 18 MV photons, though 18 MV were less preferable due to 
greater loss of lateral electronic equilibrium [16]. Nevertheless, target 
location may influence selection of photon energy. The peripheral or 
cranially located PTV may be planned to higher doses as its location 
appears to compromise dose-volume constraints less than the PTVs with 
more central or caudal location [9]. In our study, independently of energy 
and dose computation algorithm, patients with peripheral tumors in the 
upper lobes showed the best dose distributions in all targets and best 
sparing OARs. In other cases of the cranially sited tumors dose coverage 
was not as good as expected due to target complexity; central location of 
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tumor may advocate use of lower energy. Photon energy may not have 
significant impact on dose distribution in peripheral cranially located 
tumors. More caution should be taken in selecting photon energy in case 
of central and lower lobe tumors. 
 
Conclusions 
We have compared 6 MV and 18 MV photons for IMRT treatment 
of NSCLC, as applied in the Radiotherapy Department of the Ghent 
University Hospital. IMRT of NSCLC resulted in dose degradation and 
higher inhomogeneity in the PTV when using 18 MV as compared to 6 
MV photon beams. Using for final dose calculation MCDE algorithm also 
favored 6 MV in dose coverage of the PTV. Selection of 18 MV or 6 MV 
photons for IMRT of lung cancer depends on priority ranking of the 
endpoints as well as the individual patient. In the absence of highly 
accurate and, therefore, acceptable dose computation algorithms such as 
MCDE and CS, 6 MV photons may be the prudent choice. 
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Abstract 
The conversion of computed tomography (CT) numbers into material composition and mass 
density data influences the accuracy of patient dose calculations in Monte Carlo treatment 
planning (MCTP). The aim of our work was to develop a CT conversion scheme by performing 
a stoichiometric CT calibration. Fourteen dosimetrically equivalent tissue subsets (bins), of 
which ten bone bins, were created. After validating the proposed CT conversion scheme on 
phantoms, it was compared to a conventional 5 bin scheme with only 1 bone bin. This resulted 
in dose distributions D14 and D5 for nine clinical patient cases in a European multi-centre study. 
The observed local relative differences in dose to medium were mostly smaller than 5%. The 
dose–volume histograms of both targets and organs at risk were comparable, although within 
bony structures D14 was found to be slightly but systematically higher than D5. Converting dose 
to medium to dose to water (D14 to D14wat and D5 to D5wat) resulted in larger local differences as 
D5wat became up to 10% higher than D14wat. In conclusion, multiple bone bins need to be 
introduced when Monte Carlo (MC) calculations of patient dose distributions are converted to 
dose to water. 
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1. Introduction 
In Monte Carlo treatment planning (MCTP), the conversion of computed 
tomography (CT) numbers into material properties is one of the main 
factors that determine the accuracy of patient dose calculations (du Plessis 
et al 1998). To interrelate the CT number and the electron density (or 
stopping power for protons) of a tissue, the CT number scale is often 
divided into a number of subsets (DeMarco et al 1998, Hartmann Siantar 
et al 1997, Ma et al 1999, Wang et al 1998). Typically, six or less different 
media are defined, e.g. air, lung, fat, water, muscle and bone. Certain 
Monte Carlo (MC) implementations use a larger number of materials, e.g. 
MCV (Siebers et al 2000a) and the commercial implementation by 
Nucletron of the VMC++ code (Kawrakow 2001). These systems use over 
50 and over 20 materials, respectively. Verhaegen and Devic (2005) have 
shown that the misassignment of media can lead to large dose errors in 
MCTP (up to 10% for MV photons). The CT scanner is often calibrated 
using tissue equivalent materials. However, the elemental composition of 
those tissue substitutes differs from that of real tissues, resulting in 
significantly different calibration curves of CT number to electron density 
(or proton stopping power). For an accurate extraction of tissue properties 
from CT data, a stoichiometric calibration method was proposed by 
Schneider et al (1996). First, a set of materials (which do not necessarily 
have to be tissue equivalent) with known elemental compositions and 
physical densities is scanned to measure the corresponding CT numbers. 
Next, the results are fitted to a theoretical parameter equation 
interrelating the CT number and the physical density and atomic number 
(Z) of each material, at the effective energy of the kV imaging spectrum. 
Finally, the fitted parameters can be used to calculate the CT numbers of 
real tissues using tabulated composition data. 
The influence of differences in tissue composition on MC dose 
calculations has been investigated by du Plessis et al (1998). They 
combined the 16 most common human tissue types into dosimetrically 
equivalent subsets with constant elemental composition by performing 
MC calculations within homogeneous phantoms. Using a clinical 8 MV 
photon beam, seven subsets were found to be sufficient to obtain a dose 
calculation accuracy of 1%. However, for lung and bone further 
subdivision turned out to be necessary by varying the physical density 
while keeping the elemental composition constant. The disadvantage of 
the method of du Plessis et al (1998) is that the application of the resulting 
CT conversion is limited to the beam quality under consideration. 
Schneider et al (2000) therefore proposed a CT conversion method for MC 
simulations based on the stoichiometric calibration method. Considering 
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71 human tissues, they created 24 different subsets with constant 
elemental composition based on the estimated accuracy of the calculated 
CT numbers. 
Instead of converting CT numbers into tissue parameters like 
elemental composition and mass density, one could also directly extract 
interaction probabilities from the CT number. This approach is used by 
the electron MC code VMC (Kawrakow et al 1996) and its photon 
extension XVMC (Fippel 1999). The main advantage is that there is no 
need to specify any boundaries separating tissue subsets. However, most 
MC codes explicitly need the elemental composition within each patient 
voxel to obtain interaction data for dose calculations. Therefore, the 
VMC/XVMC approach is more difficult to implement in such codes. 
The aim of our work was to propose a CT conversion method that 
is based on the stoichiometric calibration method and that makes use of 
dosimetrically equivalent tissue subsets based on a clinical 6 MV photon 
beam, in order to combine the methods of  Schneider et al (2000) and du 
Plessis et al (1998). Evaluations were performed by means of a MC slab 
phantom and the Gammex RMI 461A head/body CT phantom using 
inserts from the Gammex RMI 465 electron density CT phantom 
(Gammex RMI, Middleton, WI, USA). Furthermore, the effect of selecting 
a different photon beam quality (15 MV photons) or a different beam 
modality (electrons) was investigated. The resulting 6 MV photon binning 
scheme was compared to a conventional scheme with only 5 bins. For this 
purpose a multi-centre study was set up. A stoichiometric CT calibration 
was performed at seven European centres. Finally, our investigation was 
focused towards the clinical evaluation of patient treatment plans. 
Attention was paid to the conversion from dose to medium to dose to 
water. 
2. Materials and methods 
2.1. Influence of material composition on photon attenuation and energy 
deposition 
The elemental composition of a material influences dose calculation both 
through its attenuation and energy deposition characteristics. To 
determine for which types of human tissue an accurate CT conversion is 
important and why, mass attenuation coefficients and mass stopping 
power values were studied for a set of materials (air, water, lung, adipose, 
muscle, cartilage and cortical bone) as well as for the individual elements 
that are present within these materials. The attenuation coefficients of the 
individual elements were taken from the National Institute of Standards 
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and Technology (NIST) photon cross sections (XCOM) database10 
(Hubbell and Seltzer 2004). The mass attenuation coefficient of a mixture 
can be calculated as the weighted sum of the coefficients of the 
constituent elements (Jackson and Hawkes 1981). The elemental 
composition of the human tissues was obtained from ICRU report 44 
(ICRU 1989). Mass stopping power values for both the individual 
elements and human tissues were computed using the NIST electron 
stopping power and range (ESTAR) database11. 
2.2. Stoichiometric calibration 
The following set of materials with known elemental composition was 
used to calibrate the Siemens Somatom Plus 4 CT scanner at Ghent 
University Hospital (GUH): PMMA, polystyrene, Gammex RMI solid 
water, Gammex RMI lung equivalent material and CaCl2 solutions in 
water of 5, 10, 15, 20, 25, 30 and 35% by weight (maximum solubility 
around 40%). Table 1 reports their mass density and elemental 
composition data. A scan protocol used routinely for radiotherapy 
treatment planning was selected; the tube voltage was 120 kV. For each 
material the average CT number and standard deviation were determined 
within a manually drawn region of interest (ROI) on the CT image. 
Depending on the shape of each material sample, a circular or rectangular 
ROI was used in order to cover an area as large as possible within the 
homogeneous material. The stoichiometric calibration procedure of 
Schneider et al (1996) was applied. It makes use of the following empirical 
formula for parametrization of the total attenuation coefficient µ of a 
mixture of elements (with elemental weights wi , atomic numbers Zi and 
atomic masses Ai) provided by Jackson and Hawkes (1981): 
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In this formula ρ is the mass density and NA is the Avogadro constant. Kph 
characterizes the cross section of photoelectric absorption, while Kcoh 
characterizes the cross sections of both the coherent scattering and the 
binding correction for the incoherent scattering. KKN represents the Klein–
Nishina coefficient. Kph, Kcoh and KKN depend on the effective energy of 
the CT scanner spectrum. The CT number H is expressed in Hounsfield 
units (HU) and calculated as follows: 
                                              
10 Available online: http://physics.nist.gov/PhysRefData/Xcom/Text/XCOM.html. 
11 Available online: http://physics.nist.gov/PhysRefData/Star/Text/ESTAR.html. 
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Table 1. Mass density ρ and elemental weights wi of the set of materials used for the 
stoichiometric calibration of the Siemens Somatom Plus 4 CT scanner at Ghent University 
Hospital. 
Material ρ (g cm-3) wH wC wN wO wMg wSi wCl wCa 
PMMA 1.190 0.081 0.599 0 0.320 0 0 0 0 
Polystyrene 1.040 0.077 0.923 0 0 0 0 0 0 
Gammex RMI solid 
watera 1.035 0.081 0.673 0.024 0.198 0 0 0.001 0.023 
Gammex RMI lung 
equivalent materiala 0.300 0.085 0.593 0.020 0.181 0.112 0.008 0.001 0 
CaCl2 solution 5% 1.035 0.106 0 0 0.844 0 0 0.032 0.018 
CaCl2 solution 10% 1.080 0.101 0 0 0.799 0 0 0.064 0.036 
CaCl2 solution 15% 1.126 0.095 0 0 0.755 0 0 0.096 0.054 
CaCl2 solution 20% 1.171 0.090 0 0 0.710 0 0 0.128 0.072 
CaCl2 solution 25% 1.216 0.084 0 0 0.666 0 0 0.160 0.090 
CaCl2 solution 30% 1.261 0.078 0 0 0.622 0 0 0.192 0.108 
CaCl2 solution 35% 1.307 0.073 0 0 0.577 0 0 0.224 0.126 
a As supplied by the manufacturer. 
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As we only need the attenuation coefficient relative to water to calculate 
the CT number, only two parameters (Kph/KKN and Kcoh/KKN) have to be 
determined by a fit of the measured CT numbers to equations (1) and (2). 
The above-mentioned set of calibration materials allowed us to 
perform a CT scanner calibration for a large range of CT number values 
through the range of CaCl2 solutions. However, the fact that these 
solutions need to be fabricated in-house complicated the calibration of CT 
scanners at other centres. Therefore, a Gammex RMI 465 electron density 
CT phantom was sent around to perform the stoichiometric calibration. 
This phantom consists of a 33 cm diameter disc made out of Gammex 
RMI solid water that includes a matrix of twenty 2.8 cm diameter holes. 
Interchangeable rods of various tissue and water substitutes can be fitted 
into these holes. For the calibrations 17 different material inserts were 
used: LN-300 and LN-450 lung equivalent materials, AP6 adipose, 
polyethylene, breast, CT solid water, CB3 resin, CT solid water, brain, 
liver, IB1 inner bone, CB4 resin, acrylic, B200 bone mineral, CB2–10% 
CaCO3, CB2–30% CaCO3, CB2–50% CaCO3 and SB3 cortical bone. Their 
mass density and elemental composition data were reported by Watanabe 
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(1999). Circular ROIs with a diameter of approximately 2.5 cm were 
drawn manually on the CT images to determine the average CT number 
and its standard deviation for each insert. So, the ROIs were 
approximately the same among the centres. To evaluate the 
stoichiometric calibration using the Gammex RMI 465 phantom, the 
phantom was first scanned on the Siemens Somatom Plus 4 CT scanner at 
GUH and the measured CT numbers for each insert were compared to 
calculations based on the original stoichiometric calibration (using the set 
of materials listed in table 1). The same scan protocol was used for both 
calibrations. Next, the phantom was sent to seven different centres in 
Europe. A list of the studied CT scanner types and their respective 
locations can be found in table 2. Each centre used a different scan 
protocol, depending on the local radiotherapy treatment planning 
procedure. 
 
Table 2. Results of the stoichiometric calibration using the Gammex RMI 465 electron density 
CT phantom. All measurements were performed at a tube voltage of 120 kV. 
CT scanner Location  Kph/KKN Kcoh/KKN 
Siemens Somatom Plus 4 Ghent University Hospital, 
Belgium 
4.24 × 10-5 a -1.77 × 10-3 a 
Philips Gemini GXL PET/CT Ghent University Hospital, 
Belgium 
1.99 × 10-5 9.26 × 10-4 
Siemens Somatom Sensation Open  University Hospital Tübingen, 
Germany 
2.11 × 10-5 3.70 × 10-4 
Siemens Somatom Sensation Open Velindre Cancer Centre, 
Cardiff, UK 
2.30 × 10-5 3.49 × 10-5 
Siemens Somatom Sensation Cardiac 64 Clinica Quadrantes, Lisbon, 
Portugal 
2.65 × 10-5 -2.84 × 10-4 
Toshiba Xvision/EX HUV Macarena, Seville, Spain 3.89 × 10-5 -8.37 × 10-4 
GE HiSpeed QX/i  Royal Marsden Hospital, 
London, UK 
2.78 × 10-5 -3.98 × 10-4 
GE ProSpeed Inselspital Radioonkologie, 
Bern, Switzerland 
1.11 × 10-5 4.79 × 10-3 
a Stoichiometric calibration using the set of materials from table 1 instead of the Gammex RMI 
465 phantom. 
 
2.3. Dosimetrically equivalent tissue subsets 
After the stoichiometric calibration of each CT scanner, the fitted values 
of Kph/KKN and Kcoh/KKN were used to calculate the CT numbers of the 71 
human tissues that were also considered by Schneider et al (2000, tables 3–
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5). Mass density and elemental composition data were taken from 
literature (Woodard and White 1986, White et al 1987, ICRU 1989). 
The mass density was calibrated continuously in terms of the CT 
number, as a different value can be assigned to each individual voxel of a 
MC scoring grid in the BEAMnrc/DOSXYZnrc system (Rogers et al 2002). 
A mass density calibration curve consisting of three separate linear least-
squares fits (for air and lung, soft tissues, and bone tissues) was created 
for each of the CT scanners listed in table 2. 
To extract the elemental composition data, the CT number scale 
was divided into dosimetrically equivalent tissue subsets (bins). To 
determine the necessary number of subsets, DOSXYZnrc calculations 
were performed within homogeneous phantoms with dimensions of 31 × 
31 × 20 cm3. The incident beam was a 10 × 10 cm2 6 MV photon field 
produced by the Elekta SLiplus linear accelerator at GUH (Van de Walle 
et al 2003). The dimensions of the scoring grid voxels on the central axis 
were 1 cm in the X and Y directions for all voxels, and 2 mm (voxels 1–
20), 4 mm (voxels 21–25) and 1 cm (voxels 26–39) in the Z direction. For 
each voxel on the central axis, our aim was to keep the maximum 
deviation between the depth dose curves calculated within two materials 
representing adjacent tissue subsets below 1%. The statistical uncertainty 
(1σ) of the MC calculations was less than 0.5% within each voxel on the 
central axis. Depth dose curves were calculated for air, lung, soft tissues 
and bone tissues. Each tissue subset was represented by the elemental 
composition that corresponds with the mean CT number of the subset. As 
suggested by Schneider et al (2000), the elemental composition of human 
adipose, muscle or bone tissues can be interpolated in good 
approximation between either adipose tissue 3 and adrenal gland, GI 
tract and connective tissue, or bone marrow and cortical bone, depending 
on the CT number. Starting from a conventional 5 bin scheme (air, lung, 
adipose, muscle and bone), additional bins were inserted and the 
corresponding depth dose curves were calculated until the above-
mentioned accuracy requirement was fulfilled. To eliminate the influence 
of mass density on the determination of the number of subsets, it was set 
to 1 g cm−3 for all materials. The number of tissue subsets necessary to 
achieve dosimetric equivalence within 1% was determined for the 
Siemens Somatom Plus 4 CT scanner at GUH. An equal number of bins 
were created for the other CT scanners listed in table 2, taking into 
account their individual stoichiometric calibration. 
To evaluate whether the proposed binning scheme for 6 MV 
photons is also sufficient for MC calculations using another beam 
modality and/or a different energy, similar depth dose curves were 
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calculated for the proposed bone subset materials of the Siemens 
Somatom Plus 4 CT scanner at GUH using a 15 MV photon beam and a 
6.6 MeV electron beam (Gaussian energy spectrum with a full width at 
half maximum value of 0.2 MeV), respectively. 
2.4. MC slab phantoms 
To evaluate our division of the human bone tissues into a number of 
subsets, we first performed DOSXYZnrc calculations within MC 
phantoms. Two heterogeneous slab geometries were defined, consisting 
of a 0.1 cm and a 1 cm thick layer of bone, respectively, embedded within 
adipose tissue. The phantom dimensions were 31 × 31 × 16 cm3. The bone 
layers were located perpendicularly to the Z-axis either between Z = 5 cm 
and Z = 5.1 cm depth or between Z = 5 cm and Z = 6 cm depth. The 
incident beam was the 10 × 10 cm2 6MV photon field produced by the 
Elekta SLiplus linear accelerator at GUH. The dimensions of the scoring 
grid voxels on the central axis were 1 cm in the X and Y directions for all 
voxels, and down to 0.5 mm in the Z direction for the voxels close to the 
interfaces between the adipose tissue and the bone layer. 
The vertebral column was used to represent the bone layer. Its CT 
number was calculated using the stoichiometric calibration data of the 
Siemens Somatom Plus 4 CT scanner at GUH; the elemental composition 
data were taken from White et al (1987). For each geometry (with a 0.1 cm 
or a 1 cm bone layer), depth dose curves were calculated with the bone 
layer represented according to the new binning scheme (with multiple 
bone bins) on the one side, and a conventional binning scheme with a 
single bone bin representing the material composition of ICRU cortical 
bone (ICRU 1989) on the other side. For both calculations equal values of 
the mass density were assigned to the bone layer. The value was derived 
from the calculated CT number using the mass density calibration curve 
of the Siemens Somatom Plus 4 CT scanner at GUH. The resulting depth 
dose curves were compared voxel by voxel along the Z-axis as well as by 
calculating differences in area below the curves within the bone layer. 
2.5. Gammex RMI 461A head/body CT phantom 
In addition to the MC slab phantoms, the accuracy of our CT conversion 
procedure was evaluated on the Gammex RMI 461A phantom. This 
phantom consists of a 33 cm outer diameter annulus made out of RMI 
solid water with a central hole into which the inserts of the Gammex RMI 
465 tissue calibration phantom can be fitted. The following six inserts 
were used: LN-300 and LN-450 lung equivalent materials, B200 bone 
mineral, CB2–10% CaCO3, CB2–30% CaCO3 and CB2–50% CaCO3. 
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DOSXYZnrc was used to calculate dose profiles within a large water 
phantom positioned 100 cm below the source of the Elekta Precise linear 
accelerator. The incident beam was a 6MV photon field with dimensions 
of 10×10 cm2 at the phantom surface. The Gammex RMI 461A phantom 
was placed just below the water surface and the dose profiles were 
determined along the X-axis at depths of 12 cm and 15 cm below the 
phantom. The phantom was scanned on the Siemens Somatom Plus 4 
scanner at GUH with the different inserts specified above. For each insert, 
the average CT number was determined within a manually drawn 
circular ROI with a diameter of approximately 2.5 cm. Next, the CT 
number was converted into a homogeneous material composition and 
mass density. Two sets of DOSXYZnrc calculations were performed, one 
using the material properties derived from our CT conversion and 
another by modelling the phantom with the exact material properties. The 
dimensions of the scoring grid voxels along the calculated dose profiles 
were 0.25 × 1 × 4 cm3. 
2.6. Patient dose calculations 
Finally, our CT conversion procedure was evaluated on patients. Nine 
patient cases were selected at four different centres (patient numbers 1, 2–
3, 4–6 and 7–9, respectively), of which three oropharyngeal cancer 
patients (patient numbers 1, 3 and 8), three laryngeal cancer patients (5, 6 
and 9), one lung cancer patient (2), one breast cancer patient (4) and 
one patient with a brain tumour (7). Patients 7 and 8 were treated using a 
3D conformal treatment technique, while patients 1–3, 4–5 and 9 received 
intensity-modulated radiation therapy (IMRT) treatment. For the breast 
cancer patient a single field was evaluated. The selection of patients was 
based on the presence of bony structures close to or within the high dose 
region, since this is what our CT conversion focuses on as will be 
explained in section 3.1. For each patient two MC calculations were 
performed: the material composition of every voxel was determined once 
applying the proposed CT conversion scheme and once using a 
conventional 5 bin scheme. This 5 bin scheme was derived from the 
proposed 14 bin scheme by keeping the first 4 bins and replacing bins 5–
14 by a single bin representing the material composition of ICRU cortical 
bone. The mass density was derived directly from the CT number in the 
same, continuous manner for both sets of calculations. In this way two 
dose distributions were generated for each patient, which will further be 
referred to as D14 and D5. Dose difference maps (DD) were created by 
calculating the local relative difference in dose between D14 and D5. 
Values of DD were only assigned to voxels for which the local value of 
D14 was higher than 50% of the isocentric value of D14. This was done to 
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avoid the occurrence of large local relative dose differences 
corresponding to small absolute dose differences within the low dose 
regions, which are not clinically relevant and may thus lead to 
misinterpretation. Additionally, dose–volume histograms (DVHs) of the 
relevant target structures and organs at risk were created for each patient. 
Whereas conventional dose calculations for photon beam treatment 
planning report dose to water, MC dose engines calculate dose to 
medium. When comparing MC results with results obtained by 
conventional systems, the MC dose distributions must thus be converted 
to dose to water. Additionally, dosimetry calibration protocols are 
generally based on absorbed dose to water standards. Although it would 
be possible to convert measurements and conventional dose results to 
dose to medium, the most important reason for converting dose to 
medium to dose to water is that tumour control probability (TCP) and 
normal tissue complication probability (NTCP) data are usually given in 
terms of dose to water and it will take a lot of effort and time before 
biological data can be made available in terms of dose to medium. Liu 
and Keall (2002) have elaborated on this issue in a point-counterpoint 
discussion. 
Siebers et al (2000b) have proposed a method to convert dose to 
medium to dose to water by applying Bragg–Gray cavity theory. They 
have shown that a single correction factor can be used for each material—
as long as it is not air—throughout the field for a given photon energy. 
Their post-processing method proved to be equally valid as performing 
the conversion online during the MC simulations. We have computed the 
conversion factor for each material of the proposed CT conversion scheme 
of each CT scanner as the ratio of the water and medium mass stopping 
powers at an effective electron energy of 1 MeV. As will be shown in 
section 3.1 and figure 2, the conversion factor of cortical bone amounts up 
to almost 1.13, while the conversion factors for lung and soft tissues differ 
only 1 or a few % from 1, respectively. Hence, large errors may arise 
when converting dose to medium to dose to water if the wrong bone 
composition is assigned. To evaluate the effect of possible conversion 
errors caused by taking into account an insufficient number of bone bins 
in a clinical situation, we have converted the above-mentioned MC dose 
distributions D14 and D5 of each of the nine selected patient cases from 
dose to medium to dose to water. The converted dose distributions are 
referred to as D14wat and D5wat. Dose to water difference maps (DDwat) 
were created by calculating the local relative dose difference between 
D14wat and D5wat, but values were only assigned to voxels for which the 
local value of D14 was greater than 50% of the isocentric value of D14. 
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Again, DVHs of the relevant target structures and organs at risk were 
created for each patient. 
Finally, to illustrate the influence of using a wrong CT conversion 
scheme (e.g. from another CT scanner) on patient dose calculations, an 
additional oropharyngeal patient case treated using a 3D conformal 
technique was selected. Two CT scanners were chosen from table 2 based 
on the differences between their mass density calibration curves: the 
Siemens Somatom Plus 4 CT scanner at GUH (A) and the Siemens 
Somatom Sensation Open CT scanner at the University Hospital of 
Tuebingen (B). For the selected patient MC dose calculations were 
performed using the proposed 14 bin CT conversion schemes of both CT 
scanners A and B, resulting in the dose distributions DA and DB. These 
dose distributions were compared by means of isodifference plots in 
transversal planes. 
3. Results and discussion 
3.1. Influence of material composition on photon attenuation and energy 
deposition 
Figure 1(a) shows the mass attenuation coefficient of each material 
relative to that of water as a function of the photon energy in the range of 
100 keV to 20 MeV. The attenuation properties of tissues like lung, 
adipose, muscle and cartilage are more or less water equivalent. 
However, the curves for air and cortical bone clearly deviate. This is due 
to the H- and Ca-content of those tissues: figure 1(b) shows the mass 
attenuation coefficient of the individual elements. Lung tissue contains 
10.3% by weight of hydrogen, whereas dry air does not contain any 
hydrogen. This is the main cause of the discrepancy between the mass 
attenuation coefficients of lung and air, the latter being about 10% lower 
than the former. The ‘cartilage–high Ca’ curve in figure 1(a) illustrates the 
influence of calcium. This curve was created by setting the calcium 
content of cartilage to that of cortical bone, i.e. 22.5% by weight, while 
rescaling the other elemental weights. Additionally, the hydrogen content 
of cartilage (9.6% by weight) is higher than that of cortical bone (3.4% by 
weight), which accounts for the remaining shift. Therefore, an accurate 
conversion of CT numbers into elemental H- and Ca-weights is of high 
importance, as these weights strongly influence photon attenuation (Seco 
and Evans 2006). Figure 2(a) shows the water-to-material relative mass 
stopping power as a function of the electron energy in the range of 100 
keV to 30 MeV; values for the individual elements are shown in figure 
2(b). The energy deposition depends primarily on the hydrogen content. 
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Figure 1. (a) Mass attenuation coefficients of different materials relative to that of water as a 
function of photon energy (MeV). The ‘cartilage–high Ca’ curve was created by setting the 
calcium content of cartilage to that of cortical bone, i.e. 22.5% by weight, while rescaling the 
other elemental weights. (b) Mass attenuation coefficients of individual elements (cm2 g−1) as 
a function of photon energy (MeV). 
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Figure 2. (a) Mass stopping power of water relative to that of different materials as a function 
of electron energy (MeV). (b) Mass stopping powers of individual elements (MeV cm2 g−1) as 
a function of electron energy (MeV). 
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For radiotherapy beams with photon energies between 0.1 and 10 
MeV the Compton effect is the dominant interaction process. As the 
probability for Compton interaction is proportional to the electron 
density of a material, it will depend significantly on the hydrogen content 
(Seco and Evans 2006). At diagnostic imaging energies, however, the 
calcium content of a material will strongly increase the importance of the 
photo-electric and Rayleigh scattering terms because of their strong Z-
dependence. Because dose calculations use material property data 
extracted from CT images, the calcium content may indirectly influence 
the dose calculations if not properly accounted for when converting CT 
numbers into electron density. Thus, it is particularly important to be able 
to distinguish lung from air (different H-content) as well as different bone 
compositions from each other (different H- and Ca-contents) to perform 
accurate MC patient dose calculations. Magnetic resonance imaging 
(MRI) techniques may allow us to visualize the H-content within patients, 
e.g. throughout the lungs. However, the resulting images are generally 
characterized by a low signal-to-noise ratio and poor resolution. At 
present, the most practical approach seems to be the selection of a 
different CT number boundary between air and lung depending on the 
tumour site, i.e. lower for lung tumours (to assign lung to patient voxels 
with low CT numbers) and higher for head and neck tumours (to avoid 
the assignment of lung to patient voxels with low CT numbers, which is 
anatomically impossible). This matter will not be examined any further in 
this paper. Instead, our CT conversion procedure will focus on the 
division of the human bone tissues into a sufficient number of subsets. 
3.2. Stoichiometric calibration 
A fit of the measured CT number data to equations (1) and (2) for the set 
of materials listed in table 1 resulted in values of Kph/KKN and Kcoh/KKN of 
4.24 × 10−5 and −1.77 × 10−3, respectively, for the Siemens Somatom Plus 4 
CT scanner at GUH. The R2-value of the fit was 0.999. The occurrence of a 
negative value for Kcoh/KKN has been addressed by de Kock and Schreuder 
(1996). In his reply, Schneider has suggested repeated air calibration 
measurements and separate scans for each material to obtain a positive 
Kcoh. We performed all scans in a clinical setting, i.e. in the same 
circumstances as for real patients. In any case, the negative Kcoh yields 
excellent results. The possibility of decreasing the number of fitting 
parameters to avoid the occurrence of a negative Kcoh value is discussed in 
an appendix to this paper. 
Figure 3 shows calculated versus measured CT numbers for the 
inserts of the Gammex RMI 465 phantom for the same CT scanner. The 
calculations were performed using the stoichiometric calibration curve 
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based on the set of materials from table 1. The R2-value of the 1:1 fit was 
0.983. The largest deviations occur for B200 bone mineral, CB2–50% 
CaCO3 and SB3 cortical bone (and to a lesser extent for AP6 adipose). AP6 
adipose and B200 bone mineral are the only material inserts containing 
fluorine (3.1% and 16.7%, respectively), while CB2–50% CaCO3 and SB3 
cortical bone are the inserts with the highest calcium content (20.0% and 
27.0%, respectively). 
Verhaegen and Devic (2005) have already pointed out problems 
with the use of tissue substitutes containing fluorine, e.g. Teflon, to 
perform CT calibrations for MC dose calculations. None of the human 
body tissues contains fluorine. On the other hand, the stoichiometric 
calibration procedure should be able to accurately predict the CT number 
of every material with a known composition, on the condition that 
equation (1) is a valid approximation. The difference between the 
attenuation coefficient of elemental fluorine calculated through this 
equation and the value of the same coefficient according to the NIST 
database (Hubbell and Seltzer 2004) is about−1.5% for an effective CT 
scanner energy around 70 keV, which cannot account for the large 
discrepancies observed in figure 4. Possibly there is a difference between 
the elemental composition data of our calibration materials and the data 
available in the literature. 
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Figure 3. Calculated versus measured CT numbers for the inserts of the Gammex RMI 465 
phantom listed in section 1.2 for the Siemens Somatom Plus 4 CT scanner at Ghent 
University Hospital. Calculations were performed using the stoichiometric calibration based 
on the set of materials from table 1. The half width of each error bar is equal to one standard 
deviation of the measured CT number. 
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The inaccuracy of attenuation coefficients of materials containing 
considerable amounts of calcium calculated through equation (1) has been 
reported by de Kock and Schreuder (1996). Schneider et al (2000) have 
provided an interpolation formula for the CT number of a medium that is 
composed of only two components. We used this formula to compute 
additional ‘measurement’ data for artificial CaCl2 and CaCO3 solutions 
with a high calcium content (up to 40% by weight). From a comparison 
between these interpolated and the calculated (using the stoichiometric 
calibration curve based on the set of materials from table 1) CT numbers it 
was clear that equation (1) overestimated the CT number for materials 
with a high calcium content. Moreover, the deviations increased as the 
calcium content became higher. For materials with wCa greater than 20%, 
the R2-value of the fit was equal to 0.711. The difference between the 
attenuation coefficient of elemental calcium calculated through equation 
(1) and the value of the same coefficient according to the NIST database 
(Hubbell and Seltzer 2004) is about 4.1% for an effective CT scanner 
energy around 70 keV, while the observed discrepancies were clearly 
larger. 
We extended the equation used to predict CT numbers from 
material properties with two purely empirical fitting parameters a and b, 
in addition to Kph/KKN and Kcoh/KKN. We thus allowed a linear decrease of 
the calculated CT number with respect to the CT number calculated 
according to the original equation, for materials with wCa greater than 
20%: H = (1 − a)Horiginal + b. In this way, an excellent correspondence 
between calculated and measured CT numbers could be obtained for 
these materials (a = 0.297, b = 242, R2 = 0.996). Only for the artificial 
CaCO3 solution containing 40% by weight of calcium the result still was 
not satisfactory. However, the maximum calcium content of even the 
most dense human bone is at most 30%. We investigated the dosimetric 
relevance of this empirical extension by calculating the CT number for 27 
human bone tissues based on both the original and the extended fit. We 
determined the corresponding tissue bins according to the binning 
scheme based on the original fit, which will be presented in section 3.3. 
For 23 tissues the bin number was the same; for the other four tissues the 
difference was 1 bin. As the dose difference between adjacent bins is less 
than 1%, we conclude that the empirical extension of the calibration 
equation was not dosimetrically relevant. Hence, the observed differences 
between calculated and measured CT numbers for materials with a high 
calcium content are acceptable for our purposes. 
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The Gammex RMI 465 phantom was sent around to different 
centres to perform a stoichiometric calibration of the CT scanner. Because 
of the observed discrepancies between the calculated and measured CT 
numbers of the inserts containing fluorine (AP6 adipose and B200 bone 
mineral), these data were omitted to fit the measured data to equations (1) 
and (2). The resulting values of Kph/KKN and Kcoh/KKN are listed in table 2. 
This table illustrates the variety in stoichiometric calibration results found 
for the investigated scan protocols at different centres. It is absolutely 
necessary to perform an individual stoichiometric calibration for each CT 
scanner and scan protocol used for radiotherapy treatment planning. The 
same scan protocol has to be selected to calibrate the CT scanner and to 
scan patients. If several scan protocols are used depending on the tumour 
site, several CT conversion schemes will need to be created at each 
institution, as different values of the fitted parameters will occur for the 
same CT scanner using different protocols. 
3.3. Dosimetrically equivalent tissue subsets 
The mass density calibration curve for the Siemens Somatom Plus 4 
scanner at GUH is shown in figure 4. Compared to air/lung and bone, the 
fit for the soft tissues is clearly worse. This is due to the limited ability to 
distinguish soft tissues by means of their CT number in the range 
between 0 and 100 HU as shown by Schneider et al (2000), figure 3. It 
appears that the first two linear regression curves could be combined into 
a single curve representing air, lung and soft tissues together. Because the 
individual fits were performed separately, there is a discontinuity 
between the regression curves of soft and bone tissues. Its effect was 
evaluated through the comparison of depth dose curves calculated within 
homogeneous phantoms, corresponding to the soft and bone tissues just 
left and right of the discontinuity at H = 100, respectively. The maximal 
deviation was equal to 1.07% found at 0.3 cm depth. Therefore, the 
potential misassignment of a voxel with a CT number close to 100 HU to 
the last soft tissue bin or first bone tissue bin will not have severe 
consequences for the performed dose calculations, and the discontinuity 
between the mass  density calibration curves is acceptable. 
For the other CT scanners listed in table 2, similar curves were 
obtained. 
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Figure 4. Mass density calibration curve of the Siemens Somatom Plus 4 CT scanner at Ghent 
University Hospital. The equation of each linear regression curve is displayed as well as the 
corresponding correlation coefficient. 
 
The proposed conversion of CT numbers into elemental 
composition data is presented in table 3 for the Siemens Somatom Plus 4 
scanner at GUH. Air and lung were assigned an individual bin each. Two 
bins were created for soft tissue, i.e. for adipose- and muscle-like tissues. 
The maximal deviation between the depth dose curves of both subset 
representatives was 0.97% (found at 2.9 cm depth). Ten equidistant bins 
were created for bone. The maximal deviation between the depth dose 
curves of two adjacent subsets was found between the first two bins, and 
was equal to 1.01% (found at 3.5 cm depth). Based on these findings, 14 
tissue subsets were created for each of the CT scanners listed in table 2. 
For 15 MV photons, the deviation between the depth dose curves of 
the first and last bone bin was below 1% at all calculated depths. Indeed, 
figure 2 clearly shows an intersection between the mass stopping power 
curves of cartilage and cortical bone at an electron energy of about 20 
MeV. Thus, for high energy photon beams used for radiation therapy it 
will not be necessary to introduce as many bone bins as for low energy 
beams. The proposed binning scheme can therefore be used for 6 MV 
beams as well as for higher energies. 
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Table 3. Proposed conversion of CT numbers into elemental weight data wi for the Siemens 
Somatom Plus 4 CT scanner at Ghent University Hospital. Hl and Hu are the lower and upper 
boundaries of each CT number interval. 
Hl Hu wH wC wN wO wNa wMg wP wS wCl wAr wK wCa 
 -900   0.755 0.232      0.013   
-900 -100 0.103 0.105 0.031 0.749 0.002  0.002 0.003 0.003  0.002  
-100 20 0.112 0.533 0.011 0.341 0.001   0.001 0.001    
20 100 0.101 0.156 0.040 0.693 0.003  0.001 0.003 0.002  0.001  
100 250 0.095 0.453 0.025 0.355 0.001  0.021 0.002 0.001  0.001 0.046
250 400 0.084 0.401 0.028 0.369 0.001 0.001 0.036 0.002 0.001  0.001 0.077
400 550 0.075 0.355 0.030 0.381 0.001 0.001 0.048 0.002 0.001  0.001 0.105
550 700 0.067 0.316 0.033 0.392 0.001 0.001 0.059 0.002 0.001   0.128
700 850 0.060 0.281 0.035 0.401 0.001 0.001 0.068 0.002    0.149
850 1000 0.053 0.250 0.037 0.410 0.001 0.001 0.077 0.003    0.168
1000 1150 0.048 0.223 0.038 0.417 0.001 0.002 0.084 0.003    0.184
1150 1300 0.043 0.198 0.040 0.423 0.001 0.002 0.091 0.003    0.199
1300 1450 0.038 0.176 0.041 0.429 0.001 0.002 0.097 0.003    0.212
1450  0.034 0.156 0.042 0.435 0.001 0.002 0.103 0.003    0.224
 
For 6.6 MeV electrons, the maximal deviation between the depth 
dose curves of two adjacent bone bins was found between the first two 
bins, and was equal to 2.2% (found at 2.3 cm depth), whereas 
approximately 85% and 95% of all bone bins differ less than 1% and 2%, 
respectively. The larger than 1% differences are possibly due to a larger 
effect of electron elastic scattering in the dose deposition for electron 
beams compared to photon beams. Additionally, there is a large dose 
gradient at this depth (18.9% mm−1 for the depth dose curve of the first 
bone bin), which affects the comparison of the two bone bins. In the first 
part of the depth dose curve, which is reasonably flat and which is the 
part that is most relevant to radiotherapy treatment planning, the 
maximal deviation between the depth dose curves of two adjacent bone 
bins is again found between the first two bins but only amounts to 0.7%. 
We therefore consider our proposed CT conversion scheme suitable for 
photons as well as for electrons. For high energy electrons used for 
radiotherapy the proposed CT conversion scheme will be satisfactory a 
fortiori, due to the smaller difference between the mass stopping power 
values of different bone compositions at higher electron energies. 
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3.4. MC slab phantoms 
For the elemental composition of the vertebral column a CT number value 
of 520 HU was calculated. Thus, the vertebral column would be modelled 
as the third bone bin by our proposed 14 bin CT conversion scheme (table 
3) and as ICRU cortical bone by the conventional 5 bin scheme. The 
calculated mass density value was 1.323 g cm−3. Figure 5 shows the 
resulting depth dose curves for both values of the bone layer thickness 
(0.1 cm and 1 cm). Local absolute dose differences up to 4.1% (0.1 cm) and 
6.4% (1 cm) were observed within the bone layer, and up to 3.3% (0.1 cm) 
and 4.0% (1 cm) within the adjacent adipose tissue. The differences in area 
below the depth dose curves within the bone layer were more limited: 
2.3% (0.1 cm) and 2.4% (1 cm), respectively. 
The calculations for the 0.1 cm thick layer of bone allow us to study 
energy deposition effects around bony structures embedded within soft 
tissue, while the calculations for the 1 cm thick layer additionally allow us 
to study attenuation effects within the bony structure itself. The results 
indicate that although large dose deviations may be observed locally in or 
around bony structures within patients, the influence of introducing a 
larger number of bone bins on integrated dose quantities, e.g. DVHs, is 
likely to remain limited. 
3.5. Gammex RMI 461A head/body CT phantom 
Both sets of DOSXYZnrc calculations were compared by averaging the 
absolute value of the dose difference over the 13 central voxels along the 
X-axis and by normalizing the result using the average dose calculated 
within the central voxel. The following results were obtained at 12 cm and 
15 cm depth, respectively: 1.0% and 1.1% for LN-300, 0.5% and 0.6% for 
LN-450, 1.4% and 1.5% for B200 bone mineral, 0.6% and 0.5% for CB2–
10% CaCO3, 0.4% and 0.6% for CB2–30% CaCO3 and 0.2% and 0.2% for 
CB2–50% CaCO3. These numbers confirm the adequacy of our CT 
conversion procedure. Because the average CT number was converted 
into a homogeneous material composition and mass density for each 
insert, the influence of scanning artefacts on the calculations was 
excluded. 
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Figure 5. Depth dose curves within MC slab phantoms consisting of a 0.1 cm (a) and a 1 cm 
(b) thick layer of vertebral column (520 HU) embedded within adipose tissue. Calculations 
were performed with the vertebral column layer represented according to a conventional 5 
bin CT conversion scheme (dotted lines) and our proposed 14 bin CT conversion scheme 
(solid lines) for the Siemens Somatom Plus 4 CT scanner at Ghent University Hospital. The 
mass density of the bone layer was equal to 1.323 g cm−3. 
3.6. Patient dose calculations 
Figure 6 illustrates the attributed material numbers for the proposed 14 
bin conversion scheme for patient 3 in a sagittal slice through the 
isocentre (a), as well as the D14 (b) and DD (c) distributions. The material 
numbers of the 5 bin conversion scheme result from the 14 bin conversion 
scheme by replacing all numbers greater than or equal to 5 by 5. Figure 7 
shows DD as a histogram for each patient. It is clear that the observed 
relative differences between D14 and D5 are spread approximately 
symmetrically around DD = 0% and are mostly smaller than 5%. The 
largest local dose differences were reported for patient number 1, which 
was the patient with the smallest voxel size, i.e. 2 × 2 ×5 mm3. The voxel 
size of the dose calculation grid was 5 × 5 × 5 mm3 for patients 2–4, 4 × 4 × 
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3 mm3 for patients 5–6 and 4 × 4 × 4 mm3 for patients 7–9. Despite the 
observed local differences for each patient, the D14- and D5-DVHs of the 
target structures and relevant organs at risk were hardly distinguishable 
from each other. However, for bony structures like the mandible, maxilla 
or parts of the PTV for certain patients D14 was found to be slightly but 
systematically higher than D5. This is due to the higher mass stopping 
power values of soft bony tissues compared to hard ones like cortical 
bone as shown in figure 2. Figure 8(a) illustrates the DVHs of D14 and D5 
for patient 3. 
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Figure 6. Sagittal views through the isocentre (0, 0, 0) for patient 3, showing the material 
numbers for the 14 bin conversion scheme (a), the dose distribution D14 in Gy (b) and the 
absolute value (%) of the local dose difference distributions DD (c) and DDwat (d). Contoured 
structures: PTV1 (red), PTV2 (orange), skin (blue), brainstem (yellow), mandible (green) and 
the spinal cord (cyan). 
Table 4 shows the dose to medium to dose to water conversion 
factors for each material of the proposed CT conversion scheme of the 
Siemens Somatom Plus 4 CT scanner at GUH. For the other CT scanners 
listed in table 2, similar tables were obtained. Siebers et al (2000b) have 
associated errors up to 1.3% with these conversion factors, provided that 
a sufficient number of materials are included in the conversion process 
(Fippel and Nuesslin 2000, Siebers et al 2000c). Figure 6(d) illustrates the 
dose to water difference distribution DDwat for patient 3 in a sagittal slice 
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through the isocentre. Compared to DD(med) shown in figure 6(c), it is 
clear that the observed differences were larger, particularly in the bony 
tissue surrounding the spinal cord. Similar observations were made for 
the other patients in case of bony structures close to or within the high 
dose regions, but not for the lung and breast cancer patients. 
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Figure 7. Histograms of the relative dose to medium differences DD (%) between the MC 
dose distributions D14 and D5, which were calculated based on a 14 bin and a 5 bin CT 
conversion scheme, respectively. Each histogram was plotted using a bin width of 0.4%. 
 
Table 4. Dose to medium to dose to water conversion factors for the proposed CT conversion 
scheme of the Siemens Somatom Plus 4 CT scanner at Ghent University Hospital. The CT 
number interval and elemental composition corresponding to each material number are 
summarized in table 3. 
Material number Conversion factor 
1 1.110 
2 0.996 
3 0.995 
4 1.013 
5 1.024 
6 1.040 
7 1.054 
8 1.068 
9 1.079 
10 1.090 
11 1.100 
12 1.117 
13 1.125 
14 1.129 
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Figure 8. Dose–volume histograms of relevant target structures and organs at risk for patient 
3 for D14 (solid lines) and D5 (dashed lines) (a) and for D14wat (solid lines) and D5wat (dashed 
lines) (b). 
 
Figure 9 shows DDwat histograms for each patient. Unlike for DD, 
there is a distinct asymmetry in the histograms towards negative dose 
difference values, i.e. D5wat is higher than D14wat. This is due to the fact that 
for the 5 bin CT conversion scheme all bony tissues are classified as 
cortical bone and therefore the dose to water is over 10% higher than the 
dose to medium within those voxels. For the 14 bin CT conversion 
scheme, the dose to medium to dose to water correction is only a few % 
for the first bone bin, while this number quickly rises for the next bone 
bins. Therefore, possible errors during the conversion from dose to 
medium to dose to water, caused by considering an insufficient number 
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Figure 9. Histograms of the relative dose to water differences DDwat (%) between the MC 
dose distributions D14wat and D5wat. D14wat and D5wat result from the conversion of D14 and D5 
from dose to medium to dose to water. Each histogram was plotted using a bin width of 0.4%. 
of bone subsets, will naturally be most apparent within the voxels of 
which the real composition differs the most from the assigned 
composition, in our case within the softest bone tissues for the 5 bin CT 
conversion scheme. The clear lump around −11% in the DDwat histogram 
of patient number 9 was caused by the cartilage tissue of the larynx and 
the spinal cord; for other patients the lumps visible in the histograms 
were primarily due to the skull (patient 7), the skull base (patients 5, 6 
and 8), the mandible (patients 5 and 8) and the spinal cord (patient 5). For 
patient 1, the large amount of bony tissue present within the high dose 
region caused a shift of the maximum of the histogram of about 5% 
towards negative dose difference values. 
Although histograms are a good means to visualize the dose 
difference distribution, attention should also be paid to the clinical 
significance of the observed differences, i.e. to take into account their 
location with respect to the tumour and organs at risk. Indeed, if 
considerable errors are encountered within bony tissue that is not part of 
or close to any relevant structures there is less cause for concern with 
regard to the patient’s treatment. To evaluate the effect of the observed 
dose differences on the dose delivered to relevant structures it is best to 
look at DVHs. Figure 8(b) shows the DVHs of D14wat and D5wat for patient 
3. The most apparent differences occur between the curves of both PTVs 
and the mandible. Note that—in contrast to figure 8(a)—D5wat is higher 
than D14wat within the bony structures. While the presence of soft bony 
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tissues in the 14 bin CT conversion scheme increases the calculated dose 
to medium compared to the 5 bin CT conversion scheme because of the 
higher mass stopping power values, the DVHs change sides when the 
dose is converted to dose to water because the conversion factors for soft 
bony tissues are smaller. These opposite effects somewhat limit the 
observed dose to water differences between the 14 and 5 bin CT 
conversion schemes. Similar observations were made for the DVHs of 
bony structures within other patients. The largest difference was 
observed for patient 9, for whom the minimal dose received by 5% of the 
PTV volume was 10% higher for D5wat than for D14wat. It is thus highly 
important to use a CT conversion scheme that discriminates between 
different bone compositions when evaluating the dose to water. 
With regard to the comparison of MC calculations using CT 
conversion schemes of different CT scanners, the dose difference 
distribution between DA and DB was calculated as 200%—DA/DB for each 
patient voxel. The results are shown in figure 10. It is clear that the 
differences are almost everywhere within 2% and mostly even within 1%. 
Despite the quite large difference of 268 HU between the calculated CT 
numbers of cortical bone for both CT calibrations (1535 HU for CT 
scanner A versus 1267 HU for CT scanner B), the influence on dose errors 
is apparently limited. This finding is in agreement with the statement of 
Constantinou et al (1992) that heterogeneity correction factors used by 
conventional dose engines for photon beam calculations are relatively 
insensitive to small changes in the CT number. 
4. Conclusions 
The conversion of CT numbers into material properties strongly 
influences the accuracy of patient dose calculations in Monte Carlo 
treatment planning. By studying the attenuation and energy deposition 
properties of human tissues as well as individual elements, we have 
shown that it is particularly important to distinguish lung from air and 
different bone compositions from each other. The aim of our work was to 
develop a CT conversion scheme by performing a stoichiometric 
calibration of the CT scanner and by creating dosimetrically equivalent 
tissue subsets or bins. While each subset corresponds to a fixed material 
composition, the mass density could be calibrated continuously against 
the CT number. The proposed CT conversion scheme consisted of 14 bins: 
air, lung, adipose, muscle and 10 bone bins. It was validated by 
performing MC calculations within virtual MC slab phantoms and within 
a real CT phantom containing different inserts. While the proposed CT 
conversion scheme was developed for a clinical 6 MV photon beam, it is 
also suitable for higher energy photons and for electrons. 
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Figure 10. Isodifference plots showing values of 200%—DA/DB for several transversal slices 
for an oropharyngeal cancer patient case. DA and DB are the MC dose distributions calculated 
based on the CT conversion schemes of two different CT scanners. Values were only 
assigned to voxels that received more than 10% of the target prescription dose; voxels with a 
mass density value below 0.1 g cm−3 were not taken into account. 
The main focus of our work was to evaluate the proposed CT 
conversion scheme on patient treatment plans by means of a European 
multi-centre study. Nine patient cases with different tumour locations 
were selected. The proposed 14 bin CT conversion scheme was compared 
to a conventional 5 bin CT conversion scheme. The observed local relative 
differences in dose to medium were mostly smaller than 5%. The DVHs of 
the target and organs at risk were similar for both conversion schemes; 
only within certain bony structures D14 was found to be slightly but 
systematically higher than D5. However, after converting the results to 
dose to water D5wat became up to 10% higher than D14wat. Indeed, the 
correction factor for cortical bone exceeds 1.10, while it only deviates a 
few % from 1 for soft bony tissues. It is clear that multiple bone bins need 
to be introduced when MC calculations of patient dose distributions are 
converted to dose to water. A comparison of the CT conversion schemes 
of different CT scanners showed that the influence of selecting the wrong 
conversion scheme is limited as the local dose to medium errors were 
below 2%. 
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Appendix. Stoichiometric calibration: fitting parameters 
The stoichiometric calibration procedure of Schneider et al (1996) involves 
the determination of two parameters (Kph/KKN and Kcoh/KKN) through a 
least-squares fit of measured CT numbers to equations (1) and (2). In this 
way, however, negative Kcoh/KKN values were obtained for several CT 
scan protocols of our multi-centre study (table 2). Although the good 
quality of the fits based on these parameter values was shown in section 
3.2, the occurrence of non-meaningful Kcoh/KKN values may indicate that 
the model of Schneider et al is overdetermined. Indeed, Kph/KKN and 
Kcoh/KKN are both functions of energy and are thus interrelated. The fits 
were repeated using this relationship instead of treating Kph/KKN and 
Kcoh/KKN as independent free parameters. 
According to the parametrization of the total elemental attenuation 
coefficient by Rutherford et al (1976) (Schneider et al 1996, equation (7)), 
the ratio between Kph/KKN and Kcoh/KKN can be determined as follows: 
( )
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. (A.1) 
In this equation, (µ/ρ)ph and (µ/ρ)coh are the mass attenuation coefficients 
for photoelectric absorption and coherent scattering, respectively. While 
Kph/KKN and Kcoh/KKN are assumed to depend only on energy, the mass 
attenuation coefficients depend both on the element (Z) and energy. 
Values for (µ/ρ)ph and (µ/ρ)coh can be obtained as a function of photon 
energy from the NIST XCOM database (Hubbell and Seltzer 2004). 
Although the location-dependent energy spectrum of the CT scanner is 
unknown, an excellent linear relationship was obtained between the 
logarithms in base 10 of both parameters for the entire range of CT 
photon energies (20–120 keV). For oxygen (the most abundant element in 
human tissues) and calcium (the second most abundant element in 
cortical bone, after oxygen), respectively: 
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Clearly, the assumption that energy- and material-dependent factors can 
be separated is not entirely exact. Taking relationship (A.2) into account 
during the fit of measured CT data for the set of materials listed in table 1, 
resulted in values of Kph/KKN and Kcoh/KKN of 2.94 × 10−5 and 1.44 × 10−3, 
respectively, for the Siemens Somatom Plus 4 CT scanner at GUH. 
Similarly, the use of (A.3) resulted in Kph/KKN and Kcoh/KKN values equal to 
3.08 × 10−5 and 1.09 × 10−3, respectively. The R2-values of the fits based on 
(A.2) and (A.3) were both 0.998. The fits were thus hardly worse 
compared to the original fit (R2 = 0.999), which treated Kph/KKN and 
Kcoh/KKN as independent free parameters. 
Alternatively, the mass attenuation coefficient of a mixture can be 
calculated as the weighted sum of the coefficients of the constituent 
elements (Jackson and Hawkes 1981): 
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For each element i, values of (µ/ρ)i are available as a function of photon 
energy from the NIST XCOM database (Hubbell and Seltzer 2004). A 
quadratic fit can be performed through the 60, 80 and 100 keV data 
points. We assume that the unknown location-dependent energy 
spectrum of the CT scanner can be represented by a sole effective energy 
value Eeff. In this way, the CT number can be calculated as a function of 
Eeff through equations (A.4) and (2). The parametrization of the 
attenuation coefficient (1) is thus abandoned. The CT scanner can then be 
calibrated by determining the value of Eeff through a least-squares fit of 
measured against calculated CT numbers. As in the previous approach, 
only one fitting parameter is used. For the set of materials listed in table 1, 
this approach resulted in a value of Eeff equal to 73.0 keV, for the Siemens 
Somatom Plus 4 CT scanner at GUH. The R2-value of the fit was 0.998. 
In conclusion, in addition to the stoichiometric calibration 
procedure with two fitting parameters proposed by Schneider et al (1996), 
two alternative approaches were presented in this appendix. Both 
methods use only one fitting parameter, either Kcoh/KKN or Eeff. By 
decreasing the number of independent fitting parameters, the unphysical 
negative Kcoh/KKN values disappeared. For both alternative approaches, 
the quality of the stoichiometric calibration fit was hardly affected 
compared to the original two-parameter approach. However, both 
alternative methods require the use of experimental data from the NIST 
database. For the second alternative approach, fits of (µ/ρ)i against Eeff had 
to be performed for all constituent elements of the calibration materials 
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and human tissues, compared to only one fit of Kph/KKN against Kcoh/KKN 
for the first alternative approach, thus introducing more uncertainty. On 
the other hand, the second alternative approach does not require the 
assumption that the mass attenuation coefficient can be parametrized by 
separating energy- and material-dependent factors. Throughout our 
paper, we have applied the original stoichiometric calibration procedure 
of Schneider et al, because it leads to very good results in practice. The 
occurrence of negative Kcoh/KKN values has no impact on our proposed CT 
conversion method. 
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Abstract 
Purpose: To formulate uncertainty-based stopping criteria for Monte Carlo (MC) calculations of 
intensity-modulated radiotherapy and intensity-modulated arc therapy patient dose 
distributions and evaluate their influence on MC simulation times and dose characteristics. 
Methods and Materials: For each structure of interest, stopping criteria were formulated as 
follows: σ rel ≤ σ rel,tol or Dσ rel ≤ Dlimσ rel,tol within ≥95% of the voxels, where σ rel represents the 
relative statistical uncertainty on the estimated dose, D. The tolerated uncertainty (σ rel,tol) was 
2%. The dose limit (Dlim) equalled the planning target volume (PTV) prescription dose or a dose 
value related to the organ at risk (OAR) planning constraints. An intensity-modulated 
radiotherapy–lung, intensity-modulated radiotherapy–ethmoid sinus, and intensity-modulated 
arc therapy–rectum patient case were studied. The PTV-stopping criteria–based calculations 
were compared with the PTV+OAR-stopping criteria–based calculations. 
Results: The MC dose distributions complied with the PTV-stopping criteria after 14% (lung), 
21% (ethmoid), and 12% (rectum) of the simulation times of a 100 million histories reference 
calculation, and increased to 29%, 44%, and 51%, respectively, by the addition of the OAR-
stopping criteria. Dose–volume histograms corresponding to the PTV-stopping criteria, 
PTV+OAR-stopping criteria, and reference dose calculations were indiscernible. The median 
local dose differences between the PTV-stopping criteria and the reference calculations 
amounted to 1.4% (lung), 2.1% (ethmoid), and 2.5% (rectum). 
Conclusion: For the patient cases studied, the MC calculations using PTV-stopping criteria only 
allowed accurate treatment plan evaluation. The proposed stopping criteria provided a flexible 
tool to assist MC patient dose calculations. The structures of interest and appropriate values of 
σ rel,tol and Dlim should be selected for each patient individually according to the clinical 
treatment planning goals. 
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INTRODUCTION 
Highly conformal dose distributions can be created using intensity-
modulated radiotherapy (IMRT) or intensity-modulated arc therapy 
(IMAT) (1, 2). Monte Carlo (MC) techniques simulate the random 
trajectories (‘‘histories’’) of individual photons and electrons in material. 
MC techniques can provide highly accurate patient dose distributions, 
particularly in the presence of tissue inhomogeneities. Unlike analytical 
algorithms for dose calculations, MC calculations provide an average 
dose value and a value for the statistical uncertainty on the average dose 
within each scoring voxel. The statistical uncertainty decreases as the 
number of simulated histories increases. The clinical evaluation of a 
radiotherapy plan will thus depend on the number of histories used for 
the MC calculation of the patient dose distribution. From a practical 
viewpoint, it is important to determine the optimal (i.e., minimal) number 
of histories at which a clinical treatment plan can be evaluated 
adequately. 
Several investigators have studied the effect of statistical uncertainties 
on the evaluation of dose distributions. Keall et al. (3) reported that a 
statistical uncertainty of 2% at the maximal dose point did not 
significantly affect the isodose lines, dose–volume histograms (DVHs), or 
biologic dose indexes for a calculated lung treatment plan. By performing 
simulations within a water and lung computed tomography phantom, 
Buffa and Nahum (4) showed that the tumor control probability estimates 
ceased to change as a function of the number of histories when the 
standard deviation of the dose became <1.5–2%. The normal tissue 
complication probability estimates for organs at risk (OARs) were not 
considered. A more general analysis of the effect of statistical 
uncertainties on treatment plan evaluation was performed by Kawrakow 
(5), who showed that random dose uncertainties lead to statistical and 
systematic uncertainties on a ‘‘well-behaved’’ cost function defining the 
suitability of a treatment plan. The desired accuracy on the cost function 
can thus provide a stopping criterion for the MC calculation. Although a 
relative uncertainty of 2% within the planning target volume (PTV) is 
often assumed to be sufficient for accurate clinical treatment plan 
evaluation, Chetty et al. (6) have addressed the importance of considering 
the tradeoffs between uncertainties in doses to targets and ‘‘serial’’ or 
‘‘parallel’’ critical organs to determine the acceptable levels of statistical 
uncertainty. To remove the effect of statistical uncertainties on DVHs, de-
noising techniques have been developed (7, 8). Apart from the final 
treatment plan evaluation, statistical uncertainties can also influence the 
inverse MC treatment planning process by introducing noise convergence 
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errors, as shown by Jeraj and Keall (9). Ma et al. (10) have provided an 
overview of the effect of statistical uncertainties on MC treatment 
planning. 
The aim of our work was to evaluate the 2% tolerance level while 
paying attention to critical organs. For this purpose, we implemented 
uncertainty-based stopping criteria into our MC dose calculation 
software. For each structure of interest, upper limits were imposed on the 
relative and absolute statistical uncertainties. Calculations were 
performed taking into account the PTV only, and the PTV and a set of 
critical organs. Both approaches were compared for three clinical 
treatment plans: an IMRT lung cancer case, an IMRT ethmoid sinus 
cancer case, and an IMAT rectum cancer case. The evaluation of the 
observed dose differences was performed locally, as well as according to 
the DVHs. 
METHODS AND MATERIALS 
Uncertainty-based stopping criteria 
MC calculations of patient dose distributions result in values for the 
estimated dose D and the corresponding relative statistical uncertainty 
σ rel within each patient voxel. The absolute uncertainty on the estimated 
dose is equal to Dσ rel. In the BEAMnrc/DOSXYZnrc system used for the 
MC calculations in this study, the uncertainties were estimated using a 
history-by-history method (11, 12). The larger the number of histories 
used to perform the MC simulation, the lower the uncertainty will be 
within each patient voxel. To determine the simulation time that is 
necessary from a clinical viewpoint, we formulated general uncertainty-
based stopping criteria. Within each patient voxel, the following Boolean 
expression was evaluated: 
σ rel ≤ σ rel,tol OR Dσ rel ≤ Dlimσ rel,tol  (1) 
The values for the tolerated relative uncertainty σ rel,tol and the dose limit 
Dlim were defined separately for each target or OAR. We proposed 
stopping the MC simulation as soon as Expression 1 is true for ≥95% of 
the patient voxels within each structure of interest. 
For a specific patient case, the structures of interest were first listed. 
Next, the values of σ rel,tol and Dlim were assigned to each structure. 
Typically, σ rel,tol was equal to 2%. For Dlim, we selected the prescription 
dose for a target structure or a dose value related to the treatment 
planning constraints for an OAR. The rationale behind this approach is 
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explained in the ‘‘Discussion.’’ During the MC simulation, the fraction of 
voxels for which Expression 1 is true was evaluated regularly for each 
structure of interest. As soon as all evaluations resulted in fractions of 
≥95%, the simulation was stopped. Details on the MC calculations and the 
implementation of the uncertainty-based stopping criteria are provided 
below. 
MC calculations 
All MC calculations for this study were performed using the MC dose 
engine MCDE, developed by Reynaert et al. (13). By reprogramming 
DOSXYZnrc as a component module within BEAMnrc, MCDE uses the 
EGSnrc photon and electron transport algorithms (14). Because it uses no 
additional variance reduction techniques or approximations, MCDE is an 
accurate MC code for IMRT patient dose calculations. The possibility of 
simulating IMAT plans was recently included in MCDE (15). For this 
study, treatment plans were created using an in-house developed version 
(16–18) of the GRATIS software package (Sherouse Systems, Chapel Hill, 
NC). MCDE is able to simulate all beams in a single process, requiring 
only one input file. For each history, the beam angle of the simulated 
particle is randomly sampled according to the treatment plan’s monitor 
unit configuration. The MC sampling process ensures that the total 
number of simulated histories is the only quantity of interest, regardless 
of the beam angle selection. 
To incorporate the uncertainty-based stopping criteria in MCDE, the 
phantom component module was modified. In practice, the user can enter 
a list of structures of interest into the simulation input file, together with 
structure-specific values of σ rel,tol and Dlim. Each structure entry refers to 
the location of the corresponding GRATIS structure file, which can be 
imported from the treatment planning system. Additionally, the user can 
provide a density (grams per cubic centimeter) cutoff value to exclude air 
voxels from the structures of interest. All calculations were performed on 
a Linux PC cluster consisting of 31 nodes (2.4-GHz Intel Pentium IV dual 
processors with 2-GB RAM). Each time a total number of 106 histories was 
simulated on an individual cluster node, MCDE evaluated the fraction of 
voxels complying with Expression 1 for each structure and wrote these 
data to the simulation log file. σ rel,tol was multiplied before-hand by the 
square root of the number of cluster nodes in use. As soon as the 
evaluated fractions exceeded the 95% limit for all structures, the 
simulation was stopped. For each node, the simulation was halted in any 
case after 100 × 106 histories, even if not all stopping criteria had been 
fulfilled. In the remainder of this report, the numbers of simulated 
histories always refer to each individual cluster node. 
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Patient cases 
Three patients with various tumor locations were selected: a lung 
case, an ethmoid sinus case, and a rectal case. For the lung and ethmoid 
sinus cases, IMRT plans consisting of nine non–coplanar 6-MV photons 
beams with 25 and 42 beam segments in total were created. An IMAT 
plan consisting of 56 coplanar 18-MV photon beams organized in four 
arcs was created for the rectal case (18). 
For each patient, a 100 × 106-history reference dose distribution Dref 
was calculated. This simulation is referred to as MCref. Two additional 
simulations were performed taking into account uncertainty-based 
stopping criteria. In the first run (MCPTV), only the PTV was included as 
the structure of interest. In the second run (MCall), several OARs were 
added to the list of structures. The resulting dose distribution—obtained 
after simulating NPTV and Nall histories—is referred to as DPTV and Dall, 
respectively. For each patient case, the structures of interest and the 
corresponding Dlim values are listed in Table 1; σ rel,tol was equal to 2%. 
The rim and surroundings were shell-shaped critical structures created to 
avoid dose littering within the noncontoured normal tissue for the rectal 
case (19). The rim represents a region of 2 cm around the PTV, and the 
‘‘surroundings’’ is the region between the rim and the skin. Each MCDE 
scoring voxel had a radius of 2 mm. To eliminate air from the PTV, the 
density cutoff value was set to 0.5 g/cm3 in the simulation input file for 
the ethmoid sinus case. 
 
Table 1. Structures of interest and corresponding dose limit (Dlim) values for studied patient 
cases. Overview of total numbers of simulated histories N resulting from the MCPTV, MCall, 
and MCref simulations. 
Lung case  Ethmoid sinus case  Rectum case 
Structure Dlim (Gy)  Structure Dlim (Gy)  Structure Dlim (Gy) 
PTV 70  PTV 70  PTV 45 
Lungs 27  Left retina 30  Bladder 18 
Heart 55  Right retina 30  Small bowel 10 
Liver 30  Left optic nerve 45  Rim 30 
Esophagus 55  Right optic nerve 45  Surroundings 8.5 
Spinal cord 25  Optic chiasm 40    
        
No. of simulated histories (× 106) 
NPTV 14  NPTV 21  NPTV 12 
Nall 29  Nall 44  Nall 51 
Nref 100  Nref 100  Nref 100 
Abbreviations: PTV = planning target volume; MC = Monte Carlo. 
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Reporting and evaluation 
From the log file of the Dall MC simulation, the fraction of voxels 
complying with Expression 1 was set out against the number of simulated 
histories for each structure of interest. The GRATIS structure files and 
MCDE dose distributions resulting from the MCPTV, MCall, and MCref 
simulations were imported into MATLAB (The MathWorks, Natick, MA). 
Additional data analysis was performed using in-house created MATLAB 
scripts. 
For each patient and for each structure of interest, (D,σ rel) scatterplots 
after NPTV, Nall, and 100 × 106 histories were created (3). The influence of 
the number of simulated histories on the resulting dose distributions was 
evaluated by comparing the DVHs of DPTV, Dall, and Dref. Additionally, 
dose difference distributions were computed between DPTV and Dref and 
Dall and Dref. Within each structure of interest, the dose difference (in 
percentages) between a dose distribution D and Dref was calculated as 
follows (6): 
( )lim,max100 DD
DD
ref
ref−
 (2) 
Finally, the gain in simulating Nall instead of NPTV histories was 
evaluated. For the structures of interest that did not satisfy the 
uncertainty-based stopping constraints after NPTV histories, σrel–volume 
histograms of MCPTV and MCall were plotted. Only the voxels that did not 
meet the constraints were taken into account. 
RESULTS 
Lung case 
Figure 1a shows the fraction of voxels complying with the relative (σ rel ≤ 
σ rel,tol) or absolute (Dσ rel ≤ Dlimσ rel,tol) stopping constraints (see Expression 
1) as a function of the number of simulated histories for each structure of 
interest. The MCPTV and MCall simulations were stopped after NPTV = 14 × 
106 and Nall = 29 × 106 histories, respectively (Table 1). The 95% limit was 
reached first for the liver and last for the lungs. Only 36% of the ipsilateral 
lung satisfied the uncertainty-based stopping criteria after NPTV histories. 
Figure 2 shows (D,σ rel) scatterplots of MCPTV, MCall, and MCref for the 
liver, PTV, and lungs. Because of the low dose delivered to the liver 
(relative to the planning dose constraint), the absolute constraint was 
easily met for all voxels. After NPTV histories, 82% of the PTV voxels 
satisfied the constraint σ rel ≤ σ rel,tol, 84% satisfied Dσ rel ≤ Dlimσ rel,tol, and 
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97% satisfied either the relative or absolute constraint. For the lungs, the 
corresponding values were 5%, 63% and 69%; after Nall histories, these 
values were 19%, 77%, and 96%. After 100 × 106 histories, the uncertainty-
based stopping criteria were met within all voxels for each structure of 
interest. Figure 1b compares the DVHs of DPTV, Dall, and Dref for all 
structures of interest. Almost no differences could be observed among the 
three sets of DVHs. In Table 2, the median (DD50) and fifth percentile 
(DD5) values of the dose difference distributions DPTV-Dref and Dall-Dref, 
calculated according to Expression 2, are presented for each structure of 
interest. The reported values of Dall-Dref were systematically lower than 
those of DPTV-Dref, as one would expect from the use of a greater number 
of histories. For DD5, the largest differences were encountered for the 
lungs (4.0% for DPTV-Dref and 3.0% for Dall-Dref), especially within the 
ipsilateral lung, followed by the PTV and spinal cord, heart, and, finally,  
 
Fig. 1. Lung case. (a) Fraction of voxels complying with proposed uncertainty-based stopping 
constraint for each structure of interest, as function of total number of simulated histories. (b) 
Dose–volume histograms after simulation of 14 × 106 (black), 29 × 106 (dark gray), and 100 × 
106 (light gray) histories for all structures of interest. (c) Relative uncertainty–volume 
histograms after simulation of 14 × 106 (bold curves) and 29 × 106 (regular curves) histories for 
spinal cord and lungs. Only voxels that did not comply with uncertainty-based stopping 
criteria after 14 × 106 histories were taken into account. PTV = planning target volume. 
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Fig. 2. Lung case. (D,σ rel) scatterplots after simulation of 14 × 106 (black), 29 × 106 (dark gray), 
and 100 × 106 (light gray) histories for (a) liver, (b) planning target volume (PTV), and (c) 
lungs. Solid and dotted lines represent relative (σ rel ≤ σ rel,tol) and absolute (Dσ rel ≤ Dlimσ rel,tol) 
uncertainty-based stopping criteria, respectively. 
liver (0.9% for DPTV-Dref and 0.7% for Dall-Dref). This order was similar to 
the order in which the structures of interest satisfied the uncertainty-
based stopping criteria (Fig. 1). Considering DD5, it is important to keep 
in mind that these values represent the minimal dose difference 
encountered in only 5% of the structure voxels and an equal fraction of 
voxels was allowed to violate Expression 1 for each structure without 
compromising the acceptance of the uncertainty-based stopping criteria. 
Analogously, the order encountered for DD50 is similar to the order in 
which each structure reached the 50% limit in Fig. 1. The largest 
differences were encountered for the PTV (1.3% for DPTV-Dref and 1.0% for 
Dall-Dref), followed by the lungs (0.9% for DPTV-Dref and 0.7% for Dall-Dref) 
and other structures of interest, for which all DD50 values were <0.5%. 
Finally, Fig. 1c shows the σ rel–volume histograms of MCPTV and MCall for 
the structures of interest that did not satisfy the uncertainty-based 
stopping criteria after NPTV histories (i.e., the spinal cord and lungs). For 
each structure, only the voxels that did not comply with the relative or 
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absolute stopping constraint after NPTV histories were taken into account 
(i.e., 29% of the spinal cord voxels and 31% of the lung voxels). For 9% of 
the lung voxels, the relative uncertainty on the estimated dose was >4% 
after NPTV histories. After Nall histories, this was no longer the case (<1% 
of the voxels). For 16% of the lung voxels and 4% of the spinal cord 
voxels, σ rel was >3% after NPTV histories. After Nall histories, this was still 
the case for 7% of the lung voxels, but not for the spinal cord (<1% of the 
voxels). 
Table 2. Median (DD50) and 5th percentile (DD5) values of dose difference distributions DPTV-
Dref and Dall-Dref for each structure of interest of studied patient cases. 
 DD50 (%) DD5 (%) 
Structure of interest DPTV-Dref Dall-Dref DPTV-Dref Dall-Dref 
Lung case     
   PTV 1.3 1.0 3.7 2.9 
   Lungs 0.9 0.7 4.0 3.0 
      Ipsilateral lung 1.4 1.0 4.7 3.5 
      Contralateral lung 0.7 0.5 2.8 2.1 
   Heart 0.4 0.3 1.7 1.3 
   Liver 0.2 0.2 0.9 0.7 
   Esophagus 0.4 0.3 2.9 2.0 
   Spinal cord 0.5 0.4 3.8 2.8 
Ethmoid sinus case     
   PTV 1.4 1.0 4.0 3.1 
   Left retina 2.0 1.4 5.5 4.1 
   Right retina 1.8 1.4 5.1 3.7 
   Left optic nerve 1.6 1.1 4.8 4.0 
   Right optic nerve 2.1 1.3 5.4 3.9 
   Optic chiasm 1.5 1.2 4.5 3.4 
Rectum case     
   PTV 1.2 0.4 3.5 1.3 
   Bladder 2.5 0.9 7.7 2.7 
   Small bowel 1.4 0.5 9.4 3.4 
   Rim 1.5 0.5 4.5 1.6 
   Surroundings 1.9 0.7 9.7 3.5 
Dose differences computed according to Expression 2.  
Dose distributions DPTV, Dall and Dref obtained after Monte Carlo simulations of NPTV, Nall and 
100 × 106 histories, respectively (see Table 1). 
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Fig. 3. Ethmoid sinus case. (a) Fraction of voxels complying with proposed uncertainty-based 
stopping constraint for each structure of interest, as function of total number of simulated 
histories. (b) Dose–volume histograms after simulation of 21 × 106 (black), 44 × 106 (dark 
gray), and 100 × 106 (light gray) histories for all structures of interest. (c) Relative uncertainty–
volume histograms after simulation of 21 × 106 (bold curves) and 44 × 106 (regular curves) 
histories for optical structures. Only voxels that did not comply with uncertainty-based 
stopping criteria after 21 × 106 histories were taken into account. PTV = planning target 
volume. 
Ethmoid sinus case 
The fraction of voxels complying with the relative (σ rel ≤ σ rel,tol) or 
absolute (Dσ rel ≤ Dlimσ rel,tol) stopping constraints as a function of the 
number of simulated histories is shown in Fig. 3a for each structure of 
interest. The MCPTV and MCall simulations were stopped after NPTV = 21 × 
106 and Nall = 44 × 106 histories, respectively (Table 1). The PTV reached 
the 95% limit before all optical structures; the left retina reached it the last. 
Only 4% of the left retina (and even only 1% of the right retina) satisfied 
the uncertainty-based stopping criteria after NPTV histories. After NPTV 
histories, 83% of the PTV voxels satisfied the constraint σ rel ≤ σ rel,tol, 84% 
satisfied Dσ rel ≤ Dlimσ rel,tol, and 97% satisfied either the relative or absolute 
constraint. After Nall histories, all PTV voxels satisfied both constraints, 
and 49% of the voxels within the left retina satisfied σ rel ≤ σ rel,tol, 47% 
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satisfied Dσ rel ≤ Dlimσ rel,tol, and 96% satisfied either the relative or absolute 
constraint. The uncertainty-based stopping criteria were met within all 
voxels for each structure of interest after 100 × 106 histories. 
Figure 3b shows the DVHs of DPTV, Dall, and Dref for all structures of 
interest. Again, only very slight differences could be observed among the 
three sets of DVHs. The curves obtained after simulation of NPTV histories 
were already sufficiently accurate to evaluate the treatment plan. Table 2 
presents the median and fifth percentile values of the dose difference 
distributions DPTV-Dref and Dall-Dref, calculated according to Expression 2, 
for each structure of interest. For DD5, the largest differences were 
encountered for the left retina (5.5% for DPTV-Dref and 4.1% for Dall-Dref), 
followed by the right optic nerve, right retina, left optic nerve, optic 
chiasm, and, finally, the PTV (4.0% for DPTV-Dref and 3.1% for Dall-Dref). A 
similar order was encountered for DD50, with values ranging from 2.1% 
(for DPTV-Dref within the right optic nerve) to 1.0% (for Dall-Dref within the 
PTV). 
Finally, Fig. 3c shows σ rel–volume histograms of MCPTV and MCall for 
the structures of interest that did not satisfy the uncertainty-based 
stopping criteria after NPTV histories (i.e., all optical structures). For each 
structure, only the voxels that did not comply with the relative or 
absolute stopping constraints after NPTV histories were taken into account 
(i.e., 96% of the left retina, 99% of the right retina, 78% of the left optic 
nerve, 89% of the right optic nerve, and 86% of the optic chiasm voxels). 
For 39% of the left retina voxels and 4% of the right retina voxels, the 
relative uncertainty on the estimated dose was >3% after NPTV histories; 
for the other structures, σ rel was <3% within all voxels. After Nall histories, 
σ rel was still >2% for 50% of the left retina voxels and 9% of the right 
retina voxels, but for none of the voxels within the other structures. 
Rectum case 
Figure 4a shows the fraction of voxels complying with the relative 
(σ rel ≤ σ rel,tol) or absolute (Dσ rel ≤ Dlimσ rel,tol) stopping constraints as a 
function of the number of simulated histories for each structure of 
interest. The MCPTV and MCall simulations were stopped after NPTV = 12 × 
106 and Nall = 51 × 106 histories, respectively (Table 1). The 95% limit was 
reached first for the PTV and last for the surroundings. After NPTV 
histories, 99% of the PTV voxels satisfied the constraint σ rel ≤ σ rel,tol, 97% 
satisfied Dσ rel ≤ Dlimσ rel,tol, and 99% satisfied either the relative or absolute 
constraint. For the surroundings, the corresponding values were 0%, 32%, 
and 32%; after Nall histories, these values were 44%, 52%, and 96%. After 
100 × 106 histories, the uncertainty-based stopping criteria were met 
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within all voxels for each structure of interest, except for 0.3% of the 
voxels within the surroundings. 
Figure 4b compares the DVHs of DPTV, Dall, and Dref for all structures 
of interest. Again, almost no differences could be observed among the 
three sets of DVHs. Table 2 presents the median and fifth percentile 
values of the dose difference distributions DPTV-Dref and Dall-Dref, 
calculated according to Expression 2, for each structure of interest. For 
DD5, the largest differences were encountered for the surroundings (9.7% 
for DPTV-Dref and 3.5% for Dall-Dref), followed by the small bowel, bladder, 
rim, and, finally, the PTV (3.5% for DPTV-Dref and 1.3% for Dall-Dref). This 
order was similar to the order in which the structures of interest satisfied 
 
 
Fig. 4. Rectal case. (a) Fraction of voxels complying with proposed uncertainty-based 
stopping constraint for each structure of interest, as function of total number of simulated 
histories. (b) Dose–volume histograms after simulation of 12 × 106 (black), 51 × 106 (dark 
gray), and 100 × 106 (light gray) histories for all structures of interest. (c) Relative uncertainty–
volume histograms after simulation of 12 × 106 (bold curves) and 51 × 106 (regular curves) 
histories for bladder, small bowel, rim and surroundings. Only voxels that did not comply 
with uncertainty-based stopping criteria after 12 × 106 histories were taken into account. PTV 
= planning target volume. 
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the uncertainty-based stopping criteria (Fig. 4a). Again, differences of this 
magnitude were only encountered within 5% of the structure voxels. For 
DD50, the largest differences were encountered for the bladder (2.5% for 
DPTV-Dref and 0.9% for Dall-Dref), followed by the surroundings, rim, small 
bowel, and, finally, the PTV (1.2% for DPTV-Dref and 0.4% for Dall-Dref). 
Finally, Fig. 4c shows σ rel–volume histograms of MCPTV and MCall for 
the structures of interest that did not satisfy the uncertainty-based 
stopping criteria after NPTV histories (i.e., all OARs). For each structure, 
only the voxels that did not comply with the relative or absolute stopping 
constraints after NPTV histories were taken into account (i.e., 52% of the 
bladder voxels, 40% of the small bowel voxels, 48% of the rim voxels, and 
68% of the surroundings voxels). For 15% of the surroundings voxels and 
5% of the small bowel voxels, the relative uncertainty on the estimated 
dose was >5% after NPTV histories. After Nall histories, this was no longer 
the case (<1% of the voxels for both structures). For 48% of the 
surroundings voxels, 21% of the small bowel voxels and 5% of the 
bladder voxels, σ rel was >3% after NPTV histories. After Nall histories, this 
was still the case for 8% of the surroundings voxels, but not for the small 
bowel or bladder (<1% of the voxels). 
DISCUSSION 
The proposed uncertainty-based stopping criteria were based on the 
evaluation of Expression 1 within each patient voxel. This Boolean 
expression consists of two separate constraints for the relative (σ rel) and 
absolute uncertainty (Dσ rel), combined into an ‘‘OR’’ statement. Because 
of the stochastic nature of MC calculations, the aberrant behavior of the 
dose calculation results within individual voxels cannot be ruled out. For 
this reason, we allowed the statement to remain unfulfilled within no 
>5% of the voxels for each structure of interest. Similar conditions have 
been incorporated into all practical MC treatment planning systems. 
Because σ rel is inversely proportional to D1/2 (3, 7), the relative constraint 
σ rel ≤ σ rel,tol will be satisfied last within the low-dose regions. From a 
clinical viewpoint, however, it is rarely desirable to determine dose 
values far below the tolerance level with great accuracy. If the stopping 
criteria would be based on relative constraints only, the corresponding 
MC calculations would take unnecessarily long. For this reason, the 
absolute constraint Dσ rel ≤ Dlimσ rel,tol was added to Expression 1. This 
constraint allowed the absolute uncertainty to be compared with the 
product of the tolerated relative uncertainty and a dose limit value. Thus, 
for dose values less than Dlim, we allowed the relative uncertainty to 
exceed σ rel,tol. In contrast, for dose values greater than Dlim, the absolute 
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constraint becomes more difficult to satisfy than the relative constraint. 
Therefore, it is necessary to combine both constraints into an ‘‘OR’’ 
statement. This is illustrated by the presented lung case. Even after 
simulation of 100 × 106 histories, the relative constraint was satisfied only 
for a few of the voxels within the liver, and the absolute constraint was 
still not satisfied within all lung voxels. However, from a clinical 
perspective, there was clearly no point in simulating more histories. 
The values of Dlim are assigned to each structure of interest 
individually. It is important to establish a link between the way clinical 
treatment plans are prescribed and evaluated and the selected values of 
Dlim. 
For target structures, we propose to select the homogeneous target 
prescription dose for Dlim. Because D will be approximately equal to Dlim 
within each target voxel, the relative and absolute constraint will be more 
or less equivalent. 
For OARs, the added value of the absolute constraint Dσ rel ≤ Dlimσ rel,tol 
was clearly more significant. It is important to discriminate between so-
called parallel and serial OARs (3, 6). For parallel organs, such as the 
lungs, treatment planning constraints are often formulated in terms of the 
mean dose within the organ. Therefore, we selected this mean dose 
constraint for Dlim. For serial organs, such as the spinal cord, it is 
important to limit the maximal dose delivered to the organ. Because point 
doses are generally more sensitive to statistical fluctuations than derived 
dose metrics (6), the planning constraints for serial organs should be 
formulated in terms of a dose percentile such as D2 or D5, instead of the 
maximal dose. In its new report in progress, the International 
Commission on Radiological Units will recommend the use of D2 instead 
of the maximal dose for both target volumes and OARs (Vincent 
Grégoire, personal communication, 13 February 2007). The absolute 
stopping constraint Dσ rel ≤ Dlimσ rel,tol requires a value for Dlim 
representative of the average dose within the structure of interest, 
because the relative constraint σ rel ≤ σ rel,tol should still prevail within the 
high-dose regions to secure the meaning of σ rel,tol. For lack of a planning 
constraint value for the mean or median dose for serial organs, we 
selected a typical value of one of these dose indexes for Dlim. The exact 
value was not so critical, because MC simulation times will primarily be 
influenced by how fast the high-dose voxels will fulfill the relative 
constraint. For example, values of Dlim can be obtained by retrospective 
dose–volume analysis of treatment plans for patients with the same 
tumor site. For the ethmoid sinus and rectal patient cases, the values of 
Dlim for the optical structures, small bowel, rim, and surroundings were 
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thus selected. Alternatively, values of Dlim can be easily obtained by 
halving the planning constraint value of the maximal dose for the 
structure of interest. For the lung cancer patient case, the value of Dlim for 
the spinal cord was thus selected. 
Alternatively, Kawrakow (5) has presented a termination criterion for 
MC patient dose calculations using the evaluation of a cost function that 
quantifies the suitability of a treatment plan. The implementation of his 
approach requires knowledge of the acceptable uncertainty on the cost 
function. However, it is not clear how this can be determined from a 
clinical perspective. The purpose of the present study was to provide a 
practical tool capable of determining the number of histories necessary 
for accurate clinical treatment plan evaluation. Within this framework, 
the formulated uncertainty-based stopping criteria are easy to 
understand, implement, and use. 
Considering the data in Figs. 1a, 3a, and 4a, it is important to note that 
the proposed uncertainty-based stopping criteria lead to substantial 
differences in simulation time for the PTV and different OARs of interest. 
Moreover, clear differences can be observed between the shapes of the 
curves. The more homogeneous the dose delivered to a structure, the 
steeper the curve will be, because all voxels will satisfy the stopping 
criteria at approximately the same time. The most obvious example is the 
PTV, but the dose delivered to small optical structures, such as the right 
retina and right optic nerve, was also quite homogeneous. Other 
structures, such as the lungs, small bowel, and surroundings, received a 
highly inhomogeneous dose, resulting in the flat curves shown in Figs. 1a 
and 4a. 
Moreover, because of the lower density of lung tissue, σ rel will be 
greater within the lung voxels compared with the other structures of 
interest. Therefore, accurate dose computation within the lungs will cause 
the total MC simulation time to increase. 
Because of the inclusion of the absolute stopping constraint Dσ rel ≤ 
Dlimσ rel,tol, the uncertainty-based stopping criteria were easily satisfied 
within the low-dose regions. This is illustrated by the scatterplots in Fig. 
2. For certain structures of interest, such as the liver and heart, the value 
of the delivered dose was well below Dlim within each voxel. 
Figures 1c, 3c, and 4c show the gain in simulating Nall instead of NPTV 
histories. Only within the lungs, small bowel, and surroundings, were 
values of σ rel >5% encountered after NPTV histories. For the other 
structures, it seems to be less essential to increase the MC simulation time. 
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The presence of a lot of statistical noise in the lungs resulted from the low 
density of the lung tissue. For the rectal patient case, NPTV was only one-
quarter of Nall, explaining the large σ rel values encountered within the 
small bowel and surroundings. Although it is not shown by the DVHs 
because of the large volume of these structures, the noise will be evident 
from other dose distribution evaluation methods (e.g., isodose or gamma 
evaluation plots). 
For the studied patient cases, the uncertainty-based stopping criteria 
were met within all voxels for all structures of interest after simulating 
100 × 106 histories. This justified our consideration of Dref as the reference 
dose distribution, and we expect this to be valid for similar patient cases 
as well. Therefore, considering Figs. 1b, 3b, and 4b, it is clear that all 
treatment plans could be accurately evaluated using the DVHs obtained 
after NPTV histories, even for low-density OARs such as the lungs. In 
contrast, the evaluation of the uncertainty-based stopping criteria could 
depend on the treatment plan configuration. IMRT typically involves the 
delivery of a large number of small beam segments with relatively few 
monitor units per segment. In contrast to traditional inverse planning 
techniques, IMRT plans at Ghent University Hospital are created by 
direct aperture optimization (16, 17). This typically results in an 
overlapping set of small and large segments for each beam angle; 
segments created by inverse planning will generally be smaller and 
involve less overlap. For the studied patient cases, large beam segments 
will thus generally contribute more to the patient dose than for inversely 
planned cases. The influence of treatment plan configuration on the 
stopping criteria for MC dose calculations is worth additional 
investigation; however, this was beyond the scope of the present study. 
Considering the studied patient cases, the MC calculations could be 
stopped as soon as the uncertainty-based stopping criteria were satisfied 
within the PTV only, taking into account a tolerated relative uncertainty 
of 2% and a dose limit value equal to the PTV prescription dose. 
Simulating more histories did not change the DVHs of the structures of 
interest. The formulated uncertainty-based stopping criteria could be 
used to determine the MC calculation times necessary for accurate clinical 
IMRT or IMAT plan evaluations. By formulating the absolute stopping 
constraint, characteristic differences in the dose response of target 
volumes and serial and parallel OARs can be taken into account by 
including a meaningful dose limit value. Users can define their own 
structures of interest for each patient case individually and select 
appropriate values of the tolerated relative uncertainty and of the dose 
limit according to their treatment planning goals. The proposed 
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uncertainty-based stopping criteria thus provide a flexible tool to assist 
MC patient dose calculations. 
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Abstract 
Integrating Monte Carlo calculated dose distributions into an iterative aperture-based IMRT 
optimization process can improve the final treatment plan. However, the influence of large air 
cavities in the planning target volume (PTV) on the outcome of the optimization process should 
not be underestimated. To study this influence, the treatment plan of an ethmoid sinus cancer 
patient, which has large air cavities included in the PTV, is iteratively optimized in two different 
situations, namely when the large air cavities are included in the PTV and when these air 
cavities are excluded from the PTV. Two optimization methods were applied to integrate the 
Monte Carlo calculated dose distributions into the optimization process, namely the ‘Correction 
– method’ and the ‘Per Segment – method’. The ‘Correction – method’ takes the Monte Carlo 
calculated global dose distribution into account in the optimization process by means of a 
correction matrix, which is in fact a dose distribution that is equal to the difference between the 
Monte Carlo calculated global dose distribution and the global dose distribution calculated by a 
conventional dose calculation algorithm. The ‘Per Segment – method’ uses directly the Monte 
Carlo calculated dose distributions of the individual segments in the optimization process. Both 
methods tend to converge whether or not large air cavities are excluded from the PTV during 
the optimization process. However, the ‘Per Segment – method’ performs better than the 
‘Correction – method’ in both situations and the ‘Per Segment – method’ in the case where the 
large air cavities are excluded from the PTV leads to a better treatment plan then when these air 
cavities are included. Therefore we advise to exclude large air cavities and to apply the ‘Per 
Segment – method’ to integrate the Monte Carlo dose calculations into an iterative aperture-
based optimization process. Nevertheless, the ‘Correction – method’ provides a good alternative 
in the case when the external dose engine is not able to generate individual dose distributions 
for the individual segments. 
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1. Introduction 
In the standard approach of intensity modulated radiotherapy (IMRT) 
treatment plan optimization, the intensity pattern for each IMRT beam is 
modelled as a 2D map of energy fluence incident on a patient. This 
intensity pattern is divided into discrete uniform beam elements 
(beamlets or bixels) and an inverse planning or automated optimization 
system is then used to generate a set of beamlets that will produce, as 
closely as possible, the desired dose distributions. 
To produce practically deliverable treatment fields, these elementary 
beamlets are regrouped into larger fields during a process called ‘leaf 
sequencing’. However, the obtained treatment fields are only an 
approximation of the ideal intensity distribution and this usually leads to 
a reduced quality of the treatment plan. Nevertheless, there are several 
approaches to overcome the sequencer problems in IMRT optimization 
(Alber and Nüsslin 2001, Litzenberg et al 2002, Siebers et al 2002) and one 
of these approaches is the method of aperture-based optimization. 
Aperture-based optimization (Shepard et al 2002, De Gersem et al 2001) is 
a technique for IMRT that is designed to reduce the complexity of 
intensity modulated treatment plans and to facilitate the application of 
IMRT in clinical practice. This is achieved by avoiding the optimization of 
intensity maps. Instead, the planning process is based on a small, preset 
number of multileaf collimator (MLC) shapes (apertures or segments) per 
beam direction. The optimization is then either limited to calculate 
optimal weights for predefined apertures (which can be, for example, 
derived from the patient’s anatomy), or it can be extended to a 
simultaneous optimization of the shapes and weights of the apertures. 
The aim of this work is to investigate whether the final treatment plan 
obtained by an iterative aperture-based optimization process that 
incorporates a conventional dose calculation algorithm could be 
improved by integrating Monte Carlo calculated dose distributions into 
this optimization process and to illustrate the influence of large air 
cavities on the outcome of the optimization process. Two alternative 
methods are examined to integrate these Monte Carlo calculated dose 
distributions into the aperture-based optimization process applied at 
Ghent University Hospital (GUH). 
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2. Methods and materials 
2.1. IMRT optimization system 
At GUH, a segmentation-based inverse planning approach is used to 
create IMRT treatment plans for step-and-shoot delivery with a MLC. 
Starting from an initial set of beam segments, as illustrated in figure 1, the 
corresponding set of segment dose distributions is calculated by an 
external dose engine. Generally the differential scatter-air ratio dose 
calculation algorithm of GRATIS (Sherouse et al 1989) is used. As 
illustrated in a recent paper (Paelinck et al 2006) the accuracy of this 
system cannot be guaranteed, as for individual cases deviations above 
10% were obtained when comparing GRATIS DVHs to MCDE results. 
During the optimization process, a bio-physical objective function is 
maximized starting with the in-house developed Segment Weight 
Optimization Tool (SWOT) cycle, which only optimizes the weights of the 
beam segments and leaves all segment shapes unchanged. After the first 
SWOT cycle, the Segment Outline and Weight Adapting Tool (SOWAT) 
optimizes the MLC settings and weights of these segments (De Gersem et 
al 2001) and an additional SWOT cycle is performed. When the plan 
acceptance criteria are not fulfilled, a new optimization cycle is performed 
(SOWAT + SWOT). This is repeated until the plan acceptance criteria are 
fulfilled. 
 
Figure 1. Overview of the iterative optimization cycle and the different optimization 
algorithms used at Ghent University Hospital. 
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The aim of our study was to investigate whether the final treatment plan 
could be improved by integrating our Monte Carlo Dose Engine MCDE 
(Reynaert et al 2004) into the iterative optimization process and to 
illustrate the influence of large air cavities on the outcome of this 
optimization process. 
2.2. Dose computation method: ‘Correction – method’ 
The initial treatment plan calculated with GRATIS (providing a global 
dose distribution DGRATIS) is recalculated with MCDE resulting in a global 
dose distribution DMCDE. The values of the voxels in the correction matrix 
R are determined by R = DMCDE - DGRATIS, which results in a dose 
distribution that is equal to the difference between the global GRATIS 
and MCDE results. 
To take this correction matrix into account during the optimization 
process, an additional beam (‘patch-beam’) was created of which the 
weight (set to unity) and MLC settings were locked. Both SOWAT and 
SWOT cycles used the GRATIS dose distributions of the individual 
segments, plus the dose distribution of this ‘patch-beam’ to evaluate the 
outcome of the treatment plan. 
It can be expected that this method will introduce small systematic errors 
during the optimization process, because the correction matrix R (and 
inherently the dose distribution of the ‘patch-beam’) remains constant, 
while the GRATIS results for the individual beam segments are modified 
during an optimization iteration (as the MLC settings and weights of the 
individual segments are changed). Nevertheless, the ‘Correction – 
method’ is very useful if the Monte Carlo dose engine that has to be 
integrated into the optimization software is only capable of delivering a 
global dose distribution. 
2.3. Dose computation method: ‘Per Segment – method’ 
With the ‘Per Segment – method’, the Monte Carlo calculated dose 
distributions of the individual segments are used directly by the SOWAT 
and SWOT algorithms instead of the GRATIS dose distributions. No 
‘patch-beam’ has to be created. It is therefore a more accurate method of 
integrating Monte Carlo results into the optimization process. However, 
this method requires a Monte Carlo dose engine to be capable of 
delivering the dose distributions of the individual segments. 
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2.4. Clinical case 
An ethmoid sinus cancer patient case was studied with large air cavities 
present in the planning target volume (PTV). The patient was treated with 
42 6 MV beam segments impinging from 9 different directions. Starting 
from the initial plan generated by the GRATIS dose calculation algorithm, 
five additional optimization cycles (SOWAT and SWOT) were performed. 
Before the start of each cycle, a MCDE calculation was performed for both 
the ‘Correction – method’ and the ‘Per Segment – method’, thus 
providing a global dose distribution and a set of dose distributions of the 
individual segments. 
To determine the influence of the air cavities, both methods were applied 
while including/excluding the large air cavities from the original PTV. 
This allows the study of the influence of statistical noise from the MCDE 
calculations on the optimization process. The exclusion of the air cavities 
of the PTV leads to a newly defined structure and is accomplished by 
delineating these air cavities in the PTV and by subtracting these air 
cavities from the original PTV using in-house developed software. 
Treatment plans were compared by means of dose volume histograms 
(DVHs) and their corresponding values of the objective function are used 
to illustrate the convergence of the iterative optimization process. 
3. Results and discussion 
3.1. Calculation times 
The MCDE calculation times of the treatment plans obtained in the 
iterative optimization cycles with the ‘Per Segment – method’ and the 
‘Correction – method’ were almost identical, namely 4 hours on a cluster 
consisting of 34 2.4 GHz Xeon processors. 
However, to obtain the correction matrix (‘patch-beam’) for the 
‘Correction – method’, the individual dose distributions of the different 
beam segments had to be calculated first by the GRATIS dose 
computation algorithm, which requires an additional calculation time of 
about half an hour before a new optimization cycle can be started. 
With the ‘Per Segment – method’, there is no need for an extra dose 
calculation with GRATIS since these individual Monte Carlo calculated 
dose distributions are used directly in the optimization cycle. 
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3.2. Convergence of the value of the objective function 
For the initial treatment plan, the values of the objective function for the 
dose distribution calculated by GRATIS were respectively -6.2 when 
including the large air cavities in the PTV and -6.8 when excluding these 
air cavities. A recalculation of this initial treatment plan with the Monte 
Carlo dose engine MCDE provided a dose distribution from which the 
values of the objective function were equal to -14.9 and -12.6 respectively, 
as illustrated in figure 2. 
Both the ‘Correction – method’ and the ‘Per Segment – method’ tend to 
converge in both situations. However, when the air cavities are included 
in the PTV, the convergence isn’t obtained as fluently as in the situation 
without the air cavities as the values of the objective function don’t 
increase continuously. 
Figure 2 also illustrates that the results obtained with both the ‘Correction 
– method’ as well as the ‘Per Segment – method’ are quite similar when 
the air cavities are included in the PTV. However, excluding the air 
cavities from the PTV clearly leads to a larger difference between both 
methods, which leads to the conclusion that a better treatment plan is 
obtained by applying the ‘Per Segment – method’. 
 
 
Figure 2. Illustration of the convergence of the value of the objection function (OF) after five 
optimization cycles for both the ‘Correction – method’ and ‘Per Segment – method’ when 
applied in two situations: one situation in which the large air cavities are included in the 
PTV and the other situation in which these air cavities are excluded from the PTV. 
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3.3. Comparison of DVHs 
As the quantitative values of the objective function strongly depend on 
the choice of this function, the quality of the resulting treatment plan was 
also evaluated by looking at the DVHs for both methods in both 
situations (inclusion or exclusion of the air cavities from the PTV). 
A. Excluding the air cavities from the PTV. 
Looking at the DVHs for both optimization methods in the situation 
where the air cavities are excluded from the PTV in figure 3, one can 
conclude that the initial treatment plan is improved by integrating Monte 
Carlo calculated dose distributions into the iterative aperture-based 
optimization process. Moreover, in accordance to the values of the 
objective function in figure 2, the ‘Per Segment – method’ provides a 
better treatment plan compared to the ‘Correction – method’ and is 
therefore a more favourable method of integrating Monte Carlo 
calculated dose distributions into the optimization process. Nevertheless, 
not all dose engines are able to produce dose distributions for the 
individual beam segments and therefore the ‘Correction – method’ 
provides a good alternative, especially in the case when the air cavities 
are excluded from the PTV. 
B. Including the air cavities from the PTV. 
Figure 4 shows the DVHs for the ‘Per Segment – method’ applied to both 
situations (including and excluding the air cavities from the PTV). It’s 
clear that the initial treatment plan is improved in both cases. However, 
excluding the air cavities from the PTV during the optimization process 
provides a better treatment plan. This is mainly caused by the presence of 
high statistical noise on the Monte Carlo calculated dose in these air 
cavities, since relatively fewer particles will interact in air compared to 
the surrounding tissues. 
If acceptable statistical uncertainties on the dose values in these air voxels 
are required, e.g. to compute the value of the objective function, the 
calculation time of the Monte Carlo dose engine should be increased 
dramatically (by a factor of thousand) to compensate for the low density 
of air, which is not realistic at all. Denoising cannot solve this problem as 
the noise in the air cavities is too severe. Denoising techniques can 
decrease the calculation time by a factor of ten (Kawrakow 2002, El Naqa 
et al 2005), which is still not sufficient for the air voxels. 
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Figure 3. Comparison between the ‘Correction – method’ and ‘Per Segment – method’ of the 
DVHs of the initial treatment plan and the treatment plan after the fifth optimization cycle 
obtained in the situation where the air cavities are excluded from the PTV. 
Therefore each dose calculation algorithm will have to deal with the 
concept ‘dose to air’ in some way. There are several possible methods to 
achieve this. For instance, one can apply a KERMA approximation in the 
air voxels. Another possibility is to transport track-end electrons on 
straight lines by their range (Kawrakow and Fippel 2000) in these air 
regions, instead of locally depositing the track-end electrons, as is the case 
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Figure 4. Comparison of the DVHs of the initial treatment plan and the treatment plan after 
the fifth optimization cycle obtained for the ‘Per Segment – method’ in the cases where the 
air cavities are included or excluded from the PTV. 
with EGS-based Monte Carlo dose calculation algorithms. However, 
lowering the ECUT value to 0.521 MeV in our patient calculations did not 
have a significant effect on the noise in these air voxels. 
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In this paper, subtracting the volume of the air from the volume of the 
PTV (the volume of air measured 30% of the volume of the PTV) leads to 
a dose distribution in the PTV containing less statistical noise. An 
advantage of this method is that some commercially available treatment 
planning systems are provided with software to subtract structures. A 
disadvantage is that the delineation of all air cavities leads to a higher 
workload. However, one could question the subtraction of air cavities 
from the PTV on principle, as they are in fact part of the PTV. 
Nevertheless, we are interested in the dose to the tissue within the PTV 
and not in the dose to the air cavities. 
Another possible method is to adapt the DVH software and the 
calculation of the value of the objective function by the optimization 
software in such a manner that all voxels with a Hounsfield number less 
than, for instance, -500 Hounsfield units are neglected or are given a 
lower weight so they have less influence. The disadvantage of this 
method is that it is not always possible to manipulate commercially 
available DVH software or the optimization algorithm. Therefore, it is 
recommended that commercial treatment planning systems provide at 
least one of these aforementioned methods, especially those treatment 
planning systems that implement a Monte Carlo dose calculation 
algorithm. 
4. Conclusions 
By integrating Monte Carlo dose calculations into the IMRT optimization 
process the treatment plan can be further improved. Both the ‘Correction 
– method’ and ‘Per segment – method’ could be applied. However, the 
‘Per Segment – method’ performed better than the ‘Correction – method’ 
when the air cavities are excluded from the PTV. When the air cavities are 
included, both methods converge to a similar treatment plan, which is 
indeed an improvement of the initial treatment plan, although not fully 
optimized. Therefore we advise to not include air cavities and to apply 
the ‘Per Segment – method’ to integrate the Monte Carlo dose calculations 
into the optimization process. However, the ‘Correction – method’ 
provides also a good alternative when the Monte Carlo dose engine is not 
able to generate individual dose distributions. 
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Chapter  10  
Discussion 
10.1 Rationale for BCRT 
By targeting the most radiation resistant regions inside the tumor while 
maximally preserving the functionality of critical organs, BCRT may 
improve the local control versus toxicity ratio. However, a new set of 
problems and questions arise with the integration of biological imaging 
information into the IMRT treatment planning process. Indeed, the exact 
meaning of the biological imaging information remains insufficiently 
known, as well as how the radiobiological factors should be transformed 
into the desired dose prescription. Moreover, it is not clear what should 
be the optimal radiation treatment schedule.  
It has been suggested that the rationale for inhomogeneous dose 
prescription should be further investigated through fundamental 
radiobiological research and pre-clinical evaluations using animal 
models, before proceeding towards clinical implementation [1]. On the 
other hand, clinical investigations may already contribute to address 
some of the above-mentioned issues [2,3]. For a variety of tumor sites, 
phase I trials are first needed to study the dose/volume/toxicity 
relationship. Next, phase II trials with local control and site of recurrence 
as primary endpoints might test the validity of the approach. While pre-
clinical research is required to formulate stable hypotheses for safe and 
well-designed clinical trials, the results of these trials may in turn raise 
new questions and provide guidance to the fundamental research. Pre-
clinical, translational and clinical research can thus be conducted 
simultaneously.  To conduct clinical trials, the appropriate technology for 
the planning and delivery of BCRT is required [4]. In this thesis, a 
technical solution was provided for the clinical implementation of BCRT. 
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10.2 Technical solution 
10.2.1 Relationship between signal intensity and dose 
An important task in the implementation of BCRT is to quantify the 
tumor burden from the available biological imaging data and to relate it 
to the desired radiation dose. The most fundamental and logical approach 
would be to generate the dose prescription based on a biological model. 
This involves two steps: (i) translating the biological image signal 
intensity values into meaningful radiobiological parameters and (ii) 
determining the inhomogeneous dose prescription pattern from the 
known biology distribution. 
Unfortunately, for many biological imaging techniques it is not at all 
obvious which fundamental radiobiological properties are represented in 
the image and how they can be quantified. Additionally, due to technical 
limitations and the presence of image artefacts the biological image signal 
does not always accurately reflect the actual biological characteristics over 
the entire imaging volume. Provided all necessary biological parameters 
are known, radiobiological models can generate the most desirable dose 
distribution by optimizing the cell killing through maximization of the 
TCP [5-8]. 
As data on fundamental radiobiological parameters are sparse and not 
easily extracted from the available biological images, a more practical 
approach seems to be the best option at present. Several authors have 
suggested the use of a linear relationship between the biological image 
signal intensity I and the radiation dose D to be delivered in every image 
voxel [9-12]. This linear relationship is used as a reasonable starting point 
[5]. 
In the first two publications of this thesis [13,14], the prescription dose 
was escalated linearly between Dlow and Dhigh, respectively corresponding 
to Ilow and Ihigh. The values of Ilow, Ihigh, Dlow and Dhigh can be chosen freely. 
For FDG-PET guided BCRT in head and neck cancer, we wanted to 
achieve a maximal intensity range for dose escalation, while minimizing 
the influence of noise. For this purpose, Ilow and Ihigh were set equal to 25% 
and 100% of the 95th percentile PET intensity value within the PTV. For 
Dlow, the PTV prescription dose of the standard IMRT treatment was 
selected, i.e. 69 Gy in 32 fractions or 2.16 Gy per fraction. The radiation 
dose used in current clinical practice with “intent to cure” seems to be an 
acceptable value for Dlow of the BCRT dose prescription [5]. 
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In principle, the dose prescription for BCRT can be determined 
experimentally by analyzing animal data or hypothesis-driven clinical 
data. This is similar to the establishment of the empirical dose 
prescriptions for different disease sites in current clinical practice. In this 
thesis, the choice of Dhigh was determined by the dose escalation levels 
applied in the FDG-PET guided dose painting phase I clinical trial, i.e. 2.5 
and 3 Gy per fraction [15]. 
10.2.2 Treatment plan optimization 
BCRT has been implemented into the inverse treatment planning process 
at several institutions [10,11,16]. Once the desired BCRT dose prescription 
distribution is determined, IMRT optimization can proceed. The 
algorithmic segmentation-based inverse IMRT planning approach of 
GUH involves the creation of initial beam segments, followed by 
optimization of the segment weights and leaf positions [17,18]. 
To implement BCRT at GUH, a biology-based segmentation tool was first 
developed to generate initial beam segments based on the projected 
biological images [13]. The optimization engine uses an objective function 
that consists of a physical and a biological part. The physical part is 
entirely target-related and refers to target inhomogeneity and 
prescription dose values. To implement BCRT, a physical term was added 
to the objective function, which minimizes the root mean square 
deviation between the obtained and intended dose values in every PTV 
voxel [13]. 
The biological part of the objective function numerically maximizes the 
TCP while maintaining the NTCP below a certain limit. If fundamental 
radiobiological parameters could be extracted from the biological images, 
they could be used to modify the conventional TCP and NTCP formula to 
take into account a heterogeneous biology distribution. In this way, a 
biological model-based approach would allow BCRT optimization 
through the biological part of the objective function. Truly biological 
optimization of BCRT is a great challenge at present, because there is a 
lack of data that allow the development of biological models, linking the 
biological imaging information to treatment outcome. One could also take 
a “hybrid” approach, by calculating the intended dose within every 
patient voxel by means of a biological model and entering this data into 
the physical part of the objective function. The influence of the biology-
based segmentation tool and optimization settings on BCRT treatment 
planning was studied in the first publication of this thesis [13]. 
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10.2.3 Treatment plan evaluation 
The large volume of information inherent to 3D treatment design makes it 
difficult to display and assess the corresponding dose distributions in an 
objective way. The spatial characteristics of a 3D dose distribution can be 
examined in detail by means of 2D isocurves in a slice-by-slice fashion. 
However, this is only quasi-quantitative, time-consuming and not an 
efficient way to compare competing treatment plans even for 
conventional IMRT. The additional degrees of freedom provided by the 
biological images complicate BCRT treatment plan evaluation even more, 
as a homogeneous dose distribution is no longer the goal within the PTV. 
Data reduction techniques are commonly used to quantitatively assess 
treatment plans. By presenting the fractional volume of a structure of 
interest (target or OAR) receiving doses above a certain value, DVHs have 
become the most widely used IMRT treatment plan evaluation tool. 
Unfortunately, due to the non-uniform biology distribution within the 
tumor, they are not very useful for evaluating BCRT treatment plans. For 
this reason, Q-volume histograms (QVHs) were introduced in the first 
publication of this thesis [13]. Within each target voxel, Q is defined as the 
ratio of the obtained dose and the intended dose, which is calculated from 
the biological image signal intensity value. By display of the fractional 
volume for which Q is greater than each abscissa value, a QVH essentially 
is a DVH of the dose ratio distribution. In the ideal case, a QVH curve 
drops down steeply at Q = 1. To compress the quality of the obtained 
biologically conformal dose distribution into a single figure, the quality 
factor QF was introduced. QF was defined as the average absolute 
deviation of Q to 1 within the PTV. In case of a perfect biologically 
conformal dose distribution, QF = 0. QVHs can also be used for the 
comparison of BCRT with conventional IMRT treatment planning. In the 
latter case Q becomes equal to the ratio of the obtained dose and the 
uniform prescription dose within each target voxel. 
10.3 Treatment planning studies 
The feasibility of achieving deliberately inhomogeneous dose 
distributions in accordance with biological imaging information can be 
demonstrated by performing treatment planning studies. Examples of 
FMISO-PET guided BCRT for a base-of-tongue cancer case [10], FDG-PET 
and SPECT guided BCRT for 2 lung cancer cases [11], and FDG-PET 
guided BCRT for an oropharyngeal cancer case [13] have been reported.  
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In the second publication of this thesis, FDG-PET guided BCRT was used 
to create treatment plans for 15 head and neck cancer patients [14]. Two 
different levels of dose escalation were applied.  While BCRT or dose 
painting-by-numbers (“FDG-PET voxel intensity-based IMRT”) had a 
large impact on the dose distribution within the PTV compared to regular 
dose painting (“FDG-PET contour-based IMRT”), only small effects were 
observed on the dose distribution outside the PTV, especially on the dose 
delivered to the organs at risk. The resulting BCRT plans complied with 
the OAR planning constraints for all patients. 
Thorwarth et al. [19] have confirmed dose escalation using BCRT to be 
feasible in head and neck cancer under the constraint of limiting normal 
tissue doses to the level of conventional IMRT. In their planning study 
incorporating 13 patients, hypoxia dose painting-by-numbers was 
realized according to a map of dose escalation factors calculated from 
dynamic FMISO-PET data. Compared to a dose painting strategy 
delivering a 110% uniform dose escalation to a contoured FDG-PET 
lesion, improved target coverage was achieved using dose painting-by-
numbers. Moreover, an increase in TCP of 14.3% was reported for 
FMISO-PET guided dose painting-by-numbers, compared to only 1.8% 
for the uniform FDG-PET guided dose escalation. The TCP model was 
established by relating dynamic FMISO data with therapy outcome [20]. 
10.4 Current issues in BCRT 
10.4.1 Biological imaging 
One of the main challenges for BCRT in the future will be the selection of 
one or more adequate biological imaging modalities for each treatment 
site. In the ideal case, several biological image sets will be available for 
each patient. Together, they will enable us to visualize biological tumor 
characteristics that influence RT response (metabolism, proliferation, 
oxygenation, vascularization), as well as provide data on normal tissue 
functionality.  A spatially heterogeneous biology profile can thus be 
created for each patient. 
In order to achieve this, efforts should be made to explore new tracers for 
biological imaging, or – at first instance – to develop adequate image 
acquisition protocols for RT treatment planning (including image 
reconstruction and post-processing) and image quantification of existing 
and available tracers. Because of the high spatial accuracy desired for 
BCRT, image resolution is an important issue.  
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At present, PET and fMRI seem to be the most powerful imaging 
techniques to assess biological tumor properties non-invasively. FDG-PET 
can be used to identify regions of enhanced glucose metabolism. Using 
human FaDu head and neck squamous cell carcinomas in nude mice, 
Schütze et al. recently observed a greater effect on local control by 
increasing the radiation dose in tumors with higher FDG uptake, where 
the dose-response relationship appears to be steep, than in tumors with 
lower FDG uptake, where the dose-response relationship seems to be 
very shallow [21].   
FLT is preferentially used to image tumor cell proliferation. Figure 4.3 
illustrates the qualitative differences between CT, FDG-PET and FLT-PET 
images for a rectal cancer patient [22]. To visualize hypoxic regions within 
tumors, a variety of different PET tracers, such as FMISO and Cu-ATSM, 
is available. Each of them is of potential use for BCRT planning purposes 
[23,24]. In order to preserve maximal lung function, 99mTc-labelled macro-
aggregated albumin (MAA) SPECT perfusion imaging can be used to 
divert dose from well-functioning regions within the lungs towards less 
perfused regions [25].  
 
 
 
Figure 4.3: Illustration of pre-treatment CT (top), FDG-PET (centre) and FLT-PET (bottom) 
transversal images for a rectal cancer patient case (reprinted with permission from Sarah 
Roels). 
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Conventional MRI lacks the metabolic information that can accurately 
define the presence and spatial extent of active tumor. By correlating 
DCE-MRI with histopathological and clinical outcome data, however, the 
potential application of DCE-MRI as a predictor of radiation response has 
been shown [26]. Next to FMISO-PET and Cu-ATSM-PET, blood oxygen 
level dependent (BOLD) MRI is a promising technique for the assessment 
of tumor hypoxia [27]. 
For prostate tumors, the (choline + creatine)/citrate ratio can be 
determined using MRSI to mark active disease with a high degree of 
specificity [28]. For brain gliomas, the use of the choline to N-
aceltylaspartate index (CNI) determined by MRSI has been suggested to 
be more reliable in defining the location and volume of microscopic and 
actively growing disease compared to conventional MRI [29,30].  
Although the clinical application of MRSI for RT is most developed for 
gliomas and prostate cancer, it will probably be useful in many other 
areas of the body too [31].  
10.4.2 Requirement for precise treatment delivery 
BCRT does not only increase the degree of complexity of treatment 
planning, but also the level of difficulty of safe and effective treatment 
delivery. While planning is performed based on pre-treatment imaging 
data, the location of the target volume and critical organs is generally 
different at the time of delivery, both due to patient set-up variations and 
organ motion, caused by breathing for example. The highly structured 
BCRT dose distributions (see, for example, Fig. 5 on page 69) require 
highly precise treatment delivery techniques.  Image-guided RT (IGRT) 
allows imaging of the patient geometry both before and during 
irradiation and the correction of set-up errors. A variety of in-room 
medical imaging techniques were developed to facilitate IGRT. 
Electronic portal imaging devices (EPIDs) were developed early in the 
1980s to enable the verification of treatment field positions relative to the 
patient’s anatomy. At present, they are an option on all commercial linear 
accelerators. Amorphous silicon flat panel devices have been reported to 
yield an image quality superior to that of films [32], with the added 
convenience of digital recording and image processing.  
Cone-beam CT (CBCT) uses a 2D detector, for example an EPID, to 
reconstruct CT images from a single rotation of a point source on the linac 
[33]. MV CBCT uses the therapeutic beam as a source, whereas kV CBCT 
uses an X-ray tube mounted on the linac.  While it was believed initially 
that the soft-tissue visualization of CBCT could be sufficient for online 
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IGRT, even strong promoters of this technique have now started to use 
implanted fiducials for prostate RT  (Ben Heijmen, personal 
communication, 11 November 2007). At GUH, the Elekta Synergy linac is 
equipped with a kV CBCT device. Figure 4.4 shows an example of 
matched planning CT and kV CBCT images for a clinical prostate case. In 
The Netherlands, the potential of MRI for IGRT by integration of a 1.5 
Tesla MRI scanner with a 6 MV linac is being investigated [34]. 
Finally, optical tracking systems may be used to measure the position of 
external infrared markers fixed to the patient’s surface relative to a fixed 
coordinate system in the treatment room. While sub-millimeter spatial 
resolution, facilitating verification and on-line correction of the patient 
set-up within the treatment room, has been claimed to be achievable in 
real time [35], it cannot be obtained in practice in some cases, e.g. to 
accurately quantify internal prostate motion. The relationship between 
the positions of the external markers and internal structures of interest is 
established from the planning CT. Combinations with other imaging 
devices like ultrasound are also possible, to determine the exact location 
of internal structures relative to the treatment room coordinates [36]. 
 
Figure 4.4. Match of planning CT and CBCT images for a clinical prostate case. Top: coronal 
view, centre: sagittal view, bottom: transverse view. Red line: PTV, blue line: bladder, inner 
brown line: rectum, outer brown line: expanded rectum, dashed line: user-defined region of 
interest for matching purposes.  
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In case of non-gated biological imaging investigations, the use of BCRT 
could come as a relative advantage with regard to organ motion [37]. CT 
scanning can be performed fast, i.e. during a single breath-hold of the 
patient. RT delivery, however, takes several minutes. Breathing motion 
can thus cause severe problems in the delivery of conventional IMRT for 
lung cancer [38,39]. To solve this, 4D CT scanning may be performed at 
several instances of the breathing cycle to determine the exact extent of 
the breathing motion [40] and the PTV and OAR margins for treatment 
planning may be increased [41]. Several 4D techniques are available to 
take breathing motion into account during RT delivery, including 
respiratory control [42], gating and tracking [43]. Using respiratory 
control, irradiation is only performed during assisted or voluntary 
respiratory pauses at selected phases of the respiratory cycle. Gating 
involves switching the treatment beam on when the amplitude of the 
breathing motion coincides with a pre-selected sector of the breathing 
cycle. Using intra-fraction tumor tracking, the treatment beam is 
intentionally moved to follow the movement of the tumor. 
Most biological imaging examinations last much longer than CT 
scanning. PET imaging, for example, may take 30 to 45 minutes. As a 
consequence, the image is smeared out across the breathing cycle. By 
using the resulting average image signal within each patient voxel to 
guide the dose prescription, BCRT may therefore cope better with 
reproducible patient motion than conventional IMRT. Ultimately, 
however, gating and intra-fraction tumor tracking remain the best way to 
deal with breathing motion for lung cancer treatment.  
10.4.3 Inter-fraction tumor tracking 
Apart from variations in positioning and organ motion, patient anatomy 
and biological tumor characteristics themselves may also change. Indeed, 
fractionated RT typically spans about 6 weeks; during this time many 
anatomical changes may occur. First of all, the tumor will hopefully 
shrink. Both inflammation and oedema can resolve. Moreover, weight 
loss, which is a common consequence of acute treatment toxicity, can lead 
to muscle wasting and shifting of both normal tissue and tumor positions. 
A detailed study performed by Barker et al. showed significant changes in 
the position (GTV: up to 17.3 mm) and volume (GTV: medianly -1.8% 
daily or -70% in total; parotid glands: -28%) of both the GTV and OARs 
during RT for head and neck cancer [44]. When it comes to biological 
changes during therapy, the situation is even more complex as variations 
in tumor metabolism, oxygenation and vascularization may occur [45]. 
Usually, these changes do not occur in a predictable way. 
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The use of repeated imaging during RT to adjust the treatment to the 
observed changes in tumor location and extent, is called inter-fraction 
tumor tracking - a particular case of adaptive RT (ART).  Ultimately, 
IGRT technology may be used to provide per-treatment images and 
perform re-planning for immediate delivery while the patient is in the 
treatment room. Time and effort could be saved by using algorithms 
capable of deforming treatment plans according to anatomical 
deformations, instead of re-planning entirely from the start [46,47]. 
Phase I study on adaptive FDG-PET guided BCRT in head and neck 
cancer 
Several investigations have demonstrated changes in tumor glucose 
utilization during the first weeks of chemotherapy, suggesting that 
effective therapy decreases FDG uptake in the tumor [48-50]. Several 
studies have indicated the usefulness of pre-treatment FDG-PET images 
for predicting the response to RT treatment of head and neck cancer [51-
57]. By performing FDG-PET investigations before pre-operative (chemo-) 
radiotherapy and after a dose of 36 Gy, local tumor control and survival 
could be predicted for patients with oral squamous cell carcinoma [58]. 
These data support the use of consecutive pre- and per-treatment FDG-
PET imaging to adapt BCRT treatment plans during a fractionated course 
of RT for head and neck cancer. 
As re-planning more than once or twice during treatment is not practical 
at present, only small day-to-day variations need to be assumed. 
Especially for the biological images, there exists no profound evidence to 
support this hypothesis. In a future study, the magnitude of these day-to-
day changes should preferably be investigated in detail. The results are 
expected to depend not only on the investigated biological imaging 
modality and tracer, but also on the tumor type and site and even on the 
individual patient. The best timing for the per-treatment FDG-PET 
investigation is not obvious, as radiation-induced inflammation causes 
increased FDG uptake. By hypothesizing that FDG-PET imaging at the 
end of the second week of RT may detect non-responding, radioresistant 
intra-tumor regions that require a higher radiation dose, a phase I study 
on adaptive FDG-PET guided BCRT in head and neck cancer was set up 
at GUH.  
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The main objective of the study is to establish the maximum tolerated 
dose MTD) for dose escalation. The MTD is defined as the maximal 
escalation dose causing dose-limiting toxicity (DLT). DLT is defined as 
any grade 4 toxicity observed in the treated patient group during RT or 
within 3 months after the end of treatment. Secondary objectives of the 
study are to report on acute, subacute and late toxicity, recurrence and 
site of recurrence, and tumor control rates. Acute, subacute and late 
toxicity are scored during treatment, 3 months after treatment and 6 
months (and later) after treatment, respectively. To assess (sub)acute 
toxicity, the common toxicity criteria (CTC) version 2.0 are used [59]. The 
study is prospective, non-controlled and non-randomized. In total, 12 
patients are planned to be included. Table 4.1 summarizes patient 
inclusion criteria. 
Table 4.1: Patient inclusion criteria of the Phase I clinical trial on adaptive FDG-PET guided 
BCRT in head and neck cancer. 
Inclusion criteria 
- Histologically confirmed squamous cell carcinoma of oral cavity, oro- and hypopharynx and 
larynx 
- Primary unresectable tumor and/or patients refusing surgery 
- Stage T2-4 N0 M0 or Tany N+ M0 for laryngeal cancer 
- Decision of radio(chemo)therapy by Multidisciplinary Group of Head and Neck Tumors at 
GUH 
- Karnofsky performance status ≥70% 
- No prior irradiation to the head and neck region 
- No other malignancies 
 
The total treatment consists of 32 fractions (6 weeks and 2 days). In the 
standard IMRT treatment for these patients at GUH, a total dose of 69.12 
Gy (2.16 Gy per fraction) is prescribed homogeneously to the PTV 
derived from the macroscopic tumor including a margin for microscopic 
disease. For the study, two levels of dose escalation (I and II) are defined, 
and 6 patients are included at each dose level. FDG-PET/CT scanning is 
performed before the start of RT (PET/CT 1) and on Thursday of the 
second week of treatment (PET/CT 2). The total treatment is divided into 
3 separate phases (dose level I): 
• Phase 1 (25 Gy, 10 fx): FDG-PET guided BCRT based on PET/CT 1  
• Phase 2 (30 Gy, 10 fx): FDG-PET guided BCRT based on PET/CT 2 
• Phase 3 (25.92 Gy, 12 fx): standard IMRT based on PET/CT 2 
BCRT treatment planning during phases 1 and 2 is performed using 
values of Ilow and Ihigh equal to 25% and 100% of the 95th percentile PET 
intensity value within the PTV. Dlow and Dhigh are equal to 2.16 and 2.5 Gy 
per fraction (phase 1) and 2.5 and 3.5 Gy per fraction (phase 2). 
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At dose level II, the escalation dose of phase 1 is 30 Gy instead of 25 Gy 
(Dlow and Dhigh equal to 2.5 and 3.5 Gy per fraction); the other dose levels 
remain unchanged. Due to the large size of the treatment fields, treatment 
phases 1 and 2 are both delivered on 2 treatment machines at GUH: the 
Elekta SL18 and Elekta Synergy linear accelerators. Five separate 
treatment plans are thus created for each patient. The treatment delivery 
at dose level I is summarized in table 4.2. The application of CBCT and a 
high-resolution MLC on the Elekta Synergy linac ensure a highly accurate 
delivery of BCRT. 
Table 4.2: Treatment delivery for dose level I of the Phase I clinical trial on adaptive FDG-
PET guided BCRT in head and neck cancer. 
 SL 18 Synergy 
Phase 1: FDG-PET guided BCRT 
25 Gy (10 x 2.5 Gy) 
21.6 Gy 3.4 Gy 
Phase 2: FDG-PET guided BCRT 
30 Gy (10 x 3 Gy) 
21.6 Gy 8.4 Gy 
Phase 3: standard IMRT 
25.92 Gy (12 x 2.16 Gy) 
- 25.92 Gy 
Total dose: 80.92 Gy 43.2 Gy 37.72 Gy 
 
In March 2007, 6 patients enrolled the trial at dose level I. So far, the 
observed maximal CTC grades of acute dysphagia and mucositis are, 
respectively, 2 and 3 (1 patient), 3 and 2 (4 patients) and 3 and 3 (1 
patient). No events of DLT have occurred yet. Figure 4.1 shows transverse 
pre- and per-treatment FDG-PET images of a 57-year old female 
hypopharyngeal cancer patient included in the study. The QVHs and QFs 
of each treatment plan for this patient are shown in figure 4.2. 
  
Figure 4.1: Transverse slices of pre- and per-treatment FDG-PET images registered to the pre-
treatment CT of a patient included in the Phase I clinical trial on adaptive FDG-PET guided 
BCRT at GUH. 
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Figure 4.2: QVHs and QFs for each treatment plan of a patient included in the Phase I clinical 
trial on adaptive FDG-PET guided BCRT at GUH. 
10.5 Patient dose calculations 
10.5.1 The added value of Monte Carlo 
Analytical models have traditionally been used to estimate dose 
distributions for RT treatment planning. Their accuracy has increased 
steadily from measurement-based calculations to PB and CS algorithms, 
together with the available computer power in the clinic. At present, 
vendors have started to incorporate MC dose engines into their 
commercial TP software. Several investigators have evaluated the added 
value of MC compared to analytical dose calculation algorithms. 
In a number of phantom studies, MC has been reported to be superior to 
conventional techniques near low density volumes and air cavities [60-
65]. MC was compared to two different CS algorithms by Paelinck et al. 
for a 6 MV photon beam incident on a phantom with a lung insert [62]. 
While one CS algorithm systematically underestimated the dose within 
the lung-equivalent cavity by 6%, the other one overestimated the dose 
behind the cavity by 4%, as shown in figure 4.5.  
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Figure 4.5: Comparison of MC (BEAMnrc/DOSXYZnrc) and 2 CS algorithms (Helax-TMS 
version 6.1A, Nucletron, Veenendaal, The Netherlands and Pinnacle version 6.2b, Philips 
Medical Systems, Best, The Netherlands) for a 1x10 cm2 6 MV photon field incident on a 
polystyrene phantom containing a lung-equivalent cavity [62]. 
It is not obvious how to extrapolate findings for single beams crossing 
large air or lung cavities within phantoms towards clinical practice. MC 
therefore has to be compared to conventional dose calculation algorithms 
for realistic clinical cases. While it has been shown that MC is clearly 
superior to broad beam and PB algorithms for patient dose calculations 
[66-72], only a limited number of studies has been devoted to the 
comparison of MC and CS in a clinical setting. For mediastinal and breast 
treatments restricted to large fields, Francescon et al. [73] only observed 
small differences, even for single fields and large inhomogeneities. 
Reynaert et al. compared two MC and 1 CS dose calculation algorithm for 
a head and neck case [74]. While CS results were in acceptable agreement 
with MCDE, systematic errors in the DVH of the optic chiasm were 
encountered for the other MC algorithm, due to an error in the leaf 
projection. Finally, Seco et al. [75] compared PB, CS and MC for a head 
and neck case. Differences up to 10% were reported for important dose-
volume parameters of the critical structures. 
There is still a lack of studies investigating whether clinical treatment 
plans may benefit from replacing CS by MC algorithms for dose 
calculation. For this purpose, two studies were set up at Ghent University 
and GUH [76,77]. In the third publication of this thesis, MCDE was 
compared to two commercial CS algorithms and one PB algorithm for 6 
MV and 18 MV IMRT treatment plans of ten lung cancer patients [75]. Of 
both CS algorithms, one clearly performed better within the PTV, while 
the other one performed better within the OARs. It was shown that the 
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results from PB were unsatisfactory within both the PTV and OARs. In 
such a study, the analysis of individual patient results is indispensable. 
None of the studied dose calculation algorithms were consistent within 
5% in all ten patients. The choice of dose calculation algorithm may 
influence treatment planning, and thus also clinical results. If an 
algorithm leads to large deviations in one particular patient, it may no 
longer be considered suitable for clinical use. However, the possible 
disposal of a dose calculation algorithm depends on several factors, 
including the institution’s internal accuracy requirements, the accuracy of 
the dose calculation algorithm used as the reference (in this case, MCDE) 
and the availability of a practicable alternative. Of course, whatever 
algorithm one uses, it should be optimally commissioned and adequately 
benchmarked. 
In the fourth publication of this thesis, results from the previous study 
were applied to investigate an important clinical question, namely 
whether 6 MV or 18 MV photons should be preferred for IMRT treatment 
of non-small cell lung cancer [78]. Although the observed deviations were 
quite small, 6 MV photons were generally favoured by MCDE. It was 
shown that the location of the tumor and the priority ranking of the 
endpoints may influence the selection of photon beam quality. Whereas 
18 MV photons may lead to better dose uniformity within the PTV and 
improved skin sparing, 6 MV photons may reduce the irradiated volume 
of normal lung by reducing the extent of lateral electron disequilibrium.  
A second study comparing MCDE to two commercial CS algorithms was 
performed at GUH for IMRT treatment of ten ethmoid sinus cancer 
patients [77]. The PTV typically contained large natural and surgical air 
cavities, causing electron disequilibrium at the interface with the tumor 
tissue. For individual patients, large differences (>10%) were reported 
between the maximal PTV dose  calculated by the different algorithms. In 
case of MCDE, the air within the PTV produced a lot of noise on the 
resulting dose distribution. Differences above 5% between the different 
algorithms were encountered within the OARs. 
When comparing MC to conventional dose calculation algorithms in a 
clinical setting, it is interesting to distinguish between effects related to 
differences in the beam model and effects related to the particle transport 
within the patient [79]. This may help to reveal the cause of the observed 
differences. Beam model accuracy can be evaluated by comparing 
calculations within a homogeneous phantom. Chetty et al. compared MC 
with two versions of a broad beam algorithm, one with an approximate 
beam model and one with an accurate beam model [79]. For 6 MV 
photons incident on a homogeneous phantom, the agreement between 
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MC and the accurate beam model algorithm was very good. For 15 MV 
photons incident on a heterogeneous lung phantom, however, the mean 
lung dose differed 30%. The authors concluded that the importance of 
accurate particle transport becomes much greater in case of 
inhomogeneities, especially at high energies. In the third publication of 
this thesis, the influence of particle transport within the patient was 
eliminated by recomputing the dose after setting all CT voxels within the 
skin contour to water for one patient case [75]. The remaining dose 
differences between the algorithms were all clinically acceptable, and 
either due to slight discrepancies in the commissioning process or to 
differences in the beam model.  
The ultimate way of evaluating the added value of MC, is to link clinical 
outcome to the (retrospectively) observed dose differences between MC 
and the conventional dose calculation algorithm used for treatment 
planning. Possible recurrences may be linked to PTV underdosage (as 
reported by MC), while possible side effects and normal tissue 
complications may be linked to OAR overdosage. However, no such data 
are currently available for MC yet. 
10.5.2 Advancements in MCDE 
The calculation of patient dose distributions with MC is associated with 
specific issues such as linear accelerator modelling, scoring grids, 
variance reduction techniques and CT conversion. For MCDE [80], several 
of these topics had been addressed before the start of the research 
presented in this thesis. The treatment head of the Elekta SLiplus linear 
accelerator at GUH had been modelled in detail to commission 6 and 18 
MV photon beams [81,82]. By introducing a separate scoring grid and two 
different stepping algorithms, dose scoring was accelerated substantially 
[83]. The optimal scoring grid resolution was also investigated for clinical 
head and neck, and lung cancer cases [82]. Variance reduction techniques 
have deliberately been kept out of MCDE, to preserve maximal accuracy 
at the cost of calculation speed. This thesis has addressed some 
unresolved issues related to the use of MCDE for patient dose 
calculations. 
An accurate CT conversion scheme was developed in the fifth publication 
of this thesis, in which great importance was attached to the dosimetric 
relevance of introducing additional tissue composition subsets [84]. A 
collaboration between 7 different European centres was set up to 
investigate several associated issues, such as CT calibration and 
conversion of dose to medium to dose to water. As a result, a CT 
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conversion scheme incorporating 14 bins (air, lung, fat, muscle and 10 
bone bins) was proposed. The mass density can be calibrated 
continuously against the CT number. Especially for skeletal tissue, it is 
important to define a sufficiently large number of subsets with different 
chemical compositions, due to the effects resulting from the conversion 
from dose to medium to dose to water. Each CT scanner should be 
calibrated individually and a stoichiometric calibration method should be 
used [85].  
Due to the nature of the method, dose calculation using MC is very time-
consuming. The time needed to calculate patient dose distributions in the 
clinic should be as short as possible but long enough to ensure sufficiently 
accurate results. For this purpose, uncertainty-based stopping criteria 
were implemented into MCDE in the sixth publication of this thesis [86]. 
For each structure of interest, upper limits were imposed on the relative 
or absolute uncertainty on the dose within each voxel. Two clinical IMRT 
cases and one clinical IMAT case were investigated. The tolerated relative 
uncertainty was equal to 2% [87,88]. The tolerated absolute uncertainty 
should be determined taking into account the absolute dose prescription 
for the PTV and the planning constraints for the OARs. The proposed 
stopping criteria provide a practical and flexible tool for automatic 
determination of the appropriate number of histories when simulating 
patient dose distributions using MCDE. 
10.6 Monte Carlo treatment planning 
10.6.1 Monte Carlo-based IMRT optimization 
The use of inaccurate dose calculation for inverse IMRT treatment 
planning introduces two errors, a systematic error and a convergence 
error [89]. The systematic error is due to the inaccuracy of the dose 
calculation algorithm itself, while the convergence error appears because 
the beam settings resulting from optimization are different from the 
optimal settings obtained with a highly accurate dose calculation 
algorithm. Jeraj et al. compared PB, CS and MC algorithms for three 
clinical cases (lung, prostate and head and neck). The systematic error 
was about 1% of the maximal dose within the PTV and slightly larger 
outside for CS, and about 5% for PB. The convergence error was found to 
be very sensitive to the objective function and only slightly correlated to 
the systematic error. The authors concluded that the accuracy of PB is 
insufficient for IMRT optimization and CS or preferably MC should be 
used instead. 
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The presence of statistical uncertainties (noise) on the calculated MC dose 
distributions can disturb the MC-based IMRT optimization process, 
especially if dose inhomogeneity within the PTV is penalized [90]. 
Moreover, the MC dose engine cannot just replace the conventional dose 
calculation algorithm, because the total number of time-consuming MC 
calculations that can be performed is limited from a practical viewpoint. 
To introduce MC calculations in the optimization of IMRT, MC can be 
used in combination with a conventional dose calculation algorithm 
[68,91,92] or independently by specifically adapting the optimization 
software to the MC dose engine [93-95]. In both cases, a conventional dose 
calculation algorithm can still be used to obtain an initial treatment plan. 
Because as few approximations as possible are applied in MCDE, it is a 
highly accurate but rather slow MC dose engine. It was mainly developed 
as a benchmarking tool and was not specifically designed for routine use 
in the clinic. However, in the seventh publication of this thesis MCDE 
was used to investigate the feasibility of incorporating MC calculations 
into the IMRT optimization process at GUH [91]. As proof of principle, an 
ethmoid sinus patient case was considered. By computing individual MC 
dose distributions for each beam in between optimization cycles, the best 
final plan could be obtained. However, not all MC dose engines allow the 
generation of such individual dose distributions. By computing the full 
MC dose distribution in between optimization cycles, the initial treatment 
plan could still be improved. Moreover, the optimization process was 
severely disturbed by statistical noise generated by the air cavities within 
the PTV.  
10.6.2 Commercial MCTP systems 
It is obvious that RT patients may benefit from the improvements in dose 
calculation accuracy using full MC. In the third publication of this thesis, 
highly accurate dose calculations with MCDE resulted in clinically 
meaningful dose differences compared to commercial CS algorithms [76]. 
However, in many clinics the available computer power may still not 
allow full MC calculations. Nevertheless, vendors of RT TPSs have 
recently started to offer MC systems. To reduce the calculation time, 
many approximations and simplifications are often included, which may 
cause substantial dose inaccuracies. The importance of accurate linear 
accelerator modelling has been illustrated before [74]. Moreover, the 
simplification of photon or electron transport, or other techniques like 
denoising of dose distributions, may lead to loss of accuracy. Geometrical 
and scoring voxel size should also be evaluated critically [96]. In any case, 
like any other TPS commercial MC systems need to be benchmarked 
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carefully before bringing them into clinical use.  This can be done either 
by means of measurements or by comparison with accurate MC dose 
engines containing only a few approximations, like MCDE. 
The introduction of BEAM/DOSXYZ was an important step towards the 
practical implementation of MCTP. Although this package already 
enabled actual MCTP calculations, the high calculation times presented a 
major drawback. Therefore, Kawrakow et al. [97] developed the Voxel 
Monte Carlo (VMC) code as a fast MC dose engine for electron beams 
based on a set of sophisticated variance reduction techniques. For photon 
beams, Peregrine [98] was introduced as a MC dose engine using multiple 
variance reduction techniques. Later, VMC was also extended for photon 
beams, resulting in the fast X-ray Voxel Monte Carlo (XVMC) [99]. 
Together, Kawrakow and Fippel optimized XVMC [100], and each of 
them developed his own C++ version of the original Fortran code, called 
VMC++ and XVMC, respectively [101,102]. XVMC/VMC++ and 
Peregrine are the only MC dose engines implemented into commercial 
TPSs for photon RT. For electrons, the MC dose engines Dose Planning 
Method (DPM) [103], Macro Monte Carlo (MMC) [104] and PENetration 
and Energy Loss of Positrons and Electrons (PENELOPE) [105,106] were 
also implemented commercially. Table 4.3 summarizes the (future) 
availability of MC dose calculation engines in commercial TPSs, resulting 
from a survey carried out by the subcommittee on MTCP of the 
Netherlands Commission on Radiation Dosimetry [102]. 
Table 4.3: Overview of MC dose engines implemented into commercial TPSs [102]. 
Company Treatment planning system Photon MC code Electron MC code 
BrainLab iPlan RT Dose 4.0 XVMC XVMC 
XiO 4.3.0 XVMC XVMC CMS 
Monaco 4.3.0 XVMC - 
Elekta-Plan 1.1 XVMC - 
Elekta-Plan 1.2 XVMC XVMC 
Elekta 
Elekta-Plan 2.0 XVMC XVMC 
DCM (now OTP) 2.0 - VMC 
OTP 1.4 VMC++ VMC++ 
PLATO - - 
Nucletron 
TMS - - 
Philips Pinnacle3 v6.9c - DPM (modified) 
Cadplan - - Varian 
Eclipse 7.2.X - MMC 
Siemens KonRad v2.1 - - 
Dosisoft Isogray - PENELOPE 
North American Scientific Corvus, Peacock v5 Peregrine - 
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10.7 Current issues in MCTP 
10.7.1 Particle therapy 
Photons rapidly lose energy by ionization as they travel through tissue, 
whereas  charged particles deposit most of their energy at a specific 
depth. The location of this so-called Bragg peak can be precisely 
calculated as a function of the particle’s initial energy. Compared to 
conventional external photon beam RT, particle therapy may therefore 
deliver high doses directly to the target volume. By combining particles 
with different energies into a single beam, the Bragg peak can be spread-
out into a plateau. A high dose of radiation may thus be deposited 
throughout the depth of the tumor, while the tissue in front of the tumor 
is exposed to far less radiation and the tissue behind the tumor remains 
virtually damage-free. Figure 4.6 illustrates the dose distributions 
resulting from proton and photon intensity-modulated therapy for a 
paranasal sinus cancer patient. Particle therapy is particularly appropriate 
in situations where photon RT includes high risks for the patients. Deep-
seated tumors, tumors in the vicinity of OARs, radiation resistant tumors 
and paediatric tumors are particularly in favour of particle therapy. 
 
Figure 4.6: Dose distributions of proton (a) and photon (b) intensity-modulated therapy for a 
paranasal sinus cancer patient at the level of the globes (top) and petrous ridge (bottom) 
[107]. Dose levels of 76, 66 and 54 Gy were prescribed to three target volumes. The globes, the 
optic nerves and the brainstem were considered as critical structures. 
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As particle therapy delivers conformal dose distributions with very high 
precision, and steep dose gradients can be located near critical structures, 
accurate dose calculation is important. PB algorithms are usually applied 
for proton therapy calculations [108-110]. However, the 1D density 
scaling of proton pencil beams in water limits the accuracy of the PB 
calculations [111]. Although more sophisticated scaling methods have 
been introduced [111,112], the results still differ from MC dose 
distributions, because PB algorithms can only approximately deal with 
multiple elastic Coulomb scattering in heterogeneous media, and elastic 
and inelastic nuclear reactions [113]. 
The general purpose MC codes GEANT4 [114], FLUKA [115,116] and 
MCNP [117] can be used for proton therapy treatment planning. 
However, the requirement of a large material database for the cross 
sections slows down simulations in patient geometries. For this reason, 
Fippel and Soukup developed VMCpro [113], a fast MC code for proton 
therapy dose calculations based on VMC for electrons and photons 
[97,99]. 
Protons lose their energy by ionization, multiple Coulomb scattering and 
nuclear reactions. Hence, accurate conversion of CT data into mass 
density and elemental composition information is even more important 
for proton MC dose calculations than for photons. Jiang et al. [118] have 
studied the effect of three different CT conversion methods on proton MC 
simulations. Two clinical proton plans were selected for their tissue 
variety, namely a lung and a paranasal sinus cancer case. Small but 
significant differences were observed.  
Intensity-modulated proton therapy (IMPT) [119] can be achieved by 
modulating the intensity and energy of narrow beam spots that are 
delivered to the patient in a scanned pattern [120,121]. Optimization of 
IMPT is currently based on analytical dose calculation algorithms with 
limited accuracy, resulting in suboptimal dose distributions. Soukup and 
Alber recently implemented VMCpro into IMPT treatment planning 
[122]. Treatment plans for 6 clinical cases obtained using a PB algorithm 
were recalculated using MC to determine the size of the convergence 
error. For prostate cases, values up to 1% were reported for the target, 
which was caused mainly by the nuclear interactions.  Although the use 
of MC highly increased calculation times, it was shown that MC-based 
optimization of IMPT could significantly improve the optimal dose 
distribution for specific patient cases. 
Physical dose optimization for IMPT generally assumes a constant 
relative biological effectiveness (RBE), whereas in reality the biological 
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effect caused by proton beams does not depend on the physical dose 
alone, but also on the local energy spectrum [123]. By including RBE 
variations in the inverse planning process, Wilkens and Oelfke illustrated 
the importance of biological optimization for IMPT [124]. 
10.7.2 4D Monte Carlo 
Motion issues are a challenge in RT dose calculations. Time dependence 
in RT may arise from the linear accelerator or from the patient. Unlike 
conventional dose calculation algorithms, MC can take into account 
motion just through sampling. This will not greatly increase calculation 
time, because it is the total number of simulated histories that will 
determine the uncertainty on the final dose distribution. Indeed, a major 
advantage of MC over conventional dose engines is that the uncertainties 
are independent of the treatment set-up. 
The linear accelerator may be the source of time dependence when a 
dynamic MLC is used [125], or in case of IMAT treatment [126]. To take 
into account dynamic MLC movement, MC simulations can randomize 
the leaf positions from their known time-dependent distributions [127-
129]. IMAT was implemented into MCDE by Olteanu et al. [130], and a 
comparison between MCDE and CS for clinical prostate and rectum cases 
is ongoing. 
Patient-related motion may arise from set-up errors, inter-fraction organ 
motion and intra-fraction organ movement [131]. The main source of 
intra-fraction organ movement is breathing motion. Several investigators 
have integrated breathing motion into MC dose calculations. Ding et al. 
[131] used CT scans at total inhalation and total exhalation to interpolate 
scans at intermediate breathing phases. By performing a weighted sum of 
the corresponding dose maps, the actual dose distribution delivered to 
the patient was determined. However, the treatment itself stayed 
unaffected. Keall et al. [132], on the other hand, used the same beam 
directions for each CT dataset but each time confined the MLC settings to 
the PTV of the dataset (tumor tracking). The resulting dose maps were 
then combined into a so-called 4D treatment plan. A 4D MC calculation 
does not take more time than a 3D calculation, as it is the summed dose 
map that needs to be sufficiently accurate. Each individual dose map thus 
requires only a limited number of histories, whereas for a conventional 
dose calculation algorithm, the calculation time would be proportional to 
the number of breathing phases. A different approach to take into account 
the interplay effects between linear accelerator motion and patient 
motion, was introduced by Paganetti et al. [133]. They included motion 
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into the MC calculation geometry by deformation of the patient voxels 
according to the 4D CT data. Heath and Seuntjens [134] developed a so-
called voxel tracking algorithm to take into account internal and external 
contour changes by deforming the voxels. 
With the introduction of IGRT in the clinic, set-up errors and anatomy 
changes in the course of treatment can be imaged on a daily basis. Intra-
fraction organ motion can even be imaged in real time. Moreover, the 
treatment plans can be adapted based on the observed changes (ART). 4D 
MC calculations could be used to determine the actual total dose 
distribution received by the patient based on the acquired image sets and 
delivered treatment plans. 
10.7.3 MCDE for treatment plan verification 
Just like conventional TPSs, commercial MCTP systems should be 
benchmarked to detect possible errors arising from systematic errors in 
the code, problems with the beam model, CT conversion and the use of 
variance reduction techniques and de-noising methods. To commission 
MC dose engines, calculation results can be compared with 
measurements in a phantom or with calculations from an independent, 
accurate MC dose engine [74,99,135-138]. 
In the future, the Lab for Standard Dosimetry (LSD) in Ghent is likely to 
add treatment plan verification using MCDE to its service package. 
Hospitals could use this service to benchmark their commercial 
(conventional or MC-based) TPS for clinical cases. 
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Chapter  11  
Conclusions 
In this thesis, BCRT was implemented into the IMRT treatment planning 
process at GUH. The developed software allows the incorporation of one 
or more biological image sets, the specification of a bound-constrained 
linear relationship between the image signal and the desired radiation 
dose, the creation of initial beam segments based on the provided 
biological imaging data, the optimization of the segment shapes and 
weights, and the evaluation of the final treatment plan. 
The feasibility of FDG-PET guided BCRT for head and neck cancer was 
demonstrated in a planning study. BCRT did not compromise the 
planning constraints for the OARs. The obtained biological conformity 
was the best for the lowest level of dose escalation. Compared to uniform 
dose escalation within a contoured FDG-PET lesion, improved target dose 
coverage was achieved using BCRT. 
Progress in biological imaging has opened a new range of possibilities to 
individualize RT. Optimal use of the new tools for treatment planning 
and delivery will require an improved understanding of the radiobiology 
of tumors. 
MC can be used to calculate RT dose distributions with great accuracy. 
The use of MC is especially advantageous in case of small, irregular 
treatment fields delivering dose to regions of great tissue inhomogenity, 
for example in IMRT treatment of head and neck or lung tumors. In this 
thesis, the added value of MC compared to pencil beam and 
convolution/superposition algorithms was demonstrated for IMRT lung 
cancer patients.  
MCDE was developed at Ghent University as a highly accurate MC dose 
engine for IMRT patient dose calculations. In this thesis, the conversion of 
CT numbers into material composition data for MC dose calculations was 
studied in detail. Stoichiometric CT scanner calibration and the creation 
of dosimetrically equivalent tissue subsets resulted in a 14 bin CT 
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conversion scheme, suitable for RT using photons and electrons. MCDE 
was further improved by the introduction of uncertainty-based stopping 
criteria, enabling accurate clinical treatment plan evaluation in the 
shortest possible time. 
Finally, the feasibility of integrating MCDE into the IMRT optimization 
process at GUH was demonstrated for an ethmoid sinus cancer patient 
case. Patients may benefit from the improvements in dose calculation 
accuracy using full MC. MC dose engines are currently being 
implemented into commercial treatment planning systems. Highly 
accurate dose engines like MCDE are not suitable for routine clinical use, 
but they represent excellent benchmarking tools, as they can be used in 
situations where measurements are very difficult or even impossible. 
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